

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 20, 2005, 07:26:03 ; Search time 62 Seconds  
(without alignments)  
67.337 Million cell updates/sec

Title: US-10-668-181-6

Perfect score: 63

Sequence: 1 CWINNNAVRY 10

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1862951 seqs, 417491010 residues

Total number of hits satisfying chosen parameters: 1862951

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA.\*

```

1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pcp.*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pcp.*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pcp.*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pcp.*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pcp.*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pcp.*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pcp.*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pcp.*
9: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pcp.*
10: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pcp.*
11: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pcp.*
12: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pcp.*
13: /cgn2_6/ptodata/2/pubpaa/US10_PUBCOMB.pcp.*
14: /cgn2_6/ptodata/2/pubpaa/US10_PUBCOMB.pcp.*
15: /cgn2_6/ptodata/2/pubpaa/US10_PUBCOMB.pcp.*
16: /cgn2_6/ptodata/2/pubpaa/US10_PUBCOMB.pcp.*
17: /cgn2_6/ptodata/2/pubpaa/US10_PUBCOMB.pcp.*
18: /cgn2_6/ptodata/2/pubpaa/US10_PUBCOMB.pcp.*
19: /cgn2_6/ptodata/2/pubpaa/US11_PUBCOMB.pcp.*
20: /cgn2_6/ptodata/2/pubpaa/US11_PUBCOMB.pcp.*
21: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pcp.*
22: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pcp.*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	63	100.0	10	18	US-10-668-181-6
2	63	100.0	513	9	US-09-818-264-4
3	63	100.0	513	16	US-10-473-339-4
4	63	100.0	936	15	US-10-295-027-490
5	63	100.0	936	15	US-10-173-999-18
6	63	100.0	967	15	US-10-295-027-488
7	63	100.0	967	15	US-10-173-999-16
8	63	100.0	993	15	US-10-173-999-14
9	63	100.0	1000	15	US-10-295-027-486
10	63	100.0	1000	15	US-10-173-999-22
11	63	100.0	1014	14	US-10-054-044A-4
					Sequence 6, Appli
					Sequence 4, Appli
					Sequence 490, App
					Sequence 18, Appl
					Sequence 488, App
					Sequence 16, Appl
					Sequence 14, Appl
					Sequence 486, App
					Sequence 22, Appl
					Sequence 4, Appli

```

12 100.0 1014 14 US-10-120-604-4 Sequence 4, Appli
13 100.0 1014 14 US-10-120-604-139 Sequence 139, App
14 100.0 1014 14 US-10-225-567A-428 Sequence 428, App
15 100.0 1014 15 US-10-295-027-492 Sequence 492, App
16 100.0 1014 15 US-10-295-027-810 Sequence 810, App
17 100.0 1014 15 US-10-295-027-847 Sequence 847, App
18 100.0 1014 15 US-10-173-999-20 Sequence 20, Appli
19 100.0 1014 16 US-10-741-657A-2 Sequence 2, Appli
20 100.0 1014 16 US-10-723-860-2455 Sequence 2455, Ap
21 100.0 1014 16 US-10-349-538-24 Sequence 24, Appli
22 100.0 1014 20 US-11-070-456-4 Sequence 4, Appli
23 100.0 1014 20 US-11-070-456-139 Sequence 139, App
24 100.0 1038 18 US-10-668-181-2 Sequence 2, Appli
25 100.0 1252 17 US-10-505-486-38 Sequence 38, Appli
26 85.7 717 14 US-10-054-044A-2 Sequence 2, Appli
27 69.8 238 18 US-10-500-240-92 Sequence 92, Appli
28 69.8 252 18 US-10-500-240-92 Sequence 94, Appli
29 69.8 277 18 US-10-500-240-87 Sequence 87, Appli
30 69.8 284 18 US-10-500-240-88 Sequence 88, Appli
31 69.8 284 18 US-10-500-240-90 Sequence 90, Appli
32 68.3 94 16 US-10-425-115-209272 Sequence 209272
33 68.3 662 13 US-10-036-328A-8 Sequence 8, Appli
34 68.3 714 9 US-09-818-264-2 Sequence 2, Appli
35 68.3 714 16 US-10-473-339-2 Sequence 2, Appli
36 68.3 733 13 US-10-036-328A-4 Sequence 4, Appli
37 68.3 1138 13 US-10-036-328A-6 Sequence 6, Appli
38 68.3 1210 13 US-10-036-328A-2 Sequence 2, Appli
39 65.1 42 14 US-10-097-065-236 Sequence 236, App
40 65.1 42 15 US-10-372-876-236 Sequence 236, App
41 63.5 48 15 US-10-424-599-220247 Sequence 220247,
42 63.5 99 15 US-10-424-599-279922 Sequence 279922,
43 63.5 104 15 US-10-424-599-211553 Sequence 211553,
44 63.5 390 14 US-10-081-816-39 Sequence 39, Appli
45 63.5 390 15 US-10-447-328-58 Sequence 58, Appli

```

#### ALIGNMENTS

```

RESULT 1
US-10-668-181-6
; Sequence 6, Application US/10668181
; Publication NO. US20050202439A1
; GENERAL INFORMATION:
; APPLICANT: OSTERHOFF, CAROLINE
; TITLE OF INVENTION: EPIDIDYMIIS-SPECIFIC RECEPTOR PROTEIN
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/668,181
; FILING DATE: 24-Sep-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/041,745
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B. J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 35-125
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-816-4000

```

; TELEFAX: 703-816-4100  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 10 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:  
US-10-668-181-6

Query Match 100.0%; Score 63; DB 18; Length 10;  
Best Local Similarity 100.0%; Pred. No. 0.0018;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
Db 1 CWINNAVY 10  
|||||

RESULT 2  
US-09-818-264-4  
; Sequence 4, Application US/09818264  
; Patent No. US20020142951A1  
; GENERAL INFORMATION:  
; APPLICANT: WEBSTER, Marion et al.  
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED  
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR  
; FILE REFERENCE: CL001193  
; CURRENT APPLICATION NUMBER: US/09/818,264  
; CURRENT FILING DATE: 2001-03-28  
; NUMBER OF SEQ ID NOS: 5  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH: 513  
; TYPE: PRT  
; ORGANISM: Human  
US-09-818-264-4

Query Match 100.0%; Score 63; DB 9; Length 513;  
Best Local Similarity 100.0%; Pred. No. 0.072;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
Db 379 CWINNAVY 388  
|||||

RESULT 3  
US-10-473-339-4  
; Sequence 4, Application US/10473339  
; Publication No. US20040171540A1  
; GENERAL INFORMATION:  
; APPLICANT: PE CORPORATION (NY)  
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED  
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR  
; FILE REFERENCE: CL001193  
; CURRENT APPLICATION NUMBER: US/10/473,339  
; CURRENT FILING DATE: 2003-09-29  
; PRIOR APPLICATION NUMBER: PCT/US02/09317  
; PRIOR FILING DATE: 2002-03-27  
; PRIOR APPLICATION NUMBER: 09/818,264  
; PRIOR FILING DATE: 2001-03-28  
; NUMBER OF SEQ ID NOS: 5  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH: 513  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-473-339-4

Query Match 100.0%; Score 63; DB 16; Length 513;

Best Local Similarity 100.0%; Pred. No. 0.072;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
Db 379 CWINNAVY 388  
|||||

RESULT 4  
US-10-295-027-490  
; Sequence 490, Application US/10295027  
; Publication No. US20030232350A1  
; GENERAL INFORMATION:  
; APPLICANT: Afar, Daniel  
; APPLICANT: Aziz, Nataasha  
; APPLICANT: Ginsberg, Wendy M.  
; APPLICANT: Gish, Kurt C.  
; APPLICANT: Glynn, Richard  
; APPLICANT: Hevezi, Peter A.  
; APPLICANT: Mack, David H.  
; APPLICANT: Murray, Richard  
; APPLICANT: Watson, Susan R.  
; APPLICANT: Eos Biotechnology, Inc.  
; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and  
; TITLE OF INVENTION: Methods of Screening for Modulators of Cancer  
; FILE REFERENCE: 018501-012500US  
; CURRENT APPLICATION NUMBER: US/10/295,027  
; CURRENT FILING DATE: 2002-11-13  
; PRIOR APPLICATION NUMBER: US 09/663,733  
; PRIOR FILING DATE: 2000-09-15  
; PRIOR APPLICATION NUMBER: US 60/350,666  
; PRIOR FILING DATE: 2001-11-13  
; PRIOR APPLICATION NUMBER: US 60/335,394  
; PRIOR FILING DATE: 2001-11-15  
; PRIOR APPLICATION NUMBER: US 60/332,464  
; PRIOR FILING DATE: 2001-11-21  
; PRIOR APPLICATION NUMBER: US 60/334,393  
; PRIOR FILING DATE: 2001-11-29  
; PRIOR APPLICATION NUMBER: US 60/340,376  
; PRIOR FILING DATE: 2001-12-14  
; PRIOR APPLICATION NUMBER: US 60/347,211  
; PRIOR FILING DATE: 2002-01-08  
; PRIOR APPLICATION NUMBER: US 60/347,349  
; PRIOR FILING DATE: 2002-01-10  
; PRIOR APPLICATION NUMBER: US 60/355,250  
; PRIOR FILING DATE: 2002-02-08  
; PRIOR APPLICATION NUMBER: US 60/356,714  
; PRIOR FILING DATE: 2002-02-13  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 1386  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 490  
; LENGTH: 936  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-295-027-490

Query Match 100.0%; Score 63; DB 15; Length 936;  
Best Local Similarity 100.0%; Pred. No. 0.13;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
Db 748 CWINNAVY 757  
|||||

RESULT 5  
US-10-173-999-18  
; Sequence 18, Application US/10173999  
; Publication No. US2004000563A1  
; GENERAL INFORMATION:  
; APPLICANT: Mack, David H.  
; APPLICANT: Gish, Kurt C.

```

; APPLICANT: Eos Biotechnology, Inc.
; TITLE OF INVENTION: Methods of Diagnosis of Ovarian Cancer, Compositions
; TITLE OF INVENTION: and Methods of Screening for Modulators of Ovarian
; TITLE OF INVENTION: Cancer
; FILE REFERENCE: 018501-002420US
; CURRENT APPLICATION NUMBER: US/10/10/173,999
; CURRENT FILING DATE: 2002-06-17
; PRIOR APPLICATION NUMBER: US 60/299,234
; PRIOR FILING DATE: 2001-06-18
; PRIOR APPLICATION NUMBER: US 60/315,287
; PRIOR FILING DATE: 2001-08-27
; PRIOR APPLICATION NUMBER: US 60/350,666
; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US 60/372,246
; PRIOR FILING DATE: 2001-04-12
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 936
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-173-999-18

Query Match 100.0%; Score 63; DB 15; Length 936;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10
Db 748 CWINNNAVY 757

RESULT 6
US-10-295-027-488
; Sequence 488, Application US/10295027
; Publication No. US2003023350A1
; GENERAL INFORMATION:
; APPLICANT: Afar, Daniel
; APPLICANT: Aziz, Natasha
; APPLICANT: Ginsberg, Wendy M.
; APPLICANT: Gish, Kurt C.
; APPLICANT: Glynné, Richard
; APPLICANT: Hevezi, Peter A.
; APPLICANT: Mack, David H.
; APPLICANT: Murray, Richard
; APPLICANT: Watson, Susan R.
; APPLICANT: Eos Biotechnology, Inc.
; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and
; TITLE OF INVENTION: Methods of Screening for Modulators of Cancer
; FILE REFERENCE: 018501-012500US
; CURRENT APPLICATION NUMBER: US/10/295,027
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: US 09/663,733
; PRIOR FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: US 60/350,666
; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US 60/335,394
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: US 60/332,464
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: US 60/334,393
; PRIOR FILING DATE: 2001-11-29
; PRIOR APPLICATION NUMBER: US 60/340,376
; PRIOR FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: US 60/347,211
; PRIOR FILING DATE: 2002-01-08
; PRIOR APPLICATION NUMBER: US 60/347,349
; PRIOR FILING DATE: 2002-01-10
; PRIOR APPLICATION NUMBER: US 60/355,250
; PRIOR FILING DATE: 2002-02-08
; PRIOR APPLICATION NUMBER: US 60/356,714
; PRIOR FILING DATE: 2002-02-13
; Remaining Prior Application data removed - See File Wrapper or PALM.

```

```

; NUMBER OF SEQ ID NOS: 1386
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 488
; LENGTH: 967
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-295-027-488

Query Match 100.0%; Score 63; DB 15; Length 967;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10
Db 728 CWINNNAVY 737

RESULT 7
US-10-173-999-16
; Sequence 16, Application US/10173999
; Publication No. US20040005563A1
; GENERAL INFORMATION:
; APPLICANT: Mack, David H.
; APPLICANT: Gish, Kurt C.
; APPLICANT: Eos Biotechnology, Inc.
; TITLE OF INVENTION: Methods of Diagnosis of Ovarian Cancer, Compositions
; TITLE OF INVENTION: and Methods of Screening for Modulators of Ovarian
; TITLE OF INVENTION: Cancer
; FILE REFERENCE: 018501-002420US
; CURRENT APPLICATION NUMBER: US/10/173,999
; CURRENT FILING DATE: 2002-06-17
; PRIOR APPLICATION NUMBER: US 60/299,234
; PRIOR FILING DATE: 2001-06-18
; PRIOR APPLICATION NUMBER: US 60/315,287
; PRIOR FILING DATE: 2001-08-27
; PRIOR APPLICATION NUMBER: US 60/350,666
; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US 60/372,246
; PRIOR FILING DATE: 2001-04-12
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 967
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-173-999-16

Query Match 100.0%; Score 63; DB 15; Length 967;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10
Db 728 CWINNNAVY 737

RESULT 8
US-10-173-999-14
; Sequence 14, Application US/10173999
; Publication No. US20040005563A1
; GENERAL INFORMATION:
; APPLICANT: Mack, David H.
; APPLICANT: Gish, Kurt C.
; APPLICANT: Eos Biotechnology, Inc.
; TITLE OF INVENTION: Methods of Diagnosis of Ovarian Cancer, Compositions
; TITLE OF INVENTION: and Methods of Screening for Modulators of Ovarian
; TITLE OF INVENTION: Cancer
; FILE REFERENCE: 018501-002420US
; CURRENT APPLICATION NUMBER: US/10/173,999
; CURRENT FILING DATE: 2002-06-17
; PRIOR APPLICATION NUMBER: US 60/299,234
; PRIOR FILING DATE: 2001-06-18
; PRIOR APPLICATION NUMBER: US 60/315,287

```

; PRIOR FILING DATE: 2001-08-27  
; PRIOR APPLICATION NUMBER: US 60/350,666  
; PRIOR FILING DATE: 2001-11-13  
; PRIOR APPLICATION NUMBER: US 60/372,246  
; PRIOR FILING DATE: 2001-04-12  
; NUMBER OF SEQ ID NOS: 163  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 14  
; LENGTH: 993  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-173-999-14

Query Match 100.0%; Score 63; DB 15; Length 993;  
Best Local Similarity 100.0%; Pred. No. 0.13; 0; Indels 0; Gaps 0;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CWINNAVY 10  
| | | | | | | | | |  
Db 754 CWINNAVY 763

RESULT 9  
US-10-295-027-486  
; Sequence 486, Application US/10295027  
; Publication No. US2003023350A1  
; GENERAL INFORMATION:  
; APPLICANT: Afar, Daniel  
; APPLICANT: Aziz, Natasha  
; APPLICANT: Ginsberg, Wendy M.  
; APPLICANT: Gish, Kurt C.  
; APPLICANT: Glynn, Richard  
; APPLICANT: Hevezi, Peter A.  
; APPLICANT: Mack, David H.  
; APPLICANT: Murray, Richard  
; APPLICANT: Watson, Susan R.  
; APPLICANT: Eos Biotechnology, Inc.  
; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and  
; TITLE OF INVENTION: Methods of Screening for Modulators of Cancer  
; FILE REFERENCE: 018501-012500US  
; CURRENT APPLICATION NUMBER: US/10/295,027  
; CURRENT FILING DATE: 2002-11-13  
; PRIOR APPLICATION NUMBER: US 09/663,733  
; PRIOR FILING DATE: 2000-09-15  
; PRIOR APPLICATION NUMBER: US 60/350,666  
; PRIOR FILING DATE: 2001-11-13  
; PRIOR APPLICATION NUMBER: US 60/335,394  
; PRIOR FILING DATE: 2001-11-15  
; PRIOR APPLICATION NUMBER: US 60/332,464  
; PRIOR FILING DATE: 2001-11-21  
; PRIOR APPLICATION NUMBER: US 60/334,393  
; PRIOR FILING DATE: 2001-11-29  
; PRIOR APPLICATION NUMBER: US 60/340,376  
; PRIOR FILING DATE: 2001-12-14  
; PRIOR APPLICATION NUMBER: US 60/347,211  
; PRIOR FILING DATE: 2002-01-08  
; PRIOR APPLICATION NUMBER: US 60/347,349  
; PRIOR FILING DATE: 2002-01-10  
; PRIOR APPLICATION NUMBER: US 60/355,250  
; PRIOR FILING DATE: 2002-02-08  
; PRIOR APPLICATION NUMBER: US 60/356,714  
; PRIOR FILING DATE: 2002-02-13  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 1386  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 486  
; LENGTH: 1000  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-295-027-486

Query Match 100.0%; Score 63; DB 15; Length 1000;  
Best Local Similarity 100.0%; Pred. No. 0.14;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 CWINNAVY 10  
| | | | | | | | | |  
Db 761 CWINNAVY 770

RESULT 10  
US-10-173-999-22  
; Sequence 22, Application US/10173999  
; Publication No. US20040005563A1  
; GENERAL INFORMATION:  
; APPLICANT: Mack, David H.  
; APPLICANT: Gish, Kurt C.  
; APPLICANT: Eos Biotechnology, Inc.  
; TITLE OF INVENTION: Methods of Diagnosis of Ovarian Cancer, Compositions  
; TITLE OF INVENTION: and Methods of Screening for Modulators of Ovarian  
; TITLE OF INVENTION: Cancer  
; FILE REFERENCE: 018501-002420US  
; CURRENT APPLICATION NUMBER: US/10/173,999  
; CURRENT FILING DATE: 2002-06-17  
; PRIOR APPLICATION NUMBER: US 60/299,234  
; PRIOR FILING DATE: 2001-06-18  
; PRIOR APPLICATION NUMBER: US 60/315,287  
; PRIOR FILING DATE: 2001-08-27  
; PRIOR APPLICATION NUMBER: US 60/350,666  
; PRIOR FILING DATE: 2001-11-13  
; PRIOR APPLICATION NUMBER: US 60/372,246  
; PRIOR FILING DATE: 2001-04-12  
; NUMBER OF SEQ ID NOS: 163  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 22  
; LENGTH: 1000  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-173-999-22

Query Match 100.0%; Score 63; DB 15; Length 1000;  
Best Local Similarity 100.0%; Pred. No. 0.14; 0; Indels 0; Gaps 0;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CWINNAVY 10  
| | | | | | | | | |  
Db 761 CWINNAVY 770

RESULT 11  
US-10-054-044A-4  
; Sequence 4, Application US/10054044A  
; Publication No. US20030096345A1  
; GENERAL INFORMATION:  
; APPLICANT: GLUCKSMANN, Maria A  
; TITLE OF INVENTION: 15569, A NOVEL HUMAN G PROTEIN COUPLED RECEPTOR AND USES THEREFOR  
; FILE REFERENCE: 10147-60U1  
; CURRENT APPLICATION NUMBER: US/10/054,044A  
; CURRENT FILING DATE: 2002-04-19  
; PRIOR APPLICATION NUMBER: US 60/263,253  
; PRIOR FILING DATE: 2001-01-22  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 4  
; LENGTH: 1014  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-054-044A-4

Query Match 100.0%; Score 63; DB 14; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.14; 0; Indels 0; Gaps 0;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CWINNAVY 10  
| | | | | | | | | |  
Db 775 CWINNAVY 784

RESULT 12  
US-10-120-604-4  
; Sequence 4, Application US/10120604  
; Publication No. US20030096347A1  
; GENERAL INFORMATION:  
; APPLICANT: Bristol-Myers Squibb Company  
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING TWO NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR  
; FILE REFERENCE: D0143NP  
; CURRENT APPLICATION NUMBER: US/10/120,604  
; CURRENT FILING DATE: 2002-04-11  
; PRIOR APPLICATION NUMBER: US 60/283,145  
; PRIOR FILING DATE: 2001-04-11  
; PRIOR APPLICATION NUMBER: US 60/283,161  
; PRIOR FILING DATE: 2001-04-11  
; PRIOR APPLICATION NUMBER: US 60/288,468  
; PRIOR FILING DATE: 2001-05-03  
; PRIOR APPLICATION NUMBER: US 60/300,619  
; PRIOR FILING DATE: 2001-06-25  
; NUMBER OF SEQ ID NOS: 226  
; SOFTWARE: Patentin version 3.0  
; SEQ ID NO 4  
; LENGTH: 1014  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-120-604-4

Query Match 100.0%; Score 63; DB 14; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
DB 775 CWINNAVY 784

RESULT 13  
US-10-120-604-139  
; Sequence 139, Application US/10120604  
; Publication No. US20030096347A1  
; GENERAL INFORMATION:  
; APPLICANT: Bristol-Myers Squibb Company  
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING TWO NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR  
; FILE REFERENCE: D0143NP  
; CURRENT APPLICATION NUMBER: US/10/120,604  
; CURRENT FILING DATE: 2002-04-11  
; PRIOR APPLICATION NUMBER: US 60/283,145  
; PRIOR FILING DATE: 2001-04-11  
; PRIOR APPLICATION NUMBER: US 60/283,161  
; PRIOR FILING DATE: 2001-04-11  
; PRIOR APPLICATION NUMBER: US 60/288,468  
; PRIOR FILING DATE: 2001-05-03  
; PRIOR APPLICATION NUMBER: US 60/300,619  
; PRIOR FILING DATE: 2001-06-25  
; NUMBER OF SEQ ID NOS: 226  
; SOFTWARE: Patentin version 3.0  
; SEQ ID NO 139  
; LENGTH: 1014  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-120-604-139

Query Match 100.0%; Score 63; DB 14; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
DB 775 CWINNAVY 784

RESULT 14  
US-10-225-567A-428  
; Sequence 428, Application US/10225567A  
; Publication No. US20030113798A1  
; GENERAL INFORMATION:  
; APPLICANT: LifeSpan Biosciences  
; APPLICANT: Brown, Joseph P.  
; APPLICANT: Burner, Glenna C.  
; APPLICANT: Roush, Christine L.  
; TITLE OF INVENTION: ANTIGENIC PEPTIDES AND ANTIBODIES FOR G PROTEIN-COUPLED RECEPTOR.  
; FILE REFERENCE: 1920-4-4  
; CURRENT APPLICATION NUMBER: US/10/225,567A  
; CURRENT FILING DATE: 2001-12-19  
; PRIOR APPLICATION NUMBER: 60/257,144  
; PRIOR FILING DATE: 2000-12-19  
; NUMBER OF SEQ ID NOS: 2292  
; SOFTWARE: Patentin version 3.1  
; SEQ ID NO 428  
; LENGTH: 1014  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-225-567A-428

Query Match 100.0%; Score 63; DB 14; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
DB 775 CWINNAVY 784

RESULT 15  
US-10-295-027-492  
; Sequence 492, Application US/10295027  
; Publication No. US20030232350A1  
; GENERAL INFORMATION:  
; APPLICANT: Afar, Daniel  
; APPLICANT: Aziz, Natasha  
; APPLICANT: Ginsberg, Wendy M.  
; APPLICANT: Gish, Kurt C.  
; APPLICANT: Glynnne, Richard  
; APPLICANT: Hevezi, Peter A.  
; APPLICANT: Mack, David H.  
; APPLICANT: Murray, Richard  
; APPLICANT: Watson, Susan R.  
; APPLICANT: Eos Biotechnology, Inc.  
; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and  
; FILE REFERENCE: 018501-012500US  
; CURRENT APPLICATION NUMBER: US/10/295,027  
; CURRENT FILING DATE: 2002-11-13  
; PRIOR APPLICATION NUMBER: US 09/663,733  
; PRIOR FILING DATE: 2000-09-15  
; PRIOR APPLICATION NUMBER: US 60/350,666  
; PRIOR FILING DATE: 2001-11-13  
; PRIOR APPLICATION NUMBER: US 60/335,394  
; PRIOR FILING DATE: 2001-11-15  
; PRIOR APPLICATION NUMBER: US 60/332,464  
; PRIOR FILING DATE: 2001-11-21  
; PRIOR APPLICATION NUMBER: US 60/334,393  
; PRIOR FILING DATE: 2001-11-29  
; PRIOR APPLICATION NUMBER: US 60/340,376  
; PRIOR FILING DATE: 2001-12-14  
; PRIOR APPLICATION NUMBER: US 60/347,211  
; PRIOR FILING DATE: 2002-01-08  
; PRIOR APPLICATION NUMBER: US 60/347,349  
; PRIOR FILING DATE: 2002-01-10  
; PRIOR APPLICATION NUMBER: US 60/355,250  
; PRIOR FILING DATE: 2002-02-08  
; PRIOR APPLICATION NUMBER: US 60/356,714  
; PRIOR FILING DATE: 2002-02-13

; Remaining Prior Application data removed - See File Wrapper or PALM.  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 492  
; LENGTH: 1014  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-295-027-492

Query Match 100.0%; Score 63; DB 15; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10  
| | | | | | | | | |  
Db 775 CWINNNAVY 784

RESULT 16  
US-10-295-027-810  
; Sequence 810, Application US/10295027  
; Publication No. US20030232350A1  
; GENERAL INFORMATION:  
; APPLICANT: Afar, Daniel  
; APPLICANT: Aziz, Natasha  
; APPLICANT: Ginsberg, Wendy M.  
; APPLICANT: Gish, Kurt C.  
; APPLICANT: Glynn, Richard  
; APPLICANT: Hevezi, Peter A.  
; APPLICANT: Mack, David H.  
; APPLICANT: Murray, Richard  
; APPLICANT: Watson, Susan R.  
; APPLICANT: Eos Biotechnology, Inc.  
; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and  
; FILE REFERENCE: 018501-012500US  
; CURRENT FILING DATE: 2002-11-13  
; PRIOR FILING DATE: 2000-09-15  
; PRIOR APPLICATION NUMBER: US 60/350,666  
; PRIOR FILING DATE: 2001-11-13  
; PRIOR APPLICATION NUMBER: US 60/335,394  
; PRIOR FILING DATE: 2001-11-15  
; PRIOR APPLICATION NUMBER: US 60/332,464  
; PRIOR FILING DATE: 2001-11-21  
; PRIOR APPLICATION NUMBER: US 60/334,393  
; PRIOR FILING DATE: 2001-11-29  
; PRIOR APPLICATION NUMBER: US 60/340,376  
; PRIOR FILING DATE: 2001-12-14  
; PRIOR APPLICATION NUMBER: US 60/347,211  
; PRIOR FILING DATE: 2002-01-08  
; PRIOR APPLICATION NUMBER: US 60/355,250  
; PRIOR FILING DATE: 2002-01-10  
; PRIOR APPLICATION NUMBER: US 60/356,714  
; PRIOR FILING DATE: 2002-02-13  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 1386  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 810  
; LENGTH: 1014  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-295-027-810

Query Match 100.0%; Score 63; DB 15; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10  
| | | | | | | | | |

Db 775 CWINNNAVY 784  
RESULT 17  
US-10-295-027-847  
; Sequence 847, Application US/10295027  
; Publication No. US20030232350A1  
; GENERAL INFORMATION:  
; APPLICANT: Afar, Daniel  
; APPLICANT: Aziz, Natasha  
; APPLICANT: Ginsberg, Wendy M.  
; APPLICANT: Gish, Kurt C.  
; APPLICANT: Glynn, Richard  
; APPLICANT: Hevezi, Peter A.  
; APPLICANT: Mack, David H.  
; APPLICANT: Murray, Richard  
; APPLICANT: Watson, Susan R.  
; APPLICANT: Eos Biotechnology, Inc.  
; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and  
; FILE REFERENCE: 018501-012500US  
; CURRENT FILING DATE: 2002-11-13  
; PRIOR FILING DATE: 2000-09-15  
; PRIOR APPLICATION NUMBER: US 60/350,666  
; PRIOR FILING DATE: 2001-11-13  
; PRIOR APPLICATION NUMBER: US 60/335,394  
; PRIOR FILING DATE: 2001-11-15  
; PRIOR APPLICATION NUMBER: US 60/332,464  
; PRIOR FILING DATE: 2001-11-21  
; PRIOR APPLICATION NUMBER: US 60/334,393  
; PRIOR FILING DATE: 2001-11-29  
; PRIOR APPLICATION NUMBER: US 60/340,376  
; PRIOR FILING DATE: 2001-12-14  
; PRIOR APPLICATION NUMBER: US 60/347,211  
; PRIOR FILING DATE: 2002-01-08  
; PRIOR APPLICATION NUMBER: US 60/347,349  
; PRIOR FILING DATE: 2002-01-10  
; PRIOR APPLICATION NUMBER: US 60/355,250  
; PRIOR FILING DATE: 2002-02-08  
; PRIOR APPLICATION NUMBER: US 60/356,714  
; PRIOR FILING DATE: 2002-02-13  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 1386  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 847  
; LENGTH: 1014  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-295-027-847

Query Match 100.0%; Score 63; DB 15; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10  
| | | | | | | | | |  
Db 775 CWINNNAVY 784

RESULT 18  
US-10-173-999-20  
; Sequence 20, Application US/10173999  
; Publication No. US20040005563A1  
; GENERAL INFORMATION:  
; APPLICANT: Mack, David H.  
; APPLICANT: Gish, Kurt C.  
; APPLICANT: Eos Biotechnology, Inc.  
; TITLE OF INVENTION: Methods of Diagnosis of Ovarian Cancer, Compositions  
; TITLE OF INVENTION: and Methods of Screening for Modulators of Ovarian  
; TITLE OF INVENTION: Cancer  
; FILE REFERENCE: 018501-002420US

; CURRENT APPLICATION NUMBER: US/10/173,999  
; CURRENT FILING DATE: 2002-06-17  
; PRIOR APPLICATION NUMBER: US 60/299,234  
; PRIOR FILING DATE: 2001-06-18  
; PRIOR APPLICATION NUMBER: US 60/315,287  
; PRIOR FILING DATE: 2001-08-27  
; PRIOR APPLICATION NUMBER: US 60/350,666  
; PRIOR FILING DATE: 2001-11-13  
; PRIOR APPLICATION NUMBER: US 60/372,246  
; PRIOR FILING DATE: 2001-04-12  
; NUMBER OF SEQ ID NOS: 163  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 1014  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-173-999-20

Query Match 100.0%; Score 63; DB 15; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
Db 775 CWINNAVY 784

## RESULT 19

US-10-741-657A-2  
; Sequence 2, Application US/10741657A  
; Publication No. US20040197325A1  
; GENERAL INFORMATION:  
; APPLICANT: Protein Labs  
; TITLE OF INVENTION: ANTIBODIES AGAINST GPR64 AND USES THEREOF  
; FILE REFERENCE: 05882.0177.NPUS01  
; CURRENT APPLICATION NUMBER: US/10/741,657A  
; CURRENT FILING DATE: 2003-12-19  
; NUMBER OF SEQ ID NOS: 30  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 2  
; LENGTH: 1014  
; TYPE: PRT  
; ORGANISM: Homo Sapiens  
US-10-741-657A-2

Query Match 100.0%; Score 63; DB 16; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
Db 775 CWINNAVY 784

## RESULT 20

US-10-723-860-2455  
; Sequence 2455, Application US/10723860  
; Publication No. US20040253606A1  
; GENERAL INFORMATION:  
; APPLICANT: Aziz, Natasha  
; APPLICANT: Ginsburg, Wendy M.  
; APPLICANT: Zlotnik, Albert  
; TITLE OF INVENTION: Methods of Diagnosis of Soft Tissue Sarcoma, Compositions &  
; TITLE OF INVENTION: Methods for Screening for Soft Tissue Sarcoma Modulators  
; FILE REFERENCE: 05882.0193.NPUS01  
; CURRENT APPLICATION NUMBER: US/10/723,860  
; CURRENT FILING DATE: 2003-11-26  
; PRIOR FILING DATE: 2002-11-26  
; NUMBER OF SEQ ID NOS: 8393  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 2455  
; LENGTH: 1014

; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-723-860-2455

Query Match 100.0%; Score 63; DB 16; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
Db 775 CWINNAVY 784

## RESULT 21

US-10-349-528-24  
; Sequence 24, Application US/10349528  
; Publication No. US20040253668A1  
; GENERAL INFORMATION:  
; APPLICANT: RAMANATHAN, Chandra  
; APPLICANT: GOPAL, Shuba  
; APPLICANT: MINTIER, Gabe  
; APPLICANT: FEDER, John  
; TITLE OF INVENTION: NOVEL G PROTEIN-COUPLED RECEPTOR (GPCR) VARIANTS AND METHODS OF  
; TITLE OF INVENTION: USE THEREOF  
; FILE REFERENCE: D0210  
; CURRENT APPLICATION NUMBER: US/10/349,528  
; CURRENT FILING DATE: 2003-01-22  
; NUMBER OF SEQ ID NOS: 35  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 24  
; LENGTH: 1014  
; TYPE: PRT  
; ORGANISM: HOMO SAPIENS  
US-10-349-528-24

Query Match 100.0%; Score 63; DB 16; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
Db 775 CWINNAVY 784

## RESULT 22

US-11-070-456-4  
; Sequence 4, Application US/11070456  
; Publication No. US20050148016A1  
; GENERAL INFORMATION:  
; APPLICANT: Bristol-Myers Squibb Company  
; TITLE OF INVENTION: NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR HGPRBMV298v1 POLYPEPTIDES  
; FILE REFERENCE: D0143 DIV1  
; CURRENT APPLICATION NUMBER: US/11/070,456  
; CURRENT FILING DATE: 2005-03-02  
; PRIOR APPLICATION NUMBER: US 60/283,145  
; PRIOR FILING DATE: 2001-04-11  
; PRIOR APPLICATION NUMBER: US 10/120,604  
; PRIOR FILING DATE: 2002-04-11  
; PRIOR APPLICATION NUMBER: US 60/283,161  
; PRIOR FILING DATE: 2001-04-11  
; PRIOR APPLICATION NUMBER: US 60/288,468  
; PRIOR FILING DATE: 2001-05-03  
; PRIOR APPLICATION NUMBER: US 60/300,619  
; PRIOR FILING DATE: 2001-06-25  
; NUMBER OF SEQ ID NOS: 226  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 4  
; LENGTH: 1014  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-11-070-456-4

Query Match 100.0%; Score 63; DB 20; Length 1014;





GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 20, 2005, 05:49:15 ; Search time 21 Seconds  
(without alignments)  
35.547 Million cell updates/sec

Title: US-10-668-181-6  
Perfect score: 63  
Sequence: 1 CWINNAVVPY 10

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/ptodata/1/iaa/5A\_COMB.pep.\*  
2: /cgn2\_6/ptodata/1/iaa/5B\_COMB.pep.\*  
3: /cgn2\_6/ptodata/1/iaa/6A\_COMB.pep.\*  
4: /cgn2\_6/ptodata/1/iaa/6B\_COMB.pep.\*  
5: /cgn2\_6/ptodata/1/iaa/PCTUS\_COMB.pep.\*  
6: /cgn2\_6/ptodata/1/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	41	65.1	314	US-09-107-532A-7216	Sequence 7216, Ap
2	40	63.5	440	US-09-054-272-34	Sequence 34, Appl
3	40	63.5	440	US-09-919-497-80	Sequence 80, Appl
4	40	63.5	443	US-09-949-016-9574	Sequence 9574, Ap
5	39	61.9	541	US-09-976-594-931	Sequence 931, Appl
6	38	60.3	438	US-08-848-762-8	Sequence 8, Appl
7	38	60.3	439	US-09-252-991A-28726	Sequence 28726, A
8	38	60.3	685	US-08-947-965-72	Sequence 72, Appl
9	38	60.3	686	US-08-947-965-73	Sequence 73, Appl
10	37	58.7	208	US-09-248-796A-17615	Sequence 17615, A
11	37	58.7	222	US-08-440-517A-3	Sequence 3, Appl
12	37	58.7	223	US-09-092-160-3	Sequence 9, Appl
13	37	58.7	233	US-09-112-498A-9	Sequence 9, Appl
14	37	58.7	769	US-09-248-796A-16368	Sequence 16368, A
15	37	58.7	1272	US-09-543-681A-5732	Sequence 5732, Ap
16	36	57.1	29	US-08-637-759B-101	Sequence 101, Appl
17	36	57.1	29	US-08-871-355A-101	Sequence 101, Appl
18	36	57.1	29	US-09-201-945-101	Sequence 101, Appl
19	36	57.1	118	US-09-489-039A-12473	Sequence 12473, A
20	36	57.1	196	US-09-134-001C-4649	Sequence 4649, Ap
21	36	57.1	228	US-08-440-517A-2	Sequence 2, Appl
22	36	57.1	228	US-09-092-160-2	Sequence 2, Appl
23	36	57.1	237	US-09-112-498A-7	Sequence 7, Appl
24	36	57.1	238	US-09-328-352-5904	Sequence 5904, Ap
25	36	57.1	254	US-09-071-252-37	Sequence 37, Appl
26	36	57.1	501	US-08-408-095-31	Sequence 31, Appl
27	36	57.1	686	US-08-947-965-70	Sequence 70, Appl

## ALIGNMENTS

## RESULT 1

US-09-107-532A-7216  
; Sequence 7216, Application US/09107532A  
; Patent No. 6583275  
; GENERAL INFORMATION:  
; APPLICANT: Lynn A Doucette-Stamm and David Bush  
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO  
; ENTEROCOCCUS FAECIUM FOR DIAGNOSTICS AND THERAPEUTICS  
; NUMBER OF SEQUENCES: 7310  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: GENOME THERAPEUTICS CORPORATION  
; STREET: 100 Beaver Street  
; CITY: Waltham  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02154  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: CD-ROM ISO9660  
; COMPUTER: PC  
; OPERATING SYSTEM: <Unknown>  
; SOFTWARE: ASCII  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/107,532A  
; FILING DATE: 30-Jun-1998

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/085,598  
FILING DATE: 14 May 1998  
APPLICATION NUMBER: 60/051571  
FILING DATE: July 2, 1997

ATTORNEY/AGENT INFORMATION:  
NAME: Ariniello, Pamela Deneke  
REGISTRATION NUMBER: 40,489  
REFERENCE/DOCKET NUMBER: GTC-012  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (781)893-5007  
TELEFAX: (781)893-8277

INFORMATION FOR SEQ ID NO: 7216:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 314 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
HYPOTHETICAL: YES  
ORIGINAL SOURCE:  
ORGANISM: Enterococcus faecium  
FEATURE:  
NAME/KEY: misc feature  
LOCATION: (B) LOCATION 1...314  
SEQUENCE DESCRIPTION: SEQ ID NO: 7216:  
US-09-107-532A-7216

Sequence 6485, Ap  
Sequence 26, Appl  
Sequence 38489, A  
Sequence 53706, A  
Sequence 72, Appl  
Sequence 6014, Ap  
Sequence 70, Appl  
Sequence 5540, Ap  
Sequence 5, Appl  
Sequence 10866, A  
Sequence 7087, Ap  
Sequence 15937, A  
Sequence 12982, A  
Sequence 20781, A  
Sequence 3934, Ap  
Sequence 3935, Ap  
Sequence 6, Appl

28 35 55.6 107 4 US-09-513-999C-6485  
29 35 55.6 221 3 US-09-129-030-26  
30 35 55.6 224 3 US-09-129-030-24  
31 35 55.6 240 4 US-09-270-767-38489  
32 35 55.6 240 4 US-09-270-767-53706  
33 35 55.6 289 4 US-09-071-035-72  
34 35 55.6 301 4 US-09-134-000C-6014  
35 35 55.6 312 4 US-09-071-035-70  
36 35 55.6 354 4 US-09-328-352-5540  
37 35 55.6 365 4 US-09-801-874-5  
38 35 55.6 371 4 US-09-902-540-10866  
39 35 55.6 416 4 US-09-949-016-7087  
40 35 55.6 511 4 US-09-902-540-15937  
41 35 55.6 590 4 US-09-489-039A-12982  
42 34 54.0 82 4 US-09-248-796A-20781  
43 34 54.0 111 4 US-09-621-976-3934  
44 34 54.0 112 4 US-09-621-976-3935  
45 34 54.0 131 4 US-09-433-241A-6

Query Match 65.1%; Score 41; DB 4; Length 314;  
Best Local Similarity 55.6%; Pred. No. 49;  
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2 WINNNVYF 10  
Db 289 WVNKRIFY 297  
|:|:| :|:|

## RESULT 2

US-09-054-272-34  
; Sequence 34, Application US/09054272  
; Patent No. 6692909  
; GENERAL INFORMATION:  
; APPLICANT: Lander, Eric S.  
; APPLICANT: Daley, George Q.  
; APPLICANT: Cargill, Michele  
; APPLICANT: Ireland, James S.  
; APPLICANT: Rozen, Steven G.  
; TITLE OF INVENTION: CODING SEQUENCE POLYMORPHISMS  
; TITLE OF INVENTION: IN VASCULAR PATHOLOGY GENES  
; NUMBER OF SEQUENCES: 59  
; CORRESPONDENCE ADDRESS:  
; ADDRESS: HAMILTON, BROOK, SMITH & REYNOLDS, P.C.  
; STREET: Two Militia Drive  
; CITY: Lexington  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02173  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows 95  
; SOFTWARE: FASTSEQ for Windows Version 2.0b  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/054,272  
; FILING DATE: 01-APR-1998  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Granahan, Patricia  
; REGISTRATION NUMBER: 32,227  
; REFERENCE/DOCKET NUMBER: WHI98-05  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 781-861-6240  
; TELEFAX: 781-861-9540  
; TELEX:  
; INFORMATION FOR SEQ ID NO: 34:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 440 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; FRAGMENT TYPE: internal

US-09-054-272-34

Query Match 63.5%; Score 40; DB 4; Length 440;  
Best Local Similarity 60.0%; Pred. No. 1e+02;  
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 CWINNNVYF 10  
Db 98 CWIDNTRVY 107  
|:|:| :|:|

## RESULT 3

US-09-919-497-80  
; Sequence 80, Application US/09919497  
; Patent No. 6773883

; GENERAL INFORMATION:  
; APPLICANT: Mutter, George L.  
; TITLE OF INVENTION: PROGNOSTIC CLASSIFICATION OF ENDOMETRIAL CANCER  
; FILE REFERENCE: B0801/7225  
; CURRENT APPLICATION NUMBER: US/09/919,497  
; PRIOR FILING DATE: 2001-07-31  
; PRIOR APPLICATION NUMBER: US 60/221,735  
; PRIOR FILING DATE: 2000-07-31  
; NUMBER OF SEQ ID NOS: 100  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 80  
; LENGTH: 440  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; US-09-919-497-80

Query Match 63.5%; Score 40; DB 4; Length 440;  
Best Local Similarity 60.0%; Pred. No. 1e+02;  
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 CWINNNVYF 10  
Db 98 CWIDNTRVY 107  
|:|:| :|:|

## RESULT 4

US-09-949-016-9574  
; Sequence 9574, Application US/09949016  
; Patent No. 6812339  
; GENERAL INFORMATION:  
; APPLICANT: VENTER, J. Craig et al.  
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED  
; FILE REFERENCE: CL001307  
; CURRENT APPLICATION NUMBER: US/09/949,016  
; CURRENT FILING DATE: 2000-04-14  
; PRIOR APPLICATION NUMBER: 60/241,755  
; PRIOR FILING DATE: 2000-10-20  
; PRIOR APPLICATION NUMBER: 60/237,768  
; PRIOR FILING DATE: 2000-10-03  
; PRIOR APPLICATION NUMBER: 60/231,498  
; PRIOR FILING DATE: 2000-09-08  
; NUMBER OF SEQ ID NOS: 207012  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 9574  
; LENGTH: 443  
; TYPE: PRT  
; ORGANISM: Human  
; US-09-949-016-9574

Query Match 63.5%; Score 40; DB 4; Length 443;  
Best Local Similarity 60.0%; Pred. No. 1e+02;  
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 CWINNNVYF 10  
Db 101 CWIDNTRVY 110  
|:|:| :|:|

## RESULT 5

US-09-976-594-931  
; Sequence 931, Application US/09976594  
; Patent No. 6673549  
; GENERAL INFORMATION:  
; APPLICANT: Furness, Michael  
; APPLICANT: Buchbinder, Jenny  
; TITLE OF INVENTION: GENES EXPRESSED IN C3A LIVER CELL CULTURES TREATED WITH STEROIDS  
; FILE REFERENCE: PA-0041 US  
; CURRENT APPLICATION NUMBER: US/09/976,594  
; CURRENT FILING DATE: 2001-10-12  
; PRIOR APPLICATION NUMBER: 60/240,409  
; PRIOR FILING DATE: 2000-10-12  
; NUMBER OF SEQ ID NOS: 1143

```
; SOFTWARE: PERL Program
; SEQ ID NO 931
; LENGTH: 541
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No. 6673549 1530186CD1
US-09-976-594-931

Query Match      61.9%; Score 39; DB 4; Length 541;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 5; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY      1 CWINNAVYF 10
Db      304 CWIQDPVIF 313
      |||||:::

RESULT 6
US-08-846-762-8
; Sequence 8, Application US/08846762A
; Patent No. 5994072
; GENERAL INFORMATION:
; APPLICANT: Lam, Joseph S.
; APPLICANT: Burrows, Lori
; APPLICANT: Charter, Deborah
; APPLICANT: de Kievit, Teresa
; TITLE OF INVENTION: No. 5994072el Proteins Involved in the Synthesis and Assembly
; FILE REFERENCE: 6580-089
; CURRENT APPLICATION NUMBER: US/08/846,762A
; CURRENT FILING DATE: 1997-04-30
; NUMBER OF SEQ ID NOS: 100
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
; LENGTH: 438
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-08-846-762-8

Query Match      60.3%; Score 38; DB 2; Length 438;
Best Local Similarity 44.4%; Pred. No. 2.1e+02;
Matches 4; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      2 WWINNAVYF 10
Db      27 WWINNYIYH 35
      |||||:::

RESULT 7
US-09-252-991A-28726
; Sequence 28726, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 28726
; LENGTH: 439
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-28726

Query Match      60.3%; Score 38; DB 4; Length 439;
```

```
Best Local Similarity 44.4%; Pred. No. 2.1e+02;
Matches 4; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      2 WWINNAVYF 10
Db      28 WWINNYIYH 36
      |||||:::

RESULT 8
US-08-947-965-72
; Sequence 72, Application US/08947965A
; Patent No. 6004790
; GENERAL INFORMATION:
; APPLICANT: Dijkhuizen, Lubbert
; APPLICANT: Dijkstra, Bauke
; APPLICANT: Andersen, Carsten
; APPLICANT: Osten, Claus von der
; TITLE OF INVENTION: Cyclomaltodextrin Glucanotransferase
; FILE REFERENCE: 4285.204-US
; CURRENT APPLICATION NUMBER: US/08/947,965A
; CURRENT FILING DATE: 1997-10-09
; EARLIER APPLICATION NUMBER: 0477/95
; EARLIER FILING DATE: 1995-04-21
; EARLIER APPLICATION NUMBER: 1173/95
; EARLIER FILING DATE: 1995-10-17
; EARLIER APPLICATION NUMBER: 1281/95
; EARLIER FILING DATE: 1995-11-16
; EARLIER APPLICATION NUMBER: PCT/DK96/00179
; EARLIER FILING DATE: 1996-04-22
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 72
; LENGTH: 685
; TYPE: PRT
; ORGANISM: Bacillus sp.
US-08-947-965-72

Query Match      60.3%; Score 38; DB 3; Length 685;
Best Local Similarity 55.6%; Pred. No. 3.4e+02;
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      2 WWINNAVYF 10
Db      413 WINNDVIY 421
      |||||:::

RESULT 9
US-08-947-965-73
; Sequence 73, Application US/08947965A
; Patent No. 6004790
; GENERAL INFORMATION:
; APPLICANT: Dijkhuizen, Lubbert
; APPLICANT: Dijkstra, Bauke
; APPLICANT: Andersen, Carsten
; APPLICANT: Osten, Claus von der
; TITLE OF INVENTION: Cyclomaltodextrin Glucanotransferase
; FILE REFERENCE: 4285.204-US
; CURRENT APPLICATION NUMBER: US/08/947,965A
; CURRENT FILING DATE: 1997-10-09
; EARLIER APPLICATION NUMBER: 0477/95
; EARLIER FILING DATE: 1995-04-21
; EARLIER APPLICATION NUMBER: 1173/95
; EARLIER FILING DATE: 1995-10-17
; EARLIER APPLICATION NUMBER: 1281/95
; EARLIER FILING DATE: 1995-11-16
; EARLIER APPLICATION NUMBER: PCT/DK96/00179
; EARLIER FILING DATE: 1996-04-22
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 73
; LENGTH: 686
```

```
; TYPE: PRT
; ORGANISM: Bacillus sp.
US-08-947-965-73

Query Match      60.3%; Score 38; DB 3; Length 686;
Best Local Similarity 55.6%; Pred. No. 3.4e+02;
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2 WINNAVY 10
Db 413 WINNDVIIY 421

RESULT 10
US-09-248-796A-17615
; Sequence 17615, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
; APPLICANT: Keith Weinstock et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
; FILE REFERENCE: 107196.132
; CURRENT APPLICATION NUMBER: US/09/248.796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/074,725
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096,409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 17615
; LENGTH: 208
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-17615

Query Match      58.7%; Score 37; DB 4; Length 208;
Best Local Similarity 40.0%; Pred. No. 1.4e+02;
Matches 4; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1 CWINNAVY 10
Db 16 CWNNSVLFV 25

RESULT 11
US-08-440-517A-3
; Sequence 3, Application US/08440517A
; Patent No. 5959082
; GENERAL INFORMATION:
; APPLICANT: COSGROVE, DANIEL J.;
; APPLICANT: GUILTINAN, MARK;
; APPLICANT: SCHERBAN, TATYANA;
; APPLICANT: SHI, JUN
; TITLE OF INVENTION: PURIFIED EXPANSIN PROTEINS
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: INTELLECTUAL PROPERTY OFFICE, THE
; ADDRESSEE: PENNSYLVANIA STATE UNIVERSITY
; STREET: 113 TECHNOLOGY CENTER
; CITY: UNIVERSITY PARK
; STATE: PENNSYLVANIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 16802-7000
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: NEC 286
; OPERATING SYSTEM: DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA: US/08/440.517A
; APPLICATION NUMBER: 530
; FILING DATE:
; CLASSIFICATION:
; INFORMATION FOR SEQ ID NO: 3:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 222
; TYPE: AMINO ACID
; TOPOLOGY: UNKNOWN
US-08-440-517A-3

Query Match      58.7%; Score 37; DB 2; Length 222;
Best Local Similarity 66.7%; Pred. No. 1.5e+02;
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 WINNAVY 10
Db 5 WINAHATFY 13

RESULT 12
US-09-092-160-3
; Sequence 3, Application US/09092160C
; Patent No. 6255466
; GENERAL INFORMATION:
; APPLICANT: Cosgrove, Daniel J
; APPLICANT: McQueen-Mason, Simon
; APPLICANT: Guiltinan, Mark J
; APPLICANT: Scherban, Tatyana
; APPLICANT: Shi, Jun
; TITLE OF INVENTION: PURIFIED EXPANSIN PROTEINS
; FILE REFERENCE: 1194/IC114US3
; CURRENT APPLICATION NUMBER: US/09/092,160C
; CURRENT FILING DATE: 1998-06-05
; EARLIER APPLICATION NUMBER: 08/440,517
; EARLIER FILING DATE: 1995-05-12
; EARLIER APPLICATION NUMBER: 08/242,090
; EARLIER FILING DATE: 1994-05-12
; EARLIER APPLICATION NUMBER: 08/060,944
; EARLIER FILING DATE: 1993-05-12
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 222
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: rice expansin
; NAME/KEY: UNSURE
; LOCATION: (14)..(58)
; OTHER INFORMATION: Xaa is unknown or other.
US-09-092-160-3

Query Match      58.7%; Score 37; DB 3; Length 222;
Best Local Similarity 66.7%; Pred. No. 1.5e+02;
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 WINNAVY 10
Db 5 WINAHATFY 13

RESULT 13
US-09-112-498A-9
; Sequence 9, Application US/09112498A
; Patent No. 6458928
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: MICROBIAL SWOLLENIN PROTEIN, DNA SEQUENCES
; TITLE OF INVENTION: ENCODING SUCH SWOLLENINS AND METHOD OF PRODUCING SUCH
; TITLE OF INVENTION: SWOLLENINS
; NUMBER OF SEQUENCES: 31
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
```

; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/112.498A  
; FILING DATE:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 98/14226  
; FILING DATE: 11-JUL-1997  
; APPLICATION NUMBER: US 08/893.766  
; FILING DATE: 11-JUL-1997  
; INFORMATION FOR SEQ ID NO: 9:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 233 amino acids  
; TYPE: amino acid  
; TOPOLOGY: unknown  
; MOLECULE TYPE: protein  
US-09-112-498A-9

Query Match 58.7%; Score 37; DB 4; Length 233;  
Best Local Similarity 66.7%; Pred. No. 1.6e+02;  
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 2 WINNNAVFY 10  
||| :|||  
Db 16 WINAHATFY 24

RESULT 14  
US-09-248-796A-16368  
; Sequence 16368, Application US/09248796A  
; Patent No. 6747137  
; GENERAL INFORMATION:  
; APPLICANT: Keith Weinstock et al  
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICANS  
; TITLE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS  
; FILE REFERENCE: 107196.132  
; CURRENT APPLICATION NUMBER: US/09/248.796A  
; CURRENT FILING DATE: 1999-02-12  
; PRIOR APPLICATION NUMBER: US 60/074,725  
; PRIOR FILING DATE: 1998-02-13  
; PRIOR APPLICATION NUMBER: US 60/096,409  
; PRIOR FILING DATE: 1998-08-13  
; NUMBER OF SEQ ID NOS: 28208  
; SEQ ID NO 16368  
; LENGTH: 769  
; TYPE: PRT  
; ORGANISM: Candida albicans  
US-09-248-796A-16368

Query Match 58.7%; Score 37; DB 4; Length 769;  
Best Local Similarity 55.6%; Pred. No. 5.5e+02;  
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 2 WINNNAVFY 10  
||| :|||  
Db 166 WINKNELY 174

RESULT 15  
US-09-543-681A-5732  
; Sequence 5732, Application US/09543681A  
; Patent No. 6605709  
; GENERAL INFORMATION:  
; APPLICANT: GARY BRETON  
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PROTEUS MIRABILIS  
; TITLE OF INVENTION: DIAGNOSTICS AND THERAPEUTICS  
; FILE REFERENCE: 2709.1002-001  
; CURRENT APPLICATION NUMBER: US/09/543.681A  
; CURRENT FILING DATE: 2000-04-05  
; PRIOR APPLICATION NUMBER: US 60/128,706  
; PRIOR FILING DATE: 1999-04-09  
; NUMBER OF SEQ ID NOS: 8344  
; SEQ ID NO 5732  
; LENGTH: 1272  
; TYPE: PRT

; ORGANISM: Proteus mirabilis  
US-09-543-681A-5732

Query Match 58.7%; Score 37; DB 4; Length 1272;  
Best Local Similarity 71.4%; Pred. No. 9.3e+02;  
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CWINNNA 7  
||| :|||  
Db 719 CWVNPNA 725

Search completed: October 20, 2005, 05:50:24  
Job time : 22 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 20, 2005, 07:25:13 ; Search time 164 Seconds  
(without alignments)  
23.583 Million cell updates/sec

Title: US-10-668-181-6

Perfect score: 63

Sequence: 1 CWINNNAVPY 10

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A\_Geneseq\_16Dec04:\*  
1: Geneseqp1980s:\*  
2: Geneseqp1990s:\*  
3: Geneseqp2000s:\*  
4: Geneseqp2001s:\*  
5: Geneseqp2002s:\*  
6: Geneseqp2003as:\*  
7: Geneseqp2003bs:\*  
8: Geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	63	100.0	328	4 AAM24057	Aam24057 Human EST
2	63	100.0	513	6 ABG73644	Abg73644 Human G-p
3	63	100.0	936	7 ADB80454	Adb80454 Ovarian c
4	63	100.0	936	7 Adn39172	Adn39172 Cancer/an
5	63	100.0	966	8 ADN88596	Adn88596 Human epi
6	63	100.0	967	7 ADB80452	Adb80452 Ovarian c
7	63	100.0	967	7 Adn39170	Adn39170 Cancer/an
8	63	100.0	979	8 ADN88599	Adn88599 Human epi
9	63	100.0	987	8 ADN88607	Adn88607 Human epi
10	63	100.0	993	7 ADB80450	Adb80450 Ovarian c
11	63	100.0	993	8 ADN88601	Adn88601 Human epi
12	63	100.0	995	8 ADN88609	Adn88609 Human epi
13	63	100.0	1000	7 ADB80458	Adb80458 Ovarian c
14	63	100.0	1000	7 Adn39168	Adn39168 Cancer/an
15	63	100.0	1001	8 ADN88605	Adn88605 Human epi
16	63	100.0	1001	8 ADN88603	Adn88603 Human epi
17	63	100.0	1013	3 AAB01247	Aab01247 Human HE6
18	63	100.0	1014	6 ABJ38840	Abj38840 Human G-p
19	63	100.0	1014	6 ABJ38832	Abj38832 Human epi
20	63	100.0	1014	6 ABP81971	Abp81971 Human G p
21	63	100.0	1014	6 ABR61472	AbR61472 Human sec
22	63	100.0	1014	7 ADB80456	Adb80456 Ovarian c
23	63	100.0	1014	7 Adn39174	Adn39174 Cancer/an
24	63	100.0	1014	7 Adn39529	Adn39529 Cancer/an
25	63	100.0	1014	7 Adn39492	Adn39492 Cancer/an

## ALIGNMENTS

## RESULT 1

AAM24057

ID AAM24057 standard; protein; 328 AA.

XX AC AAM24057;

XX 12-OCT-2001 (first entry)

XX DE Human EST encoded protein SEQ ID NO: 1582.

XX KW Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;

XX KW tomato; monkey; dog; sea urchin; expressed sequence tag; EST;

XX KW diagnostics; forensic test; gene mapping; genetic disorder; biodiversity; gene therapy; nutrition.

XX OS Homo sapiens.

XX PN WO200154477-A2.

XX PD 02-AUG-2001.

XX PF 25-JAN-2001; 2001WO-US002687.

XX PR 25-JAN-2000; 2000US-00491404.

XX PR 17-JUL-2000; 2000US-00617746.

XX PR 03-AUG-2000; 2000US-00631451.

XX PR 15-SEP-2000; 2000US-00663870.

XX PA (HYSE-) HYSEQ INC.

XX PI Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Asundi V;

XX PI Cao Y, Drmanac RA, Zhang J, Werhman T;

XX DR WPI; 2001-476164/51.

XX DR N-PSDB; AAH98716.

XX PT Isolated polypeptide for treatment of diseases, diagnostics, raising antibodies and research use.

XX PS Claim 20; Page 1081-1082; 1275pp; English.

XX CC The present invention provides the protein and coding sequences of novel proteins from a variety of organisms, including human, dog, cat, horse, cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea urchin and tomato. These were derived from expressed sequence tags (ESTs) from the organism of interest. They can be used in diagnostics, forensics, gene mapping, identification of mutations, to assess biodiversity and for nutritional purposes. The present sequence is a

Adp03579 Human GPC  
Ado29079 Human nov  
Adq19636 Human sof  
Adq09616 Human G p  
Adn88592 Human epi  
Adn88597 Human epi  
Adn88598 Human epi  
Aaw36903 Human epi  
Adn88606 Human epi  
Adn88600 Human epi  
Adn88608 Human epi  
Adn88604 Human epi  
Adn88602 Human epi  
Adn88610 Human epi  
Adf70415 Orphan re  
Aau99588 Human G p  
Adn88617 Mouse epi  
Adn88613 Mouse epi  
Adn88616 Mouse epi  
Adn88615 Mouse epi

26 63 100.0 1014 7 ADP03579  
27 63 100.0 1014 8 ADO29079  
28 63 100.0 1014 8 ADQ19636  
29 63 100.0 1014 8 ADQ09616  
30 63 100.0 1017 8 ADN88592  
31 63 100.0 1020 8 ADN88597  
32 63 100.0 1033 8 ADN88598  
33 63 100.0 1038 2 AAW36903  
34 63 100.0 1041 8 ADN88606  
35 63 100.0 1047 8 ADN88600  
36 63 100.0 1049 8 ADN88608  
37 63 100.0 1055 8 ADN88604  
38 63 100.0 1057 8 ADN88602  
39 63 100.0 1071 8 ADN88610  
40 63 100.0 1252 7 ADF70415  
41 54 85.7 717 5 AAU99588  
42 54 85.7 982 8 ADN88617  
43 54 85.7 993 8 ADN88613  
44 54 85.7 1005 8 ADN88616  
45 54 85.7 1006 8 ADN88615

CC protein of the invention  
 XX Sequence 328 AA;  
 SQ Query Match 100.0%; Score 63; DB 4; Length 328;  
 Best Local Similarity 100.0%; Pred. No. 0.055;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
 DB 89 CWINNAVY 98  
 |||||

RESULT 2  
 ABG73644  
 ID ABG73644 standard; protein; 513 AA.  
 XX AC ABG73644;  
 XX DT 11-MAR-2003 (first entry)  
 XX DE Human G-protein coupled receptor associated protein SEQ ID 4.  
 XX KW G-protein coupled receptor; secretin receptor subfamily; human; GPCR;  
 KW protease; Parkinson's disease; receptor.  
 XX OS Homo sapiens.  
 XX US2002142951-A1.  
 XX PN 03-OCT-2002.  
 XX PD 28-MAR-2001; 2001US-00818264.  
 XX PF 28-MAR-2001; 2001US-00818264.  
 XX PR 28-MAR-2001; 2001US-00818264.  
 XX PA (WEBS/) WEBSTER M.  
 PA (BEAS/) BEASLEY E M.  
 PA (KETCH/) KETCHUM K A.  
 PA (DFRA/) DI FRANCESCO V.  
 XX PI Webster M, Beasley EM, Ketchum KA, Di Francesco V;  
 XX WPI; 2003-138646/13.  
 XX PT New human protease peptides, useful for preparing a composition for  
 PT treating a disease or condition mediated by human proteases e.g.  
 PT Parkinson's disease.  
 XX PS Disclosure; Fig 2; 84pp; English.

CC This invention describes a novel human G-protein coupled receptor, its  
 CC allelic variants, orthologs or fragments of the polypeptide. The  
 CC invention also describes (1) an isolated antibody that selectively binds  
 CC to the peptide; (2) an isolated nucleic acid comprising a sequence or its  
 CC complement that hybridizes under stringent conditions to the opposite  
 CC strand of the sequence encoding the protease or its allelic variant;  
 CC ortholog or fragment; (3) a gene chip comprising the isolated nucleic  
 CC acid of (2); (4) a transgenic non-human animal comprising the isolated  
 CC nucleic acid of (2); (5) a vector comprising the isolated nucleic acid of  
 CC (2); (6) a host cell containing the vector of (5); (7) a method for  
 CC producing the novel peptide; (8) detecting the presence of the novel  
 CC peptide or nucleic acid of (2) in a sample; (9) identifying a modulator  
 CC of, or an agent that binds to, the novel peptide; (10) a pharmaceutical  
 CC composition comprising the agent that binds to the novel peptide and a  
 CC carrier; (11) treating a disease or condition mediated by human proteases  
 CC; (12) identifying a modulator of the expression of the novel peptide;  
 CC and (13) an isolated human protease peptide having a sequence that shares  
 CC at least 70 % homology with the protease described in the invention. The  
 CC product of the invention can be used in gene therapy or for preparing a  
 CC composition for treating a disease or condition mediated by a human  
 CC protease protein e.g. Parkinson's disease. This sequence represents a  
 CC protein associated with the human G-protein coupled receptor (GPCR)

CC related to the secretin receptor subfamily, described in the disclosure  
 CC of the invention  
 XX Sequence 513 AA;  
 SQ Query Match 100.0%; Score 63; DB 6; Length 513;  
 Best Local Similarity 100.0%; Pred. No. 0.089;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
 DB 379 CWINNAVY 388  
 |||||

RESULT 3  
 ADB80454  
 ID ADB80454 standard; protein; 936 AA.  
 XX AC ADB80454;  
 XX DT 04-DEC-2003 (first entry)  
 XX DE Ovarian cancer-associated protein #9.  
 XX KW cytostatic; gene therapy; vaccine; ovarian cancer; diagnosis;  
 KW post-operative chemotherapy; radiation therapy; tumour prognosis;  
 KW pre-cancerous lesion detection.  
 XX OS Homo sapiens.  
 XX WO2002102235-A2.  
 XX PD 27-DEC-2002.  
 XX PF 18-JUN-2002; 2002WO-US019297.  
 XX PR 18-JUN-2001; 2001US-0299234P.  
 PR 27-AUG-2001; 2001US-0315287P.  
 PR 05-SEP-2001; 2001US-0317544P.  
 PR 13-NOV-2001; 2001US-0350666P.  
 PR 12-APR-2002; 2002US-0372246P.  
 XX PA (EOSB-) EOS BIOTECHNOLOGY INC.  
 XX PI Mack DH, Gish KC;  
 XX WPI; 2003-167431/16.  
 XX DR N-PSDB; ADB80453.  
 XX PT Detecting an ovarian cancer-associated transcript in a cell from a  
 PT patient, comprises contacting a biological sample from the patient with a  
 PT polynucleotide that hybridizes to an ovarian cancer gene.  
 XX PS Claim 13; Page 280; 332pp; English.

CC The invention relates to a method of detecting an ovarian cancer-  
 CC associated transcript in a cell from a patient, by contacting a  
 CC biological sample from the patient with a polynucleotide that selectively  
 CC hybridizes to a sequence at least 80% identical to any of 80  
 CC nucleic acid sequences given in the specification. The method is useful  
 CC in diagnosing ovarian cancer and in identifying and using agents and/or  
 CC targets that inhibit ovarian cancer. The nucleic acid molecule,  
 CC polypeptide and the antibody may also be used in detecting ovarian  
 CC cancers, monitoring and early detection of relapse following treatment,  
 CC monitoring response to therapy, selecting patients for post-operative  
 CC chemotherapy or radiation therapy, in selecting mode of therapy,  
 CC determining tumour prognosis, early detection of pre-cancerous lesions,  
 CC and as vaccines. This sequence corresponds to one of the proteins used  
 CC for the detection method of the invention.

XX Sequence 936 AA;  
 SQ Query Match 100.0%; Score 63; DB 7; Length 936;



Best Local Similarity 100.0%; Pred. No. 0.17; Mismatches 0; Indels 0; Gaps 0;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10  
Db 748 CWINNNAVY 757

RESULT 4  
ADN39172  
ID ADN39172 standard; protein; 936 AA.  
XX AC ADN39172;  
XX 17-JUN-2004 (first entry)  
XX DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:490.  
XX KW Human; differential expression; cancer; angiogenic disorder;  
KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;  
KW inflammatory disease; autoimmune disease;  
KW retinal neovascularisation syndrome; scarring; uterine fibroid;  
KW detection; diagnosis; prognosis; drug screening; drug targeting;  
KW wound healing; contraception; cytostatic; cardiac; immunomodulatory;  
KW vulnery; gene therapy; vaccine.  
XX OS Homo sapiens.  
XX PN WO2003042661-A2.  
XX PD 22-MAY-2003.  
XX PF 13-NOV-2002; 2002WO-US036810.  
XX PR 13-NOV-2001; 2001US-0350666P.  
PR 21-NOV-2001; 2001US-0332464P.  
PR 29-NOV-2001; 2001US-0334393P.  
PR 03-DEC-2001; 2001US-0335394P.  
PR 14-DEC-2001; 2001US-0340376P.  
PR 08-JAN-2002; 2002US-0347211P.  
PR 10-JAN-2002; 2002US-0347349P.  
PR 08-FEB-2002; 2002US-035250P.  
PR 13-FEB-2002; 2002US-0356714P.  
PR 20-FEB-2002; 2002US-0359077P.  
PR 29-MAR-2002; 2002US-0368809P.  
PR 04-APR-2002; 2002US-0370110P.  
PR 12-APR-2002; 2002US-0372246P.  
PR 05-JUN-2002; 2002US-0386614P.  
PR 16-JUL-2002; 2002US-0396839P.  
PR 22-JUL-2002; 2002US-0397775P.  
PR 22-JUL-2002; 2002US-0397845P.  
PR 09-SEP-2002; 2002US-0409450P.  
XX PA (BOSB-) EOS BIOTECHNOLOGY INC.  
XX PF Afar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevezi PA;  
PI Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;  
XX WPI; 2003-468649/44.  
XX N-PSDB; ADN39171.  
XX Determining the presence or absence of a pathological cell in a patient,  
PT useful for diagnosing, prognosing or treating cancer, comprises detecting  
PT a nucleic acid in a biological sample.  
XX Claim 12; SEQ ID NO 490; 1385pp; English.  
XX The invention relates to nucleic acids and proteins (ADN38683-ADN40064)  
CC whose expression is upregulated or downregulated in specific cancers or  
CC other diseases such as angiogenic or fibrotic disorders, and to methods  
CC of determining the presence or absence of a pathological cell in a  
CC patient by detecting a nucleic acid at least 80% identical to those of  
CC the invention or by detecting a polypeptide of the invention. The

CC invention also relates to expression vectors and host cells comprising a  
CC nucleic acid of the invention; antibodies which specifically bind a  
CC polypeptide of the invention; use of such antibodies for drug targeting;  
CC and methods of screening for modulators of activity or expression of the  
CC polypeptides and nucleic acids. The nucleic acids, polypeptides, and  
CC antibodies and methods are useful for diagnosing, prognosing and treating  
CC cancer and other conditions such as psoriasis, ischaemia, heart disease,  
CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal  
CC neovascularisation syndromes, scarring and uterine fibroids. They may  
CC also be useful in wound healing and in contraception. The present  
CC sequence represents a polypeptide of the invention.  
XX SQ Sequence 936 AA;  
Query Match 100.0%; Score 63; DB 7; Length 936;  
Best Local Similarity 100.0%; Pred. No. 0.17; Mismatches 0; Indels 0; Gaps 0;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10  
Db 748 CWINNNAVY 757

RESULT 5  
ADN88596  
ID ADN88596 standard; protein; 966 AA.  
XX AC ADN88596;  
XX 29-JUL-2004 (first entry)  
XX DE Human epididymis-specific receptor protein-6 delta 24 (HE6delta24) #1.  
XX KW Human epididymis-specific receptor protein-6; HE6;  
KW male reproductive disorder; infertility; antifertility; contraceptive;  
KW human epididymis-specific receptor protein-6 delta 24; HE6delta24;  
XX mutant; muten; receptor.  
XX OS Homo sapiens.  
XX OS Synthetic.  
XX PN WO2004037860-A1.  
XX PD 06-MAY-2004.  
XX PF 21-OCT-2003; 2003WO-EP011662.  
XX PR 22-OCT-2002; 2002US-0419979P.  
XX PA (SCHD ) SCHERING AG.  
XX PI Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
PI Gottwald U, Nubbemeyer R;  
XX WPI; 2004-357427/33.  
XX N-PSDB; ADN88595.  
XX Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
PT polypeptide, useful for isolating agents used for treating male  
PT infertility, or for male contraception.  
XX Claim 55; SEQ ID NO 34; 127pp; English.  
XX The invention relates to the human epididymis-specific receptor protein-6  
CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)  
CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
CC polypeptide. The invention also relates to an antibody or its fragment  
CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
CC composition comprising an antiserum nucleotide which can bind with any of  
CC the nucleotide sequences encoding an epididymis-specific receptor protein  
CC -6 of the invention, a pharmaceutical composition for treating a male  
CC reproductive disorder comprising a polynucleotide of the invention, a  
CC method of diagnosing infertility in a male mammal and a method of

CC treating infertility in a male mammal. The polynucleotides encoding the  
 CC polypeptides are useful for isolating an agent that modulates expression  
 CC or activity of the polypeptides. The sequences are useful for diagnosing  
 CC a male reproductive disorder. This sequence represents an HB6delta24  
 CC mutant polypeptide of the invention.  
 XX  
 SQ Sequence 966 AA;

Query Match 100.0%; Score 63; DB 8; Length 966;  
 Best Local Similarity 100.0%; Pred. No. 0.18;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNNAVY 10  
 |||||  
 Db 778 CWINNNNAVY 787

RESULT 6  
 ADB80452  
 ID ADB80452 standard; protein; 967 AA.  
 XX  
 AC ADB80452;  
 XX  
 DT 04-DEC-2003 (first entry)  
 XX  
 DE Ovarian cancer-associated protein #8.  
 XX  
 KW cytostatic; gene therapy; vaccine; ovarian cancer; diagnosis;  
 KW post-operative chemotherapy; radiation therapy; tumour prognosis;  
 KW pre-cancerous lesion detection.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2002102235-A2.  
 XX  
 PD 27-DEC-2002.  
 XX  
 PF 18-JUN-2002; 2002WO-US019297.  
 XX  
 PR 18-JUN-2001; 2001US-0299234P.  
 PR 27-AUG-2001; 2001US-0315287P.  
 PR 05-SEP-2001; 2001US-0317544P.  
 PR 13-NOV-2001; 2001US-0350666P.  
 PR 12-APR-2002; 2002US-0372246P.  
 XX  
 PA (EOSB-) EOS BIOTECHNOLOGY INC.  
 XX  
 PI Mack DH, Gish KC;  
 XX  
 DR WPI: 2003-167431/16.  
 DR N-PSDB; ADB80451.  
 XX  
 PT Detecting an ovarian cancer-associated transcript in a cell from a  
 PT patient, comprises contacting a biological sample from the patient with a  
 PT polynucleotide that hybridizes to an ovarian cancer gene.  
 XX  
 PS Claim 13; Page 279; 332pp; English.  
 XX

CC The invention relates to a method of detecting an ovarian cancer-  
 CC associated transcript in a cell from a patient, by contacting a  
 CC biological sample from the patient with a polynucleotide that selectively  
 CC hybridizes to a sequence at least 80% identical to any of one of 80  
 CC nucleic acid sequences given in the specification. The method is useful  
 CC in diagnosing ovarian cancer and in identifying and using agents and/or  
 CC targets that inhibit ovarian cancer. The nucleic acid molecule,  
 CC polypeptide and the antibody may also be used in detecting ovarian  
 CC cancers, monitoring and early detection of relapse following treatment,  
 CC monitoring response to therapy, selecting patients for post-operative  
 CC chemotherapy or radiation therapy, in selecting mode of therapy,  
 CC determining tumour prognosis, early detection of pre-cancerous lesions,  
 CC and as vaccines. This sequence corresponds to one of the proteins used  
 CC for the detection method of the invention.  
 XX

SQ Sequence 967 AA;  
 Query Match 100.0%; Score 63; DB 7; Length 967;  
 Best Local Similarity 100.0%; Pred. No. 0.18;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNNNAVY 10  
 |||||  
 Db 728 CWINNNNAVY 737  
 RESULT 7  
 ADN39170  
 ID ADN39170 standard; protein; 967 AA.  
 XX  
 AC ADN39170;  
 XX  
 DT 17-JUN-2004 (first entry)  
 XX  
 DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:488.  
 XX  
 KW Human; differential expression; cancer; angiogenic disorder;  
 KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;  
 KW inflammatory disease; autoimmune disease;  
 KW retinal neovascularisation syndrome; scarring; uterine fibroid;  
 KW detection; diagnosis; prognosis; drug screening; drug targeting;  
 KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;  
 KW vulnary; gene therapy; vaccine.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003042661-A2.  
 XX  
 PD 22-MAY-2003.  
 XX  
 PF 13-NOV-2002; 2002WO-US036810.  
 XX  
 PR 13-NOV-2001; 2001US-0350666P.  
 PR 21-NOV-2001; 2001US-0332464P.  
 PR 29-NOV-2001; 2001US-0334393P.  
 PR 03-DEC-2001; 2001US-0335394P.  
 PR 14-DEC-2001; 2001US-0340376P.  
 PR 08-JAN-2002; 2002US-0347211P.  
 PR 10-JAN-2002; 2002US-0347349P.  
 PR 08-FEB-2002; 2002US-0355250P.  
 PR 13-FEB-2002; 2002US-0356714P.  
 PR 20-FEB-2002; 2002US-0359077P.  
 PR 29-MAR-2002; 2002US-0368099P.  
 PR 04-APR-2002; 2002US-0370110P.  
 PR 12-APR-2002; 2002US-0372246P.  
 PR 05-JUN-2002; 2002US-0386614P.  
 PR 16-JUL-2002; 2002US-0396839P.  
 PR 22-JUL-2002; 2002US-039775P.  
 PR 22-JUL-2002; 2002US-0397845P.  
 PR 09-SEP-2002; 2002US-0409450P.  
 XX  
 PA (EOSB-) EOS BIOTECHNOLOGY INC.  
 XX  
 PI Afar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevesi PA;  
 PI Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;  
 XX  
 DR WPI: 2003-468649/44.  
 DR N-PSDB; ADN39169.  
 XX  
 PT Determining the presence or absence of a pathological cell in a patient,  
 PT useful for diagnosing, prognosing or treating cancer, comprises detecting  
 PT a nucleic acid in a biological sample.  
 XX  
 PS Claim 12; SEQ ID NO 488; 1385pp; English.  
 XX  
 CC The invention relates to nucleic acids and proteins (ADN39683-ADN40064)  
 CC whose expression is upregulated or downregulated in specific cancers or  
 CC other diseases such as angiogenic or fibrotic disorders, and to methods

CC of determining the presence or absence of a pathological cell in a  
 CC patient by detecting a nucleic acid at least 80% identical to those of  
 CC the invention or by detecting a polypeptide of the invention. The  
 CC invention also relates to expression vectors and host cells comprising a  
 CC nucleic acid of the invention; antibodies which specifically bind a  
 CC polypeptide of the invention; use of such antibodies for drug targeting;  
 CC and methods of screening for modulators of activity or expression of the  
 CC polypeptides and nucleic acids. The nucleic acids, polypeptides,  
 CC antibodies and methods are useful for diagnosing, prognosing and treating  
 CC cancer and other conditions such as psoriasis, ischaemia, heart disease,  
 CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal  
 CC neovascularisation syndromes, scarring and uterine fibroids. They may  
 CC also be useful in wound healing and in contraception. The present  
 CC sequence represents a polypeptide of the invention.  
 XX  
 SQ Sequence 967 AA;

Query Match 100.0%; Score 63; DB 7; Length 967;  
 Best Local Similarity 100.0%; Pred. No. 0.18;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
 |||||  
 Db 728 CWINNAVY 737

## RESULT 8

ADN88599  
 ID ADN88599 standard; protein; 979 AA.

XX AC ADN88599;

DT 29-JUL-2004 (first entry)

DE Human epididymis-specific receptor protein-6 (HE6) polypeptide #3.

KW Human epididymis-specific receptor protein-6; HE6;  
 KW male reproductive disorder; infertility; antiinfertility; contraceptive;  
 KW receptor.

XX OS Homo sapiens.

XX PN WO2004037860-A1.

XX PD 06-MAY-2004.

XX PF 21-OCT-2003; 2003WO-EP011662.

XX PR 22-OCT-2002; 2002US-0419979P.

XX PS (SCHD ) SCHERING AG.

XX PI Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
 PI Gottwald U, Nubbemeyer R;

XX DR WPI; 2004-357427/33.

XX DR N-PSDB; ADN88578.

XX PT Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
 PT polypeptide, useful for isolating agents used for treating male  
 PT infertility, or for male contraception.

XX PS Claim 59; SEQ ID NO 37; 127pp; English.

XX CC The invention relates to the human epididymis-specific receptor protein-6  
 CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)  
 CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
 CC polypeptide. The invention also relates to an antibody or its fragment  
 CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
 CC composition comprising an antisense nucleotide which can bind with any of  
 CC the nucleotide sequences encoding an epididymis-specific receptor protein  
 CC -6 of the invention, a pharmaceutical composition for treating a male  
 CC reproductive disorder comprising a polynucleotide of the invention, a

CC method of diagnosing infertility in a male mammal and a method of  
 CC treating infertility in a male mammal. The polynucleotides encoding the  
 CC polypeptides are useful for isolating an agent that modulates expression  
 CC or activity of the polypeptides. The sequences are useful for diagnosing  
 CC a male reproductive disorder. This sequence represents an HE6 polypeptide  
 CC of the invention.

XX SQ Sequence 979 AA;

Query Match 100.0%; Score 63; DB 8; Length 979;  
 Best Local Similarity 100.0%; Pred. No. 0.18;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
 |||||  
 Db 740 CWINNAVY 749

## RESULT 9

ADN88607  
 ID ADN88607 standard; protein; 987 AA.

XX AC ADN88607;

XX DT 29-JUL-2004 (first entry)

XX DE Human epididymis-specific receptor protein-6 (HE6) polypeptide #11.

KW Human epididymis-specific receptor protein-6; HE6;  
 KW male reproductive disorder; infertility; antiinfertility; contraceptive;  
 KW receptor.

XX OS Homo sapiens.

XX PN WO2004037860-A1.

XX PD 06-MAY-2004.

XX PF 21-OCT-2003; 2003WO-EP011662.

XX PR 22-OCT-2002; 2002US-0419979P.

XX PS (SCHD ) SCHERING AG.

XX PI Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
 PI Gottwald U, Nubbemeyer R;

XX DR WPI; 2004-357427/33.

XX DR N-PSDB; ADN88582.

XX PT Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
 PT polypeptide, useful for isolating agents used for treating male  
 PT infertility, or for male contraception.

XX PS Claim 58; SEQ ID NO 45; 127pp; English.

XX CC The invention relates to the human epididymis-specific receptor protein-6  
 CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)  
 CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
 CC polypeptide. The invention also relates to an antibody or its fragment  
 CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
 CC composition comprising an antisense nucleotide which can bind with any of  
 CC the nucleotide sequences encoding an epididymis-specific receptor protein  
 CC -6 of the invention, a pharmaceutical composition for treating a male  
 CC reproductive disorder comprising a polynucleotide of the invention, a  
 CC method of diagnosing infertility in a male mammal and a method of  
 CC treating infertility in a male mammal. The polynucleotides encoding the  
 CC polypeptides are useful for isolating an agent that modulates expression  
 CC or activity of the polypeptides. The sequences are useful for diagnosing  
 CC a male reproductive disorder. This sequence represents an HE6 polypeptide  
 CC of the invention.

XX SQ Sequence 987 AA;

Query Match 100.0%; Score 63; DB 8; Length 987;  
Best Local Similarity 100.0%; Pred. No. 0.18; 0; Indels 0; Gaps 0;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
DB 748 CWINNAVY 757  
|||||

RESULT 10  
ADB80450  
ID ADB80450 standard; protein; 993 AA.  
XX  
AC ADB80450;  
XX  
DT 04-DEC-2003 (first entry)  
XX  
DE Ovarian cancer-associated protein #7.  
XX  
KW cytostatic; gene therapy; vaccine; ovarian cancer; diagnosis;  
KW post-operative chemotherapy; radiation therapy; tumour prognosis;  
KW pre-cancerous lesion detection.  
XX  
OS Homo sapiens.  
XX  
FN WO2002102235-A2.  
XX  
PD 27-DEC-2002.  
XX  
PF 18-JUN-2002; 2002WO-US019297.  
XX  
PR 18-JUN-2001; 2001US-0299234P.  
PR 27-AUG-2001; 2001US-0315287P.  
PR 05-SEP-2001; 2001US-0317544P.  
PR 13-NOV-2001; 2001US-0350666P.  
PR 12-APR-2002; 2002US-0372246P.  
XX  
PA (EOSB-) EOS BIOTECHNOLOGY INC.  
XX  
PI Mack DH, Gish KC;  
XX  
DR WPI; 2003-167431/16.  
DR N-PSDB; ADB80449.  
XX  
PT Detecting an ovarian cancer-associated transcript in a cell from a  
PT patient, comprises contacting a biological sample from the patient with a  
PT polynucleotide that hybridizes to an ovarian cancer gene.  
XX  
PS Claim 13; Page 278; 332pp; English.  
XX  
CC The invention relates to a method of detecting an ovarian cancer-  
CC associated transcript in a cell from a patient, by contacting a  
CC biological sample from the patient with a polynucleotide that selectively  
CC hybridizes to a sequence at least 80% identical to any of one of 80  
CC nucleic acid sequences given in the specification. The method is useful  
CC in diagnosing ovarian cancer and in identifying and using agents and/or  
CC targets that inhibit ovarian cancer. The nucleic acid molecule,  
CC polypeptide and the antibody may also be used in detecting ovarian  
CC cancers, monitoring and early detection of relapse following treatment,  
CC monitoring response to therapy, selecting patients for post-operative  
CC chemotherapy or radiation therapy, in selecting mode of therapy,  
CC determining tumour prognosis, early detection of pre-cancerous lesions,  
CC and as vaccines. This sequence corresponds to one of the proteins used  
CC for the detection method of the invention.  
XX  
SQ Sequence 993 AA;

Query Match 100.0%; Score 63; DB 7; Length 993;  
Best Local Similarity 100.0%; Pred. No. 0.18; 0; Indels 0; Gaps 0;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
DB 748 CWINNAVY 757  
|||||

RESULT 12  
ADB88609  
ID ADB88609 standard; protein; 995 AA.  
XX

Db 754 CWINNAVY 763  
|||||

RESULT 11  
ADN88601  
ID ADN88601 standard; protein; 993 AA.  
XX  
AC ADN88601;  
XX  
DT 29-JUL-2004 (first entry)  
XX  
DE Human epididymis-specific receptor protein-6 (HE6) polypeptide #5.  
XX  
KW Human epididymis-specific receptor protein-6; HE6;  
KW male reproductive disorder; infertility; antifertility; contraceptive;  
KW receptor.  
XX  
OS Homo sapiens.  
XX  
FN WO2004037860-A1.  
XX  
PD 06-MAY-2004.  
XX  
PF 21-OCT-2003; 2003WO-EP011662.  
XX  
PR 22-OCT-2002; 2002US-0419979P.  
XX  
PA (SCHD) SCHERING AG.  
XX  
PI Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
PI Gottwald U, Nubbemeyer R;  
XX  
DR WPI; 2004-357427/33.  
DR N-PSDB; ADN88579.  
XX  
PT Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
PT polypeptide, useful for isolating agents used for treating male  
PT infertility, or for male contraception.  
XX  
PS Claim 58; SEQ ID NO 39; 127pp; English.  
XX  
CC The invention relates to the human epididymis-specific receptor protein-6  
CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)  
CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
CC polypeptide. The invention also relates to an antibody or its fragment  
CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
CC composition comprising an antisense nucleotide which can bind with any of  
CC the nucleotide sequences encoding an epididymis-specific receptor protein  
CC -6 of the invention, a pharmaceutical composition for treating a male  
CC reproductive disorder comprising a polynucleotide of the invention, a  
CC method of diagnosing infertility in a male mammal and a method of  
CC treating infertility in a male mammal. The polynucleotides encoding the  
CC polypeptides are useful for isolating an agent that modulates expression  
CC or activity of the polypeptides. The sequences are useful for diagnosing  
CC a male reproductive disorder. This sequence represents an HE6 polypeptide  
CC of the invention.  
XX  
SQ Sequence 993 AA;

Query Match 100.0%; Score 63; DB 8; Length 993;  
Best Local Similarity 100.0%; Pred. No. 0.18; 0; Indels 0; Gaps 0;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVY 10  
DB 754 CWINNAVY 763  
|||||

RESULT 12  
ADN88609  
ID ADN88609 standard; protein; 995 AA.  
XX

AC ADN88609;  
 XX 29-JUL-2004 (first entry)  
 XX Human epididymis-specific receptor protein-6 (HE6) polypeptide #13.  
 DE  
 XX Human epididymis-specific receptor protein-6; HE6;  
 KW male reproductive disorder; infertility; antiinfertility; contraceptive;  
 KW receptor.  
 KW  
 XX Homo sapiens.  
 OS  
 XX WO2004037860-A1.  
 PN  
 XX 06-MAY-2004.  
 PD  
 XX  
 XX 21-OCT-2003; 2003WO-EP011662.  
 PF  
 XX 22-OCT-2002; 2002US-0419979P.  
 PR  
 XX (SCHD ) SCHERING AG.  
 PA  
 XX Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
 PI Gottwald U, Nubbemeyer R;  
 PI  
 XX WPI; 2004-357427/33.  
 DR  
 XX N-PSDB; ADN88583.  
 DR  
 XX Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
 PT polypeptide, useful for isolating agents used for treating male  
 PT infertility, or for male contraception.  
 PT  
 XX Claim 58; SEQ ID NO 47; 127pp; English.  
 XX  
 XX The invention relates to the human epididymis-specific receptor protein-6  
 CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)  
 CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
 CC polypeptide. The invention also relates to an antibody or its fragment  
 CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
 CC composition comprising an antisense nucleotide which can bind with any of  
 CC the nucleotide sequences encoding an epididymis-specific receptor protein  
 CC -6 of the invention, a pharmaceutical composition for treating a male  
 CC reproductive disorder comprising a polynucleotide of the invention, a  
 CC method of diagnosing infertility in a male mammal and a method of  
 CC treating infertility in a male mammal. The polynucleotides encoding the  
 CC polypeptides are useful for isolating an agent that modulates expression  
 CC or activity of the polypeptides. The sequences are useful for diagnosing  
 CC a male reproductive disorder. This sequence represents an HE6 polypeptide  
 CC of the invention.  
 XX  
 SQ Sequence 995 AA;  
 Query Match 100.0%; Score 63; DB 8; Length 995;  
 Best Local Similarity 100.0%; Pred. No. 0.18;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNNAVY 10  
 DB |||||||||  
 756 CWINNNAVY 765  
 RESULT 13  
 ADN80458  
 ID ADB80458 standard; protein; 1000 AA.  
 XX  
 AC ADB80458;  
 XX  
 DT 04-DEC-2003 (first entry)  
 XX  
 DE Ovarian cancer-associated protein #11.  
 XX cytostatic; gene therapy; vaccine; ovarian cancer; diagnosis;  
 KW post-operative chemotherapy; radiation therapy; tumour prognosis;

KW pre-cancerous lesion detection.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2002102235-A2.  
 XX  
 PD 27-DEC-2002.  
 XX  
 XX 18-JUN-2002; 2002WO-US019297.  
 PF  
 XX 18-JUN-2001; 2001US-0299234P.  
 PR 27-AUG-2001; 2001US-0315287P.  
 PR 05-SEP-2001; 2001US-0317544P.  
 PR 13-NOV-2001; 2001US-0350666P.  
 PR 12-APR-2002; 2002US-0372246P.  
 XX  
 XX (EOSB-) EOS BIOTECHNOLOGY INC.  
 XX  
 XX Mack DH, Gish KC;  
 PI  
 XX WPI; 2003-167431/16.  
 DR N-PSDB; ADB80457.  
 DR  
 XX Detecting an ovarian cancer-associated transcript in a cell from a  
 PT patient, comprises contacting a biological sample from the patient with a  
 PT polynucleotide that hybridizes to an ovarian cancer gene.  
 PT  
 XX Claim 13; Page 282; 332pp; English.  
 PS  
 XX The invention relates to a method of detecting an ovarian cancer-  
 CC associated transcript in a cell from a patient, by contacting a  
 CC biological sample from the patient with a polynucleotide that selectively  
 CC hybridizes to a sequence at least 80% identical to any of one of 80  
 CC nucleic acid sequences given in the specification. The method is useful  
 CC in diagnosing ovarian cancer and in identifying and using agents and/or  
 CC targets that inhibit ovarian cancer. The nucleic acid molecule,  
 CC polypeptide and the antibody may also be used in detecting ovarian  
 CC cancers, monitoring and early detection of relapse following ovarian  
 CC monitoring response to therapy, selecting patients for post-operative  
 CC chemotherapy or radiation therapy, in selecting mode of therapy,  
 CC determining tumour prognosis, early detection of pre-cancerous lesions,  
 CC and as vaccines. This sequence corresponds to one of the proteins used  
 CC for the detection method of the invention.  
 XX  
 SQ Sequence 1000 AA;  
 Query Match 100.0%; Score 63; DB 7; Length 1000;  
 Best Local Similarity 100.0%; Pred. No. 0.18;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNNAVY 10  
 DB |||||||||  
 761 CWINNNAVY 770  
 RESULT 14  
 ADN39168  
 ID ADN39168 standard; protein; 1000 AA.  
 XX  
 AC ADN39168;  
 XX  
 XX 17-JUN-2004 (first entry)  
 DT  
 XX Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:486.  
 DE  
 XX Human; differential expression; cancer; angiogenic disorder;  
 KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;  
 KW inflammatory disease; autoimmune disease;  
 KW retinal neovascularisation syndrome; scarring; uterine fibroid;  
 KW detection; diagnosis; prognosis; drug screening; drug targeting;  
 KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;  
 KW vulnery; gene therapy; vaccine.  
 XX

OS Homo sapiens.  
 XX WO2003042661-A2.  
 XX 22-MAY-2003.  
 XX 13-NOV-2002; 2002WO-US036810.  
 XX 13-NOV-2001; 2001US-0350666P.  
 PR 21-NOV-2001; 2001US-0332464P.  
 PR 29-NOV-2001; 2001US-0334393P.  
 PR 03-DEC-2001; 2001US-0335394P.  
 PR 14-DEC-2001; 2001US-0340376P.  
 PR 08-JAN-2002; 2002US-0347211P.  
 PR 10-JAN-2002; 2002US-0347349P.  
 PR 08-FEB-2002; 2002US-0355250P.  
 PR 13-FEB-2002; 2002US-0356714P.  
 PR 20-FEB-2002; 2002US-0359077P.  
 PR 29-MAR-2002; 2002US-036809P.  
 PR 04-APR-2002; 2002US-0370110P.  
 PR 12-APR-2002; 2002US-0372246P.  
 PR 05-JUN-2002; 2002US-0386614P.  
 PR 16-JUL-2002; 2002US-0396839P.  
 PR 22-JUL-2002; 2002US-0397775P.  
 PR 22-JUL-2002; 2002US-0397845P.  
 PR 09-SEP-2002; 2002US-0409450P.  
 XX (EOSB-) EOS BIOTECHNOLOGY INC.  
 XX Afar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevezi PA;  
 PI Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;  
 XX WPI: 2003-468649/44.  
 DR N-PSDB; ADN39167.  
 XX Determining the presence or absence of a pathological cell in a patient,  
 PT useful for diagnosing, prognosing or treating cancer, comprises detecting  
 PT a nucleic acid in a biological sample.  
 XX Claim 12; SEQ ID NO 486; 1395pp; English.  
 XX The invention relates to nucleic acids and proteins (ADN38683-ADN40064)  
 CC whose expression is upregulated or downregulated in specific cancers or  
 CC other diseases such as angiogenic or fibrotic disorders, and to methods  
 CC of determining the presence or absence of a pathological cell in a  
 CC patient by detecting a nucleic acid at least 80% identical to those of  
 CC the invention or by detecting a polypeptide of the invention. The  
 CC invention also relates to expression vectors and host cells comprising a  
 CC nucleic acid of the invention; antibodies which specifically bind a  
 CC polypeptide of the invention; use of such antibodies for drug targeting;  
 CC and methods of screening for modulators of activity or expression of the  
 CC polypeptides and nucleic acids. The nucleic acids, polypeptides,  
 CC antibodies and methods are useful for diagnosing, prognosing and treating  
 CC cancer and other conditions such as psoriasis, ischaemia, heart disease,  
 CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal  
 CC neovascularisation syndromes, scarring and uterine fibroids. They may  
 CC also be useful in wound healing and in contraception. The present  
 CC sequence represents a polypeptide of the invention.  
 XX Sequence 1000 AA;  
 SQ Query Match 100.0%; Score 63; DB 7; Length 1000;  
 Best Local Similarity 100.0%; Pred. No. 0.18; 0; Gaps 0;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNAVY 10  
 DB 761 CWINNAVY 770  
 RESULT 15  
 ADN88605  
 ID ADN88605 standard; protein; 1001 AA.

XX AC ADN88605;  
 XX 29-JUL-2004 (first entry)  
 XX Human epididymis-specific receptor protein-6 (HE6) polypeptide #9.  
 DE Human epididymis-specific receptor protein-6; HB6;  
 KW Human epididymis-specific receptor protein-6; HB6;  
 KW male reproductive disorder; infertility; antifertility; contraceptive;  
 KW receptor.  
 OS Homo sapiens.  
 PN WO2004037860-A1.  
 XX 06-MAY-2004.  
 XX 21-OCT-2003; 2003WO-EP011662.  
 XX 22-OCT-2002; 2002US-0419979P.  
 XX (SCHD ) SCHERING AG.  
 XX Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
 PI Gottwald U, Nubbemeyer R;  
 XX WPI: 2004-357427/33.  
 DR N-PSDB; ADN88581.  
 XX Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
 PT polypeptide, useful for isolating agents used for treating male  
 PT infertility, or for male contraception.  
 XX Claim 58; SEQ ID NO 43; 127pp; English.  
 XX The invention relates to the human epididymis-specific receptor protein-6  
 CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)  
 CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
 CC polypeptide. The invention also relates to an antibody or its fragment  
 CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
 CC composition comprising an antisense nucleotide which can bind with any of  
 CC the nucleotide sequences encoding an epididymis-specific receptor protein  
 CC -6 of the invention, a pharmaceutical composition for treating a male  
 CC reproductive disorder comprising a polynucleotide of the invention, a  
 CC method of diagnosing infertility in a male mammal and a method of  
 CC treating infertility in a male mammal. The polynucleotides encoding the  
 CC polypeptides are useful for isolating an agent that modulates expression  
 CC or activity of the polypeptides. The sequences are useful for diagnosing  
 CC a male reproductive disorder. This sequence represents an HE6 polypeptide  
 CC of the invention.  
 XX Sequence 1001 AA;  
 SQ Query Match 100.0%; Score 63; DB 8; Length 1001;  
 Best Local Similarity 100.0%; Pred. No. 0.18; 0; Gaps 0;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNAVY 10  
 DB 762 CWINNAVY 771  
 RESULT 16  
 ADN88603  
 ID ADN88603 standard; protein; 1003 AA.  
 XX AC ADN88603;  
 XX 29-JUL-2004 (first entry)  
 DE Human epididymis-specific receptor protein-6 (HE6) polypeptide #7.  
 XX Human epididymis-specific receptor protein-6; HB6;  
 KW Human epididymis-specific receptor protein-6; HB6;

KW male reproductive disorder; infertility; antiinfertility; contraceptive;  
 KW receptor.  
 XX Homo sapiens.  
 OS WO2004037860-A1.  
 PN XX  
 PD 06-MAY-2004.  
 XX  
 XX 21-OCT-2003; 2003WO-EP011662.  
 PF XX  
 XX 22-OCT-2002; 2002US-0419979P.  
 PR XX  
 XX (SCHD ) SCHERING AG.  
 PA  
 XX Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
 PI Gottwald U, Nubbemeyer R;  
 PI  
 XX WPI; 2004-357427/33.  
 DR N-PSDB; ADN88580.  
 DR  
 XX Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
 PT polypeptide, useful for isolating agents used for treating male  
 PT infertility, or for male contraception.  
 PT  
 XX Claim 58; SEQ ID NO 41; 127pp; English.  
 PS  
 XX The invention relates to the human epididymis-specific receptor protein-6  
 CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (M56)  
 CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
 CC polypeptide. The invention also relates to an antibody or its fragment  
 CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
 CC composition comprising an antisense nucleotide which can bind with any of  
 CC the nucleotide sequences encoding an epididymis-specific receptor protein  
 CC -6 of the invention, a pharmaceutical composition for treating a male  
 CC reproductive disorder comprising a polynucleotide of the invention, a  
 CC method of diagnosing infertility in a male mammal and a method of  
 CC treating infertility in a male mammal. The polynucleotides encoding the  
 CC polypeptides are useful for isolating an agent that modulates expression  
 CC or activity of the polypeptides. The sequences are useful for diagnosing  
 CC a male reproductive disorder. This sequence represents an HE6 polypeptide  
 CC of the invention.  
 XX  
 XX Sequence 1003 AA;  
 SQ  
 Query Match 100.0%; Score 63; DB 8; Length 1003;  
 Best Local Similarity 100.0%; Pred. No. 0.18;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNAVIFY 10  
 Db 764 CWINNAVIFY 773  
 |||||  
 RESULT 17  
 AAB01247  
 ID AAB01247 standard; protein; 1013 AA.  
 XX  
 AC AAB01247;  
 XX  
 XX 03-OCT-2000 (first entry)  
 DT  
 XX Human HE6 receptor.  
 DE  
 XX Human; HE6 receptor; zsig56; seven transmembrane domain receptor;  
 KW hypotensive; antitox; cytostatic; antiinflammatory; ion homeostasis;  
 KW cardiant; neurotransmitter; neuroprotective; antiparkinsonian;  
 KW cerebroprotective; nootropic; neuroleptic; tranquiliser; antiarthritic;  
 KW reproductive; signal transduction activator; bone disease; hypertension;  
 KW renal failure; heart failure; hyperthyroidism; hyperparathyroidism;  
 KW carcinoma; sarcoidosis; pancreatitis; stress; high blood pressure;  
 KW immune depression; periodontal disease; neurodegenerative disease;  
 KW multiple sclerosis, Alzheimer's disease; Parkinson's disease;

KW schizophrenia; manic depression; stroke; rheumatoid arthritis;  
 KW male fertility; spermatogenesis stimulation; pregnancy regulation;  
 KW prostate cancer.  
 XX Homo sapiens.  
 OS WO200034473-A2.  
 PN XX  
 PD 15-JUN-2000.  
 XX  
 XX 02-DEC-1999; 99WO-US028492.  
 PF XX  
 XX 10-DEC-1998; 98US-00208691.  
 PR XX  
 XX (ZYMO ) ZYMOGENETICS INC.  
 PA  
 XX Sheppard PO, Ellsworth JL;  
 PI  
 XX WPI; 2000-442164/38.  
 DR  
 XX Novel G-protein coupled receptor zsig56 useful for treating hypertension,  
 PT hyper and hypothyroidism, inflammation, gout, carcinoma, pancreatitis,  
 PT Alzheimer's disease and Parkinson's disease, renal and heart failure.  
 PT  
 XX Disclosure; Fig 1; 121pp; English.  
 PS  
 XX The present sequence is the human HE6 receptor, which shows homology to a  
 CC seven transmembrane domain receptor designated zsig56. The full length  
 CC nucleotide sequence was obtained from a human retina library. zsig56  
 CC polypeptides, nucleic acid, agonists and/or antagonists may be used to  
 CC treat a wide range of disorders including certain bone diseases,  
 CC hypertension, renal failure, gout, congestive heart failure,  
 CC hyperthyroidism, hyperparathyroidism, certain carcinomas, sarcoidosis and  
 CC pancreatitis. They can be used to treat disorders associated with changes  
 CC in ion or electrolyte homeostasis, and stress induced disorders such as  
 CC high blood pressure, heart failure, immune depression and periodontal  
 CC disease. They may be used to treat neurodegenerative diseases, including  
 CC multiple sclerosis, Alzheimer's disease and Parkinson's disease,  
 CC schizophrenia and manic depression, and to repair nerve tissue following  
 CC damage due to strokes and brain and spinal injuries. Inflammatory  
 CC disorders such as rheumatoid arthritis can also be treated. zsig56 is  
 CC expressed in tissues associated with reproduction, i.e. the testis,  
 CC prostate and placenta, and may be used to treat male fertility by  
 CC stimulating spermatogenesis and to regulate gestation and birth. zsig56  
 CC may be useful as a marker or therapeutic agent in the treatment of  
 CC prostate cancer  
 XX  
 XX Sequence 1013 AA;  
 SQ  
 Query Match 100.0%; Score 63; DB 3; Length 1013;  
 Best Local Similarity 100.0%; Pred. No. 0.19;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNAVIFY 10  
 Db 774 CWINNAVIFY 783  
 |||||  
 RESULT 18  
 ABJ38840  
 ID ABJ38840 standard; protein; 1014 AA.  
 XX  
 AC ABJ38840;  
 XX  
 XX 17-SEP-2003 (first entry)  
 DT  
 XX Human G-protein coupled receptor HE6 protein SEQ ID 139.  
 DE  
 XX Neuroprotective; antiinflammatory; immunosuppressive; cytostatic; neural;  
 KW nephrotropic; cardiant; human G-protein receptor; HGRBM128; HGRBM129;  
 KW HGRBM129v1; HGRBM129v2; HGRBM128; HGRBM129; Immune disorder; pulmonary;  
 KW inflammatory; haematopoietic; gastrointestinal; small intestine; cancer;  
 KW proliferative; aberrant p27 regulation; FEN1; cell cycle; DNA repair;

KW apoptosis; spleen; lymph node; reproductive; oesophageal; metabolic;  
KW endocrine; colon; cervix; lung; squamous cell; renal; cardiovascular;  
KW placental; testis; heart; gene therapy.  
XX  
OS Homo sapiens.  
PN WO200283856-A2.  
XX 24-OCT-2002.  
XX  
PF 11-APR-2002; 2002WO-US011525.  
XX  
PR 11-APR-2001; 2001US-0283145P.  
PR 11-APR-2001; 2001US-0283161P.  
PR 03-MAY-2001; 2001US-0288468P.  
PR 25-JUN-2001; 2001US-0300619P.  
XX  
XX (BRIM ) BRISTOL-MYERS SQUIBB CO.  
PA  
XX Bol D, Feder J, Mintier G, Ramanathan C, Hawken DR;  
XX WPI; 2003-075538/07.  
XX  
XX New G-protein coupled receptors, HGRBM28 and HGRBM29, and their  
PT variants, useful for treating, preventing or ameliorating e.g.  
PT hematopoietic, neural, pulmonary, gastrointestinal, inflammatory or  
PT proliferative disorders.  
XX  
PS Disclosure; Fig 13; 501pp; English.  
XX  
XX This invention relates to an isolated nucleic acid molecule comprising a  
CC polynucleotide encoding a human G-protein receptor, including HGRBM28,  
CC HGRBM29, HGRBM29v1 or HGRBM29v2 polypeptides. The HGRBM28 or  
CC HGRBM29 polypeptides and nucleic acids are useful for treating,  
CC preventing or ameliorating a medical condition, e.g. an immune disorder,  
CC an inflammatory disorder, an inflammatory disorder in which G-protein  
CC coupled receptors are either directly or indirectly associated with the  
CC disorder, a hematopoietic disorder, a neural disorder, a pulmonary  
CC disorder, a gastrointestinal disorder, a disorder affecting the small  
CC intestine, a proliferative disorder, a cancer, a disorder related to  
CC aberrant p27 regulation, a disorder related to aberrant FEN1 regulation,  
CC a disorder related to aberrant cell cycle regulation, a disorder related  
CC to aberrant DNA repair regulation, a disorder related to aberrant  
CC apoptosis regulation, a disorder of the spleen, a disorder of the lymph  
CC nodes, a male or female reproductive disorder, an oesophageal disorder,  
CC metabolic disorder, an endocrine disorder, a proliferative disorder  
CC affecting the colon, cervix, lung, squamous cells or tissues, a renal  
CC disorder, a cardiovascular disorder, a placental disorder, and a disorder  
CC of the testes, heart or lymph nodes. The isolated polynucleotides of the  
CC invention may be used to treat disorders by gene therapy. This sequence  
CC represents a Human G-protein coupled receptor related protein of the  
CC invention  
XX  
XX Sequence 1014 AA;  
SQ  
Query Match 100.0%; Score 63; DB 6; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.19; Mismatches 0; Gaps 0;  
Matches 10; Conservative 0; Indels 0; Indels 0; Gaps 0;  
OY 1 CWINNAVY 10  
Db 775 CWINNAVY 784  
RESULT 19  
ABJ38832  
ID ABJ38832 standard; protein; 1014 AA.  
XX  
AC ABJ38832;  
XX  
DT 17-SEP-2003 (first entry)  
XX  
DE Human epididymis-specific G-protein coupled receptor 64 protein SEQ ID 4.

XX  
KW Neuroprotective; antiinflammatory; immunosuppressive; cytostatic; neural;  
KW nephrotropic; cardiac; human G-protein receptor; HGRBM28; HGRBM29;  
KW HGRBM29v1; HGRBM29v2; HGRBM28; HGRBM29; immune disorder; pulmonary;  
KW inflammatory; hematopoietic; gastrointestinal; small intestine; cancer;  
KW proliferative; aberrant p27 regulation; FEN1; cell cycle; DNA repair;  
KW apoptosis; spleen; lymph node; reproductive; oesophageal; metabolic;  
KW endocrine; colon; cervix; lung; squamous cell; renal; cardiovascular;  
KW placental; testis; heart; gene therapy.  
XX  
OS Homo sapiens.  
XX  
PN WO200283856-A2.  
XX  
PD 24-OCT-2002.  
XX  
PF 11-APR-2002; 2002WO-US011525.  
XX  
PR 11-APR-2001; 2001US-0283145P.  
PR 11-APR-2001; 2001US-0283161P.  
PR 03-MAY-2001; 2001US-0288468P.  
PR 25-JUN-2001; 2001US-0300619P.  
XX  
XX (BRIM ) BRISTOL-MYERS SQUIBB CO.  
PA  
XX Bol D, Feder J, Mintier G, Ramanathan C, Hawken DR;  
XX WPI; 2003-075538/07.  
XX  
XX New G-protein coupled receptors, HGRBM28 and HGRBM29, and their  
PT variants, useful for treating, preventing or ameliorating e.g.  
PT hematopoietic, neural, pulmonary, gastrointestinal, inflammatory or  
PT proliferative disorders.  
XX  
PS Disclosure; Fig 2; 501pp; English.  
XX  
XX This invention relates to an isolated nucleic acid molecule comprising a  
CC polynucleotide encoding a human G-protein receptor, including HGRBM28,  
CC HGRBM29, HGRBM29v1 or HGRBM29v2 polypeptides. The HGRBM28 or  
CC HGRBM29 polypeptides and nucleic acids are useful for treating,  
CC preventing or ameliorating a medical condition, e.g. an immune disorder,  
CC an inflammatory disorder, an inflammatory disorder in which G-protein  
CC coupled receptors are either directly or indirectly associated with the  
CC disorder, a hematopoietic disorder, a neural disorder, a pulmonary  
CC disorder, a gastrointestinal disorder, a disorder affecting the small  
CC intestine, a proliferative disorder, a cancer, a disorder related to  
CC aberrant p27 regulation, a disorder related to aberrant FEN1 regulation,  
CC a disorder related to aberrant cell cycle regulation, a disorder related  
CC to aberrant DNA repair regulation, a disorder related to aberrant  
CC apoptosis regulation, a disorder of the spleen, a disorder of the lymph  
CC nodes, a male or female reproductive disorder, an oesophageal disorder,  
CC metabolic disorder, an endocrine disorder, a proliferative disorder  
CC affecting the colon, cervix, lung, squamous cells or tissues, a renal  
CC disorder, a cardiovascular disorder, a placental disorder, and a disorder  
CC of the testes, heart or lymph nodes. The isolated polynucleotides of the  
CC invention may be used to treat disorders by gene therapy. This sequence  
CC represents a Human G-protein coupled receptor related protein of the  
CC invention  
XX  
XX Sequence 1014 AA;  
SQ  
Query Match 100.0%; Score 63; DB 6; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.19; Mismatches 0; Gaps 0;  
Matches 10; Conservative 0; Indels 0; Indels 0; Gaps 0;  
OY 1 CWINNAVY 10  
Db 775 CWINNAVY 784  
RESULT 20  
ABP81971  
ID ABP81971 standard; protein; 1014 AA.



XX AC ABP81971;  
XX DT 04-MAR-2003 (first entry)  
XX DE Human G protein-coupled receptor GPR64 protein SEQ ID NO:428.  
XX KW G protein-coupled receptor; GPCR; antigenic peptide; gene therapy;  
KW G protein-coupled receptor modulator; antibody; immune-related disease;  
KW growth-related disease; cell regeneration-related disease; AIDS; cancer;  
KW immunological-related cell proliferative disease; autoimmune disease;  
KW Alzheimer's disease; atherosclerosis; infection; osteoarthritis; allergy;  
KW osteoporosis; cardiomyopathy; inflammation; Crohn's disease; diabetes;  
KW graft versus host disease; Parkinson's disease; multiple sclerosis; pain;  
KW psoriasis; anxiety; depression; schizophrenia; dementia; memory loss;  
KW mental retardation; epilepsy; asthma; tuberculosis; obesity; nausea;  
KW hypertension; hypotension; renal disorder; rheumatoid arthritis; trauma;  
KW ulcer.  
XX OS Homo sapiens.  
XX PN WO200261087-A2.  
XX PD 08-AUG-2002.  
XX PF 19-DEC-2001; 2001WO-US050107.  
XX PR 19-DEC-2000; 2000US-0257144P.  
XX PA (LIFE-) LIFESPAN BIOSCIENCES INC.  
XX PI Burmer GC, Roush CL, Brown JP;  
XX DR WPI; 2003-046718/04.  
XX DR N-PSDB; AB242819.  
XX PT New isolated antigenic peptides e.g., for G protein-coupled receptors  
PT (GPCR), useful for diagnosing and designing drugs for treating conditions  
PT in which GPCRs are involved, e.g. AIDS, Alzheimer's disease, cancer or  
PT autoimmune diseases.  
XX PS Disclosure; Fig 1; 533pp; English.  
XX CC The present invention describes antigenic peptides (I) comprising: (a)  
CC any one of 1601 sequences (see ABP82019 to ABP83619) of 12-24 amino  
CC acids. Also described: (1) an assay for the detection of a particular G  
CC protein-coupled receptor (GPCR) or a candidate polypeptide in a sample;  
CC and (2) an isolated antibody having high specificity and high affinity or  
CC avidity for a particular GPCR. (I) can be used as GPCR modulators and in  
CC gene therapy. The antigenic peptides for GPCRs are useful in detecting an  
CC antibody against a particular GPCR, and in the production of specific  
CC antibodies. The peptides and antibodies are also useful for detecting the  
CC presence or absence of corresponding GPCRs. The antigenic peptides for  
CC GPCRs and antibodies are useful for diagnosing and designing drugs for  
CC treating immune-related diseases, growth-related diseases, cell  
CC regeneration-related disease, immunological-related cell proliferative  
CC diseases, or autoimmune diseases, e.g. AIDS, Alzheimer's disease,  
CC atherosclerosis, bacterial, fungal, protozoan or viral infections,  
CC osteoarthritis, osteoporosis, cancer, cardiomyopathy, chronic and acute  
CC inflammation, allergies, Crohn's disease, diabetes, graft versus host  
CC disease, Parkinson's disease, multiple sclerosis, pain, psoriasis,  
CC anxiety, depression, schizophrenia, dementia, mental retardation, memory  
CC loss, epilepsy, asthma, tuberculosis, obesity, nausea, hypertension,  
CC hypotension, renal disorders, rheumatoid arthritis, trauma, ulcers, or  
CC any other disorder in which GPCRs are involved. The antibodies may be  
CC used in immunoassays and immunodiagnosis. AB242523 to AB242869 encode  
CC GPCR proteins given in ABP81675 to ABP82018, which are used in the  
CC exemplification of the present invention  
XX SQ Sequence 1014 AA;  
Query Match 100.0%; Score 63; DB 6; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.19;  
AC AC

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CWINNAVY 10  
DB 775 CWINNAVY 784  
RESULT 21  
ABR61472  
ID ABR61472 standard; protein; 1014 AA.  
XX AC ABR61472;  
XX DT 17-SEP-2003 (first entry)  
XX DE Human secretin-like G-protein coupled receptor (latrophilin #3).  
XX KW GPCR; secretin-type G-protein coupled receptor; latrophilin; cardiant;  
KW G-protein coupled receptor; cytostatic; anorectic; antidiabetic;  
KW neuroprotective; gene therapy; central nervous system; haematological;  
KW genitourological; cardiovascular; obesity; diabetes; cancer; human.  
XX OS Homo sapiens.  
XX PN WO2003051925-A1.  
XX PD 26-JUN-2003.  
XX PF 19-DEC-2002; 2002WO-EP014572.  
XX PR 19-DEC-2001; 2001US-0340825P.  
XX PR 30-AUG-2002; 2002US-0406984P.  
XX PA (FARB ) BAYER AG.  
XX PI Koehler RH;  
XX DR WPI; 2003-514042/48.  
XX PT New isolated polynucleotide, useful for preparing a medicament for  
PT modulating the activity of secretin-type GPCR (latrophilin) polypeptide  
PT in a disease, e.g., cardiovascular disease, obesity, diabetes or cancer.  
XX PS Disclosure; Page 155-158; 161pp; English.  
XX CC The invention relates to a novel isolated polynucleotide comprising e.g.  
CC a sequence encoding a secretin-type G-protein coupled receptor (GPCR)  
CC (latrophilin) polypeptide. A protein of the invention has cytostatic,  
CC cardiant, anorectic, antidiabetic, and neuroprotective activity. The  
CC polynucleotide may have a use in gene therapy. The expression vector is  
CC useful for preparing a medicament for modulating the activity of secretin  
CC -type GPCR (latrophilin) polypeptide in a disease, e.g., central nervous  
CC system, haematological, genitourological or cardiovascular disease,  
CC obesity, diabetes or cancer. The present sequence represents a secretin-  
CC type GPCR (latrophilin) polypeptide of the invention  
XX SQ Sequence 1014 AA;  
Query Match 100.0%; Score 63; DB 6; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.19;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CWINNAVY 10  
DB 775 CWINNAVY 784  
RESULT 22  
ADB80456  
ID ADB80456 standard; protein; 1014 AA.  
XX AC ADB80456;  
XX XX

DT 04-DEC-2003 (first entry)  
 XX Ovarian cancer-associated protein #10.  
 DE  
 XX cytostatic; gene therapy; vaccine; ovarian cancer; diagnosis;  
 KW post-operative chemotherapy; radiation therapy; tumour prognosis;  
 KW pre-cancerous lesion detection.  
 KW  
 XX Homo sapiens.  
 OS  
 XX WO2002102235-A2.  
 PN  
 XX 27-DEC-2002.  
 PD  
 XX  
 XX 18-JUN-2002; 2002WO-US019297.  
 PF  
 XX 18-JUN-2001; 2001US-0299234P.  
 PR  
 XX 27-AUG-2001; 2001US-0315287P.  
 PR  
 XX 05-SEP-2001; 2001US-0317544P.  
 PR  
 XX 13-NOV-2001; 2001US-0350666P.  
 PR  
 XX 12-APR-2002; 2002US-0372246P.  
 PR  
 XX (EOSB-) EOS BIOTECHNOLOGY INC.  
 PA  
 XX Mack DH, Gish KC;  
 PI  
 XX WPI; 2003-167431/16.  
 DR  
 XX N-PSDB; ADB80455.  
 DR  
 XX  
 XX Detecting an ovarian cancer-associated transcript in a cell from a  
 PT patient, comprises contacting a biological sample from the patient with a  
 PT polynucleotide that hybridizes to an ovarian cancer gene.  
 PT  
 XX Claim 13; Page 281; 332pp; English.  
 PS  
 XX The invention relates to a method of detecting an ovarian cancer-  
 CC associated transcript in a cell from a patient, by contacting a  
 CC biological sample from the patient with a polynucleotide that selectively  
 CC hybridizes to a sequence at least 80% identical to any of one of 80  
 CC nucleic acid sequences given in the specification. The method is useful  
 CC in diagnosing ovarian cancer and in identifying and using agents and/or  
 CC targets that inhibit ovarian cancer. The nucleic acid molecule,  
 CC polypeptide and the antibody may also be used in detecting ovarian  
 CC cancers, monitoring and early detection of relapse following treatment,  
 CC monitoring response to therapy, selecting patients for post-operative  
 CC chemotherapy or radiation therapy, in selecting mode of therapy,  
 CC determining tumour prognosis, early detection of pre-cancerous lesions,  
 CC and as vaccines. This sequence corresponds to one of the proteins used  
 CC for the detection method of the invention.  
 CC  
 XX Sequence 1014 AA;  
 SQ  
 Query Match 100.0%; Score 63; DB 7; Length 1014;  
 Best Local Similarity 100.0%; Pred. No. 0.19;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNAVY 10  
 Db 775 CWINNAVY 784  
 RESULT 23  
 ADN39174  
 ID ADN39174 standard; protein; 1014 AA.  
 XX  
 XX AC ADN39174;  
 XX  
 XX 17-JUN-2004 (first entry)  
 DT  
 XX Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:492.  
 DE  
 XX Human; differential expression; cancer; angiogenic disorder;  
 KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;  
 KW

KW inflammatory disease; autoimmune disease;  
 KW retinal neovascularisation syndrome; scarring; uterine fibroid;  
 KW detection; diagnosis; prognosis; drug screening; drug targeting;  
 KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;  
 KW vulnery; gene therapy; vaccine.  
 KW  
 XX Homo sapiens.  
 OS  
 XX WO2003042661-A2.  
 PN  
 XX 22-MAY-2003.  
 PD  
 XX  
 XX 13-NOV-2002; 2002WO-US036810.  
 PF  
 XX 13-NOV-2001; 2001US-0350666P.  
 PR  
 XX 21-NOV-2001; 2001US-0332464P.  
 PR  
 XX 29-NOV-2001; 2001US-0334393P.  
 PR  
 XX 03-DEC-2001; 2001US-0335394P.  
 PR  
 XX 14-DEC-2001; 2001US-0340376P.  
 PR  
 XX 08-JAN-2002; 2002US-0347211P.  
 PR  
 XX 10-JAN-2002; 2002US-0347349P.  
 PR  
 XX 08-FEB-2002; 2002US-0355250P.  
 PR  
 XX 13-FEB-2002; 2002US-0356714P.  
 PR  
 XX 20-FEB-2002; 2002US-0359077P.  
 PR  
 XX 29-MAR-2002; 2002US-0368809P.  
 PR  
 XX 04-APR-2002; 2002US-0370110P.  
 PR  
 XX 12-APR-2002; 2002US-0372246P.  
 PR  
 XX 05-JUN-2002; 2002US-0386614P.  
 PR  
 XX 16-JUL-2002; 2002US-0396839P.  
 PR  
 XX 22-JUL-2002; 2002US-0397775P.  
 PR  
 XX 22-JUL-2002; 2002US-0397845P.  
 PR  
 XX 09-SEP-2002; 2002US-0409450P.  
 PR  
 XX (EOSB-) EOS BIOTECHNOLOGY INC.  
 PA  
 XX Afar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevezi PA;  
 PI Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;  
 XX WPI; 2003-468649/44.  
 DR  
 XX N-PSDB; ADN39173.  
 DR  
 XX Determining the presence or absence of a pathological cell in a patient,  
 PT useful for diagnosing, prognosing or treating cancer, comprises detecting  
 PT a nucleic acid in a biological sample.  
 PT  
 XX Claim 12; SEQ ID NO 492; 1385pp; English.  
 PS  
 CC The invention relates to nucleic acids and proteins (ADN38683-ADN40064)  
 CC whose expression is upregulated or downregulated in specific cancers or  
 CC other diseases such as angiogenic or fibrotic disorders, and to methods  
 CC of determining the presence or absence of a pathological cell in a  
 CC patient by detecting a nucleic acid at least 80% identical to those of  
 CC the invention or by detecting a polypeptide of the invention. The  
 CC invention also relates to expression vectors and host cells comprising a  
 CC nucleic acid of the invention; antibodies which specifically bind a  
 CC polypeptide of the invention; use of such antibodies for drug targeting;  
 CC and methods of screening for modulators of activity or expression of the  
 CC polypeptides and nucleic acids. The nucleic acids, polypeptides,  
 CC antibodies and methods are useful for diagnosing, prognosing and treating  
 CC cancer and other conditions such as psoriasis, ischaemia heart disease,  
 CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal  
 CC neovascularisation syndromes, scarring and uterine fibroids. They may  
 CC also be useful in wound healing and in contraception. The present  
 CC sequence represents a polypeptide of the invention.  
 CC  
 XX Sequence 1014 AA;  
 SQ  
 Query Match 100.0%; Score 63; DB 7; Length 1014;  
 Best Local Similarity 100.0%; Pred. No. 0.19;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNAVY 10  
 Db 775 CWINNAVY 784

Db 775 CWINNNAVY 784

RESULT 24  
ADN39529

ID ADN39529 standard; protein; 1014 AA.

AC ADN39529;

XX 17-JUN-2004 (first entry)

DT

XX

DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:A129.

XX

KW Human; differential expression; cancer; angiogenic disorder;  
KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;  
KW inflammatory disease; autoimmune disease;  
KW retinal neovascularisation syndrome; scarring; uterine fibroid;  
KW detection; diagnosis; prognosis; drug screening; drug targeting;  
KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;  
KW vulnery; gene therapy; vaccine.

XX

OS Homo sapiens.

XX

XX WO2003042661-A2.

PN

XX

PD 22-MAY-2003.

XX

XX 13-NOV-2002; 2002WO-US036810.

PF

XX

PR 13-NOV-2001; 2001US-0350666P.  
PR 21-NOV-2001; 2001US-0332464P.  
PR 29-NOV-2001; 2001US-0334393P.  
PR 03-DEC-2001; 2001US-0335394P.  
PR 14-DEC-2001; 2001US-0340376P.  
PR 08-JAN-2002; 2002US-0347211P.  
PR 10-JAN-2002; 2002US-0347349P.  
PR 08-FEB-2002; 2002US-035250P.  
PR 13-FEB-2002; 2002US-0356714P.  
PR 20-FEB-2002; 2002US-0359077P.  
PR 29-MAR-2002; 2002US-036809P.  
PR 04-APR-2002; 2002US-0370110P.  
PR 12-APR-2002; 2002US-0372246P.  
PR 05-JUN-2002; 2002US-0396839P.  
PR 16-JUL-2002; 2002US-0397775P.  
PR 22-JUL-2002; 2002US-0397845P.  
PR 09-SEP-2002; 2002US-0409450P.

XX

XX (EOSB-) EOS BIOTECHNOLOGY INC.

XX

PI Afar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevezi PA;  
PI Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;

XX

DR WPI; 2003-468649/44.  
DR N-PSDB; ADN39528.

XX

PT Determining the presence or absence of a pathological cell in a patient,  
PT useful for diagnosing, prognosing or treating cancer, comprises detecting  
PT a nucleic acid in a biological sample.

XX

XX Claim 12; SEQ ID NO A129; 1385pp; English.

XX

CC The invention relates to nucleic acids and proteins (ADN39528-ADN40064)  
CC whose expression is upregulated or downregulated in specific cancers or  
CC other diseases such as angiogenic or fibrotic disorders, and to methods  
CC of determining the presence or absence of a pathological cell in a  
CC patient by detecting a nucleic acid at least 80% identical to those of  
CC the invention or by detecting a polypeptide of the invention. The  
CC invention also relates to expression vectors and host cells comprising a  
CC nucleic acid of the invention; antibodies which specifically bind a  
CC polypeptide of the invention; use of such antibodies for drug targeting;  
CC and methods of screening for modulators of activity or expression of the  
CC polypeptides and nucleic acids. The nucleic acids, polypeptides,

CC antibodies and methods are useful for diagnosing, prognosing and treating  
CC cancer and other conditions such as psoriasis, ischaemia, heart disease,  
CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal  
CC neovascularisation syndromes, scarring and uterine fibroids. They may  
CC also be useful in wound healing and in contraception. The present  
CC sequence represents a polypeptide of the invention.

XX

XX Sequence 1014 AA;

Query Match 100.0%; Score 63; DB 7; Length 1014;  
Best Local Similarity 100.0%; Pred. No. 0.19;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10  
DB 775 CWINNNAVY 784

RESULT 25  
ADN39492

ID ADN39492 standard; protein; 1014 AA.

XX

AC ADN39492;

XX

XX 17-JUN-2004 (first entry)

DT

XX

DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:A92.

XX

KW Human; differential expression; cancer; angiogenic disorder;  
KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;  
KW inflammatory disease; autoimmune disease;  
KW retinal neovascularisation syndrome; scarring; uterine fibroid;  
KW detection; diagnosis; prognosis; drug screening; drug targeting;  
KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;  
KW vulnery; gene therapy; vaccine.

XX

OS Homo sapiens.

XX

XX WO2003042661-A2.

PN

XX

PD 22-MAY-2003.

XX

XX 13-NOV-2002; 2002WO-US036810.

PF

XX

PR 13-NOV-2001; 2001US-0350666P.  
PR 21-NOV-2001; 2001US-0332464P.  
PR 29-NOV-2001; 2001US-0334393P.  
PR 03-DEC-2001; 2001US-0335394P.  
PR 14-DEC-2001; 2001US-0340376P.  
PR 08-JAN-2002; 2002US-0347211P.  
PR 10-JAN-2002; 2002US-0347349P.  
PR 08-FEB-2002; 2002US-035250P.  
PR 13-FEB-2002; 2002US-0356714P.  
PR 20-FEB-2002; 2002US-0359077P.  
PR 29-MAR-2002; 2002US-036809P.  
PR 04-APR-2002; 2002US-0370110P.  
PR 12-APR-2002; 2002US-0372246P.  
PR 05-JUN-2002; 2002US-0396839P.  
PR 16-JUL-2002; 2002US-0397775P.  
PR 22-JUL-2002; 2002US-0397845P.  
PR 09-SEP-2002; 2002US-0409450P.

XX

XX (EOSB-) EOS BIOTECHNOLOGY INC.

XX

PI Afar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevezi PA;  
PI Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;

XX

DR WPI; 2003-468649/44.  
DR N-PSDB; ADN39491.

XX

PT Determining the presence or absence of a pathological cell in a patient,  
PT useful for diagnosing, prognosing or treating cancer, comprises detecting

```

PT a nucleic acid in a biological sample.
XX
PS Claim 12; SEQ ID NO A92; 1385pp; English.
XX
CC The invention relates to nucleic acids and proteins (ADN38683-ADN40064)
CC whose expression is upregulated or downregulated in specific cancers or
CC other diseases such as angiogenic or fibrotic disorders, and to methods
CC of determining the presence or absence of a pathological cell in a
CC patient by detecting a nucleic acid at least 80% identical to those of
CC the invention or by detecting a polypeptide of the invention. The
CC invention also relates to expression vectors and host cells comprising a
CC nucleic acid of the invention; antibodies which specifically bind a
CC polypeptide of the invention; use of such antibodies for drug targeting;
CC and methods of screening for modulators of activity or expression of the
CC polypeptides and nucleic acids. The nucleic acids, polypeptides,
CC antibodies and methods are useful for diagnosing, prognosing and treating
CC cancer and other conditions such as psoriasis, ischaemia, heart disease,
CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal
CC neovascularisation syndromes, scarring and uterine fibroids. They may
CC also be useful in wound healing and in contraception. The present
CC sequence represents a polypeptide of the invention.
XX
SQ Sequence 1014 AA;
    Query Match      100.0%; Score 63; DB 7; Length 1014;
    Best Local Similarity 100.0%; Pred. No. 0.19;
    Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNNAVY 10
Db |||||
775 CWINNNNAVY 784

RESULT 26
ADP03579
ID ADP03579 standard; protein; 1014 AA.
XX
AC ADP03579;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human GPCR HE6 (GPCR 64, epididymis-specific) protein.
XX
KW GPCR; G-protein coupled receptor; neuroprotective; nootropic;
KW tranquilizer; antimigraine; neuroleptic; antimanic; antidepressant;
KW anticonvulsant; antiparkinsonian; cytotatic; cardiant; hypotensive;
KW antianginal; analgesic; anorectic; anti-HIV; antiasthmatic; osteopathic;
KW uropathic; antiulcer; antiallergic; cell cycle regulation; neurological;
KW severe mental retardation; dyskinesia; brain; spinal cord; affective;
KW neoplastic; cardiovascular; immunological; immune; endocrinal; growth;
KW eating; HIV infection; cancer; immunological; pituitary;
KW chromosome identification; gene therapy; human; receptor; HE6;
KW GPCR 64 epididymis-specific.
XX
OS Homo sapiens.
XX
PN WO2003062393-A2.
XX
PD 31-JUL-2003.
XX
PF 22-JAN-2003; 2003WO-US0001911.
XX
PR 22-JAN-2002; 2002US-0350724P.
XX
PA (BRIM ) BRISTOL-MYERS SQUIBB CO.
XX
PI Ramanathan CS, Gopal S, Mintier G, Feder JN;
XX
DR WPI; 2003-618283/58.
XX
PT New nucleic acid molecule encoding a human G-protein coupled receptor,
PT useful for diagnosing, preventing or treating diseases involving the
PT receptor, e.g. Parkinson's disease, dementia, asthma, hypertension or

```

---

```

PT cancer.
XX
PS Example 1; SEQ ID NO 24; 224pp; English.
XX
CC The invention relates to a novel isolated GPCR (G-protein coupled
CC receptor) nucleic acid molecule. The polynucleotide and polypeptide of
CC the invention demonstrate neuroprotective, nootropic, tranquiliser,
CC antimigraine, neuroleptic, antimanic, antidepressant, anticonvulsant,
CC antiparkinsonian, cytotatic, cardiant, hypotensive, antianginal,
CC analgesic, anorectic, anti-HIV, antiasthmatic, osteopathic, uropathic,
CC antiulcer and antiallergic properties. The nucleic acid molecule and
CC polypeptide of the invention may be useful in diagnosing, preventing,
CC treating or ameliorating a medical condition, such as a disorder related
CC to aberrant G-protein coupled signalling, a disorder related to aberrant
CC cell cycle regulation, neurological disorders, severe mental retardation
CC and dyskinesias, brain disorders, spinal cord disorders, affective
CC disorders, neoplastic disorders, cardiovascular disorders, immunological
CC disorders, immune-related disorders, endocrinal diseases, growth
CC disorders, eating disorders, HIV infection, cancers, metabolic disorders
CC and pituitary disorders. Furthermore, the polynucleotide may be used in
CC chromosome identification, in identifying organisms from minute
CC biological samples, in gene therapy or as a molecular weight marker. The
CC current sequence is that of a human GPCR (G-protein coupled receptor)
CC protein of the invention which was used for homology purposes.
XX
SQ Sequence 1014 AA;
    Query Match      100.0%; Score 63; DB 7; Length 1014;
    Best Local Similarity 100.0%; Pred. No. 0.19;
    Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNNAVY 10
Db |||||
775 CWINNNNAVY 784

RESULT 27
ADO29079
ID ADO29079 standard; protein; 1014 AA.
XX
AC ADO29079;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human novel GPCR GPR64, SEQ ID NO:178.
XX
KW G protein-coupled receptor; GPCR; drug screening; diagnosis;
KW transgenic mouse; neurological disorder; adrenal gland disorder;
KW colon disorder; intestinal disorder; cardiovascular disorder;
KW muscular disorder; blood disorder; immune disorder; bone disorder;
KW joint disorder; metabolic disorder; nutritive disorder; cancer;
KW kidney disorder; liver disorder; lung disorder; breast disorder;
KW ovary disorder; uterus disorder; prostate disorder; testis disorder;
KW skin disorder; stomach disorder; pancreas disorder; spleen disorder;
KW thymus disorder; thyroid disorder; antiparkinsonian; antimanic;
KW cytostatic; antiinflammatory; vasotropic; antianginal; antiarrhythmic;
KW CNS; central nervous system; respiratory; antidiarrhoeic; antidiabetic;
KW virucide; hepatotropic; antibacterial; antianaemic; antiseborrhoeic;
KW dermatological; antiulcer; antithyroid; antiallergic; anorectic;
KW immunosuppressive; nephrotropic; gene therapy; GPCR modulator; human;
KW receptor.
XX
OS Homo sapiens.
XX
PN WO2004040000-A2.
XX
PD 13-MAY-2004.
XX
PF 09-SEP-2003; 2003WO-US028226.
XX
PR 09-SEP-2002; 2002US-0409303P.
PR 09-APR-2003; 2003US-0461329P.
XX

```

PA (PRIM-) PRIMAL INC.  
 XX Gaitanaris GA, Bergmann JE, Gragerov A, Hohmann J, Li F;  
 PI Madisen L, McIlwain KL, Pavlova MN, Vassiliadis D, Zeng H;  
 XX WPI; 2004-390329/36.  
 DR N-PSDB; ADO29771.  
 XX Novel mammalian G protein coupled receptors, useful for identifying  
 PT compounds that modulates diagnosing and treating disease condition  
 PT associated with GPCR dysfunction e.g. autoimmune diseases, angina  
 PT pectoris, Parkinson's disease.  
 XX Claim 1; SEQ ID NO 178; 542pp; English.  
 XX The invention relates to human and mouse G protein-coupled receptors  
 CC (GPCRs) and nucleic acids encoding them. The invention also relates to  
 CC sequences at least 90% identical to the GPCR proteins and nucleic acids  
 CC of the invention; methods of treating, preventing or diagnosing diseases  
 CC associated with GPCRs of the invention; methods of screening for  
 CC compounds useful in the treatment of GPCR-related diseases; a transgenic  
 CC mouse comprising a GPCR gene of the invention; a mouse comprising a  
 CC mutation in a GPCR transgene or in an endogenous GPCR gene; cells derived  
 CC from the transgenic mice; kits comprising several mice, each of which has  
 CC a mutation in a different GPCR gene of the invention; and kits comprising  
 CC probes which hybridize to GPCR polynucleotides of the invention. The  
 CC invention further discloses variants of the GPCR polypeptides and vectors  
 CC comprising a GPCR nucleic acid. The GPCR nucleic acids and proteins may  
 CC be used in the diagnosis, treatment or prevention of a wide variety of  
 CC diseases including neurological disorders (e.g., Alzheimer's disease,  
 CC depression, diabetic neuropathy, Parkinson's disease or schizophrenia);  
 CC disorders of the adrenal gland; disorders of the colon or intestine  
 CC (e.g., Crohn's disease, diarrhoea, food poisoning or irritable bowel  
 CC syndrome); cardiovascular disorders (e.g., angina, cardiac arrhythmia or  
 CC myocardial infarction); muscular disorders; blood disorders (e.g.,  
 CC anaemia or leukaemia); immune disorders (e.g., autoimmune disorders or  
 CC AIDS); bone and joint disorders (e.g., osteoarthritis, rheumatoid  
 CC arthritis, gout or osteoporosis); metabolic or nutritive disorders (e.g.,  
 CC obesity, enzyme deficiency-related diseases or vitamin deficiency-related  
 CC diseases); and disorders of the kidney, liver, lung, breast, ovary,  
 CC uterus, prostate, testis, skin, stomach, pancreas, spleen, thymus and  
 CC thyroid (e.g., cancers). The present sequence represents a GPCR of the  
 CC invention. Note: The full sequence data for this patent did not form part  
 CC of the printed specification; those sequences not shown were obtained in  
 CC electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences.  
 XX SQ Sequence 1014 AA;  
 Query Match 100.0%; Score 63; DB 8; Length 1014;  
 Best Local Similarity 100.0%; Pred. No. 0.19;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNNNAVY 10  
 Db |||||  
 775 CWINNNNAVY 784  
 RESULT 28  
 ADQ19636  
 ID ADQ19636 standard; protein; 1014 AA.  
 AC ADQ19636;  
 XX DT 26-AUG-2004 (first entry)  
 XX Human soft tissue sarcoma-upregulated protein - SEQ ID 2455.  
 XX soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human.  
 XX Homo sapiens.  
 OS WO2004048938-A2.  
 PN

XX 10-JUN-2004.  
 XX 26-NOV-2003; 2003WO-US038193.  
 XX 26-NOV-2002; 2002US-0429739P.  
 XX (PROT-) PROTEIN DESIGN LABS INC.  
 XX Aziz N, Ginsburg WM, Zlotnik A;  
 XX WPI; 2004-441208/41.  
 XX Early detection of soft tissue sarcoma comprises determining expression  
 PT of a gene in a first soft tissue sample and a normal soft tissue sample  
 PT and comparing the gene expression, also useful in treating soft tissue  
 PT sarcoma.  
 XX Example 2; SEQ ID NO 2455; 210pp; English.  
 XX The invention relates to a novel method for detecting soft tissue sarcoma  
 CC which comprises obtaining a first soft tissue sample from an individual  
 CC and a normal soft tissue sample from the same or different individual,  
 CC determining the expression of a gene in both samples and comparing the  
 CC expression of the gene in both soft tissue samples, where a higher level  
 CC of protein expression in the first soft tissue sample indicates the  
 CC presence of soft tissue sarcoma. The method of the invention has  
 CC cytostatic applications and may be useful for detecting soft tissue  
 CC sarcoma, possibly via gene therapy or vaccine production. The nucleic  
 CC acid sequences may be useful in diagnostic and screening applications.  
 CC The current sequence is that of a human soft tissue sarcoma-upregulated  
 CC protein of the invention. The current sequence is not shown within the  
 CC specification per se but was submitted in CD format by the inventor.  
 XX SQ Sequence 1014 AA;  
 Query Match 100.0%; Score 63; DB 8; Length 1014;  
 Best Local Similarity 100.0%; Pred. No. 0.19;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNNNAVY 10  
 Db |||||  
 775 CWINNNNAVY 784  
 RESULT 29  
 ADQ09616  
 ID ADQ09616 standard; protein; 1014 AA.  
 XX AC ADQ09616;  
 XX DT 07-OCT-2004 (first entry)  
 XX Human G protein coupled receptor GPR64 DNA SeqID 2.  
 XX human; G protein coupled receptor; GPR64; cytotoxic; ovarian cancer;  
 KW uterine cancer; Ewing's sarcoma; cell death; cytostatic; gene therapy;  
 KW immunotherapy; cellular proliferation.  
 XX Homo sapiens.  
 OS WO2004058171-A2.  
 PN 15-JUL-2004.  
 PD 19-DEC-2003; 2003WO-US040820.  
 PF 20-DEC-2002; 2002US-0435618P.  
 PR (PROT-) PROTEIN DESIGN LABS INC.  
 XX Law D, Wang Q, Dubridge R, Bhaskar V;  
 XX

DR	WPI; 2004-525780/50.
DR	N-PSDB; ADQ09615.
XX	
PT	New antibody that inhibits binding of a GPR64 polypeptide to an antibody
PT	comprising GPR64-18, GPR64-81, GPR64-93 or GPR64-104, useful in preparing
PT	a composition for diagnosing or treating ovarian cancer.
XX	
XX	Claim 31; SEQ ID NO 2; 75pp; English.
XX	
CC	This invention relates to novel antibodies that bind to the G protein
CC	coupled receptor protein identified as GPR64, namely GPR64-1, GPR64-16,
CC	GPR64-18, GPR64-20 and GPR64-48. Specifically, it refers to the use of
CC	these anti-GPR64 antibodies as selective cytotoxic agents against GPR64
CC	expressing tumour cells such as those associated with ovarian cancer,
CC	uterine cancer and Ewing's sarcoma. The present invention describes,
CC	epitope mapping of those antibodies that show high affinity binding to
CC	GPR64 through competitive binding analyses, such that the antibodies can
CC	be assessed for GPR64 dependent cell death <i>in vitro</i> . Accordingly, they
CC	can be used to develop cytostatic compositions for gene therapy or
CC	immunotherapy that inhibit cellular proliferation of an ovarian cancerous
CC	cell and furthermore can diagnose and inhibit growth of tumour cells.
CC	This polypeptide sequence is the target human GPR64 protein of the
CC	invention.
XX	
XX	Sequence 1014 AA;
XX	
XX	Sequence 1014 AA;

CC The invention relates to the human epididymis-specific receptor protein-6 (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6) polypeptide and the rat epididymis-specific receptor protein-6 (RE6) polypeptide. The invention also relates to an antibody or its fragment specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical composition comprising an antisense nucleotide which can bind with any of the nucleotide sequences encoding an epididymis-specific receptor protein -6 of the invention, a pharmaceutical composition for treating a male reproductive disorder comprising a polynucleotide of the invention, a method of diagnosing infertility in a male mammal and a method of treating infertility in a male mammal. The polynucleotides encoding the polypeptides are useful for isolating an agent that modulates expression or activity of the polypeptides. The sequences are useful for diagnosing a male reproductive disorder. This sequence represents an HE6 polypeptide of the invention.

XX  
 SQ Sequence 1017 AA;

Query Match 100.0%; Score 63; DB 8; Length 1017;  
 Best Local Similarity 100.0%; Pred. No. 0.19;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0

QY 1 CWINNNAVY 10  
 |||||  
 DB 778 CWINNNAVY 787

RESULT 31  
 ADN88597

ID ADN88597 standard; protein; 1020 AA.  
 AC ADN88597;  
 XX  
 DT 29-JUL-2004 (first entry)  
 XX  
 DE Human epididymis-specific receptor protein-6 delta 24 (HE6delta24) #2.  
 XX  
 KW Human epididymis-specific receptor protein-6; HE6;  
 KW male reproductive disorder; infertility; antiinfertility; contraceptive;  
 KW human epididymis-specific receptor protein-6 delta 24; HE6delta24;  
 KW mutant; mutein; receptor.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN WO2004037860-A1.  
 XX  
 PD 06-MAY-2004.  
 XX  
 PF 21-OCT-2003; 2003WO-EP011662.  
 XX  
 PR 22-OCT-2002; 2002US-0419979P.  
 XX  
 PA (SCHD ) SCHERING AG.  
 XX  
 PI Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
 PI Gotwald U, Nubbemeyer R;  
 XX  
 XX WPI; 2004-357427/33.  
 DR N-PSDB; ADN88595.  
 XX  
 PT Novel isolated human, mouse or rat epididymis-specific receptor protein-6 polypeptide, useful for isolating agents used for treating male infertility, or for male contraception.  
 PT  
 XX  
 PS Claim 55; SEQ ID NO 35; 127pp; English.  
 CC  
 CC The invention relates to the human epididymis-specific receptor protein-6 (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6) polypeptide and the rat epididymis-specific receptor protein-6 (RE6) polypeptide. The invention also relates to an antibody or its fragment specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical composition comprising an antisense nucleotide which can bind with any of the nucleotide sequences encoding an epididymis-specific receptor protein -6 of the invention, a pharmaceutical composition for treating a male reproductive disorder comprising a polynucleotide of the invention, a method of diagnosing infertility in a male mammal and a method of treating infertility in a male mammal. The polynucleotides encoding the polypeptides are useful for isolating an agent that modulates expression or activity of the polypeptides. The sequences are useful for diagnosing a male reproductive disorder. This sequence represents an HE6 polypeptide of the invention.

CC the nucleotide sequences encoding an epididymis-specific receptor protein  
CC -6 of the invention, a pharmaceutical composition for treating a male  
CC reproductive disorder comprising a polynucleotide of the invention, a  
CC method of diagnosing infertility in a male mammal and a method of  
CC treating infertility in a male mammal. The polynucleotides encoding the  
CC polypeptides are useful for isolating an agent that modulates expression  
CC or activity of the polypeptides. The sequences are useful for diagnosing  
CC a male reproductive disorder. This sequence represents an HE6delta24  
CC mutant polypeptide of the invention.  
XX  
SQ Sequence 1020 AA;

Query Match 100.0%; Score 63; DB 8; Length 1020;  
Best Local Similarity 100.0%; Pred. No. 0.19;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CWINNAVY 10  
Db 832 CWINNAVY 841  
|||||

RESULT 32  
ADN88598  
ID ADN88598 standard; protein; 1033 AA.  
XX  
AC ADN88598;  
XX  
DT 29-JUL-2004 (first entry)  
XX  
DE Human epididymis-specific receptor protein-6 (HE6) polypeptide #2.  
XX  
KW Human epididymis-specific receptor protein-6; HE6;  
KW male reproductive disorder; infertility; antiinfertility; contraceptive;  
KW receptor.  
XX  
OS Homo sapiens.  
XX  
PN WO2004037860-A1.  
XX  
PD 06-MAY-2004.  
XX  
PF 21-OCT-2003; 2003WO-EP011662.  
XX  
PR 22-OCT-2002; 2002US-0419979P.  
XX  
PA (SCHD ) SCHERING AG.  
XX  
PI Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
PI Gottwald U, Nubbemeyer R;  
XX  
DR WPI; 2004-357427/33.  
XX  
DR N-PSDB; ADN88578.

PT Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
PT polypeptide, useful for isolating agents used for treating male  
PT infertility, or for male contraception.  
XX

PS Claim 58; SEQ ID NO 36; 127pp; English.  
XX  
CC The invention relates to the human epididymis-specific receptor protein-6  
CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)  
CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
CC polypeptide. The invention also relates to an antibody or its fragment  
CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
CC composition comprising an antisense nucleotide which can bind with any of  
CC the nucleotide sequences encoding an epididymis-specific receptor protein  
CC -6 of the invention, a pharmaceutical composition for treating a male  
CC reproductive disorder comprising a polynucleotide of the invention, a  
CC method of diagnosing infertility in a male mammal and a method of  
CC treating infertility in a male mammal. The polynucleotides encoding the  
CC polypeptides are useful for isolating an agent that modulates expression  
CC or activity of the polypeptides. The sequences are useful for diagnosing  
CC a male reproductive disorder. This sequence represents an HE6 polypeptide

CC of the invention.  
XX  
SQ Sequence 1033 AA;

Query Match 100.0%; Score 63; DB 8; Length 1033;  
Best Local Similarity 100.0%; Pred. No. 0.19;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CWINNAVY 10  
Db 794 CWINNAVY 803  
|||||

RESULT 33  
AAW36903  
ID AAW36903 standard; protein; 1038 AA.  
XX  
AC AAW36903;  
XX

DT 11-MAY-1998 (first entry)

DE Human epididymis-specific receptor protein.

XX Epididymis-specific receptor protein; transmembrane protein;  
KW sperm maturation; male infertility; agonist; antagonist; contraception;  
KW autoantibody; diagnostic; detection; human.  
XX  
OS Homo sapiens.

FH Key Location/Qualifiers  
FT Protein 1..1038  
FT /note= "partial protein sequence"

PN DE19617940-A1.

XX 30-OCT-1997.

PF 29-APR-1996; 96DE-01017940.

PR 29-APR-1996; 96DE-01017940.

PA (IHFH-) IHF INST HORMON & FORTPFLANZUNGS.

PI Osterhoff C, Ivell R;

DR WPI; 1997-527841/49.

DR N-PSDB; AAT97955.

PT DNA encoding epididymis-specific receptor protein - useful for developing  
PT male infertility or contraceptive treatments.

PS Claim 1; Page 19-22; 33pp; German.

CC This sequence represents a novel epididymis-specific receptor protein  
CC which is a transmembrane protein associated with the epididymis  
CC epithelium and is closely connected with sperm maturation. The protein or  
CC its derivative or fragments may be useful for detecting autoantibodies in  
CC the serum of infertile men and for developing ligands specific for the  
CC receptor, e.g. agonists that may stimulate sperm maturation and thus be  
CC useful for treating male infertility or antagonists that may be useful  
CC for contraception. The antibodies can be used to detect the receptor in  
CC vitro or in vivo. Oligonucleotides derived from the DNA sequences can be  
CC used as diagnostic probes

SQ Sequence 1038 AA;

Query Match 100.0%; Score 63; DB 2; Length 1038;  
Best Local Similarity 100.0%; Pred. No. 0.19;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CWINNAVY 10  
Db 799 CWINNAVY 808  
|||||



RESULT 34  
 ADN88606  
 ID ADN88606 standard; protein; 1041 AA.  
 AC ADN88606;  
 XX  
 XX 29-JUL-2004 (first entry)  
 DT  
 XX Human epididymis-specific receptor protein-6 (HE6) polypeptide #10.  
 DE  
 XX  
 XX Human epididymis-specific receptor protein-6; HE6;  
 KW male reproductive disorder; infertility; antiinfertility; contraceptive;  
 KW receptor.  
 KW  
 XX Homo sapiens.  
 OS  
 XX WO2004037860-A1.  
 PN  
 XX 06-MAY-2004.  
 PD  
 XX 21-OCT-2003; 2003WO-EP011662.  
 PF  
 XX 22-OCT-2002; 2002US-0419979P.  
 PR  
 XX (SCHD ) SCHERING AG.  
 PA  
 XX Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
 PI Gottwald U, Nubbemeyer R;  
 PI  
 XX WPI: 2004-357427/33.  
 DR N-PSDB; ADN88562.  
 DR  
 XX Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
 PT polypeptide, useful for isolating agents used for treating male  
 PT infertility, or for male contraception.  
 PT  
 XX Claim 58; SEQ ID NO 44; 127pp; English.  
 PS  
 XX The invention relates to the human epididymis-specific receptor protein-6  
 CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)  
 CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
 CC polypeptide. The invention also relates to an antibody or its fragment  
 CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
 CC composition comprising an antisense nucleotide which can bind with any of  
 CC the nucleotide sequences encoding an epididymis-specific receptor protein  
 CC -6 of the invention, a pharmaceutical composition for treating a male  
 CC reproductive disorder comprising a polynucleotide of the invention, a  
 CC method of diagnosing infertility in a male mammal and a method of  
 CC treating infertility in a male mammal. The polynucleotides encoding the  
 CC polypeptides are useful for isolating an agent that modulates expression  
 CC or activity of the polypeptides. The sequences are useful for diagnosing  
 CC a male reproductive disorder. This sequence represents an HE6 polypeptide  
 CC of the invention.  
 XX  
 SQ Sequence 1041 AA;  
 Query Match 100.0%; Score 63; DB 8; Length 1041;  
 Best Local Similarity 100.0%; Pred. No. 0.19;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNNNAVY 10  
 DB 802 CWINNNNAVY 811  
 |||||  
 RESULT 35  
 ADN88600  
 ID ADN88600 standard; protein; 1047 AA.  
 AC ADN88600;  
 XX  
 XX

DT 29-JUL-2004 (first entry)  
 XX Human epididymis-specific receptor protein-6 (HE6) polypeptide #4.  
 DE  
 XX Human epididymis-specific receptor protein-6; HE6;  
 KW male reproductive disorder; infertility; antiinfertility; contraceptive;  
 KW receptor.  
 KW  
 XX Homo sapiens.  
 OS  
 XX WO2004037860-A1.  
 PN  
 XX 06-MAY-2004.  
 PD  
 XX 21-OCT-2003; 2003WO-EP011662.  
 PF  
 XX 22-OCT-2002; 2002US-0419979P.  
 PR  
 XX (SCHD ) SCHERING AG.  
 PA  
 XX Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
 PI Gottwald U, Nubbemeyer R;  
 PI  
 XX WPI: 2004-357427/33.  
 DR N-PSDB; ADN88579.  
 DR  
 XX Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
 PT polypeptide, useful for isolating agents used for treating male  
 PT infertility, or for male contraception.  
 PT  
 XX Claim 58; SEQ ID NO 38; 127pp; English.  
 PS  
 XX The invention relates to the human epididymis-specific receptor protein-6  
 CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)  
 CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
 CC polypeptide. The invention also relates to an antibody or its fragment  
 CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
 CC composition comprising an antisense nucleotide which can bind with any of  
 CC the nucleotide sequences encoding an epididymis-specific receptor protein  
 CC -6 of the invention, a pharmaceutical composition for treating a male  
 CC reproductive disorder comprising a polynucleotide of the invention, a  
 CC method of diagnosing infertility in a male mammal and a method of  
 CC treating infertility in a male mammal. The polynucleotides encoding the  
 CC polypeptides are useful for isolating an agent that modulates expression  
 CC or activity of the polypeptides. The sequences are useful for diagnosing  
 CC a male reproductive disorder. This sequence represents an HE6 polypeptide  
 CC of the invention.  
 XX  
 SQ Sequence 1047 AA;  
 Query Match 100.0%; Score 63; DB 8; Length 1047;  
 Best Local Similarity 100.0%; Pred. No. 0.19;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNNNAVY 10  
 DB 808 CWINNNNAVY 817  
 |||||  
 RESULT 36  
 ADN88608  
 ID ADN88608 standard; protein; 1049 AA.  
 XX  
 AC ADN88608;  
 XX  
 XX 29-JUL-2004 (first entry)  
 DT  
 XX Human epididymis-specific receptor protein-6 (HE6) polypeptide #12.  
 DE  
 XX Human epididymis-specific receptor protein-6; HE6;  
 KW male reproductive disorder; infertility; antiinfertility; contraceptive;  
 KW receptor.  
 KW



```

OS Homo sapiens.
XX WO2004037860-A1.
XX
XX 06-MAY-2004.
XX
XX 21-OCT-2003; 2003WO-EP011662.
XX
XX 22-OCT-2002; 2002US-0419979P.
XX
XX (SCHD ) SCHERING AG.
XX
XX Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;
XX Gottwald U, Nubbemeyer R;
XX WPI; 2004-357427/33.
XX N-PSDB; ADN88581.
XX
XX Novel isolated human, mouse or rat epididymis-specific receptor protein-6
XX polypeptide, useful for isolating agents used for treating male
XX infertility, or for male contraception.
XX
XX Claim 58; SEQ ID NO 46; 127pp; English.
XX
XX The invention relates to the human epididymis-specific receptor protein-6
XX (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)
XX polypeptide and the rat epididymis-specific receptor protein-6 (RE6)
XX polypeptide. The invention also relates to an antibody or its fragment
XX specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical
XX composition comprising an antisense nucleotide which can bind with any of
XX the nucleotide sequences encoding an epididymis-specific receptor protein
XX -6 of the invention, a pharmaceutical composition for treating a male
XX reproductive disorder comprising a polynucleotide of the invention, a
XX method of diagnosing infertility in a male mammal and a method of
XX treating infertility in a male mammal. The polynucleotides encoding the
XX polypeptides are useful for isolating an agent that modulates expression
XX or activity of the polypeptides. The sequences are useful for diagnosing
XX a male reproductive disorder. This sequence represents an HE6 polypeptide
XX of the invention.
XX
XX SQ Sequence 1049 AA;
XX
XX Query Match 100.0%; Score 63; DB 8; Length 1049;
XX Best Local Similarity 100.0%; Pred. No. 0.19;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10
DB |||||
810 CWINNNAVY 819

RESULT 37
ADN88604
ID ADN88604 standard; protein; 1055 AA.
AC
AC ADN88604;
XX
XX 29-JUL-2004 (first entry)
XX
XX Human epididymis-specific receptor protein-6 (HE6) polypeptide #8.
XX
XX Human epididymis-specific receptor protein-6; HE6;
XX male reproductive disorder; infertility; antiinfertility; contraceptive;
XX receptor.
XX
XX Homo sapiens.
XX
XX WO2004037860-A1.
XX
XX 06-MAY-2004.
XX
XX 21-OCT-2003; 2003WO-EP011662.
XX

```

```

PR 22-OCT-2002; 2002US-0419979P.
XX (SCHD ) SCHERING AG.
XX
XX Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;
XX Gottwald U, Nubbemeyer R;
XX WPI; 2004-357427/33.
XX N-PSDB; ADN88581.
XX
XX Novel isolated human, mouse or rat epididymis-specific receptor protein-6
XX polypeptide, useful for isolating agents used for treating male
XX infertility, or for male contraception.
XX
XX Claim 58; SEQ ID NO 42; 127pp; English.
XX
XX The invention relates to the human epididymis-specific receptor protein-6
XX (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)
XX polypeptide and the rat epididymis-specific receptor protein-6 (RE6)
XX polypeptide. The invention also relates to an antibody or its fragment
XX specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical
XX composition comprising an antisense nucleotide which can bind with any of
XX the nucleotide sequences encoding an epididymis-specific receptor protein
XX -6 of the invention, a pharmaceutical composition for treating a male
XX reproductive disorder comprising a polynucleotide of the invention, a
XX method of diagnosing infertility in a male mammal and a method of
XX treating infertility in a male mammal. The polynucleotides encoding the
XX polypeptides are useful for isolating an agent that modulates expression
XX or activity of the polypeptides. The sequences are useful for diagnosing
XX a male reproductive disorder. This sequence represents an HE6 polypeptide
XX of the invention.
XX
XX SQ Sequence 1055 AA;
XX
XX Query Match 100.0%; Score 63; DB 8; Length 1055;
XX Best Local Similarity 100.0%; Pred. No. 0.19;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10
DB |||||
816 CWINNNAVY 825

RESULT 38
ADN88602
ID ADN88602 standard; protein; 1057 AA.
AC
AC ADN88602;
XX
XX 29-JUL-2004 (first entry)
XX
XX Human epididymis-specific receptor protein-6 (HE6) polypeptide #6.
XX
XX Human epididymis-specific receptor protein-6; HE6;
XX male reproductive disorder; infertility; antiinfertility; contraceptive;
XX receptor.
XX
XX Homo sapiens.
XX
XX WO2004037860-A1.
XX
XX 06-MAY-2004.
XX
XX 21-OCT-2003; 2003WO-EP011662.
XX
XX 22-OCT-2002; 2002US-0419979P.
XX
XX (SCHD ) SCHERING AG.
XX
XX Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;
XX Gottwald U, Nubbemeyer R;
XX WPI; 2004-357427/33.
XX

```

DR N-PSDB; ADN88580.  
 XX Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
 PT polypeptide, useful for isolating agents used for treating male  
 PT infertility, or for male contraception.  
 XX  
 PS Claim 58; SEQ ID NO 40; 127pp; English.  
 XX  
 CC The invention relates to the human epididymis-specific receptor protein-6  
 CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)  
 CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
 CC polypeptide. The invention also relates to an antibody or its fragment  
 CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
 CC composition comprising an antisense nucleotide which can bind with any of  
 CC the nucleotide sequences encoding an epididymis-specific receptor protein  
 CC -6 of the invention, a pharmaceutical composition for treating a male  
 CC reproductive disorder comprising a polynucleotide of the invention, a  
 CC method of diagnosing infertility in a male mammal and a method of  
 CC treating infertility in a male mammal. The polynucleotides encoding the  
 CC polypeptides are useful for isolating an agent that modulates expression  
 CC or activity of the polypeptides. The sequences are useful for diagnosing  
 CC a male reproductive disorder. This sequence represents an HE6 polypeptide  
 CC of the invention.  
 XX  
 SQ Sequence 1057 AA;  
 Query Match 100.0%; Score 63; DB 8; Length 1057;  
 Best Local Similarity 100.0%; Pred. No. 0.2;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNAVY 10  
 |||||||||  
 Db 818 CWINNAVY 827  
 RESULT 39  
 ADN88610  
 ID ADN88610 standard; protein; 1071 AA.  
 XX  
 AC ADN88610;  
 XX  
 DT 29-JUL-2004 (first entry)  
 XX  
 DE Human epididymis-specific receptor protein-6 (HE6) polypeptide #14.  
 XX  
 KW Human epididymis-specific receptor protein-6; HE6;  
 KW male reproductive disorder; infertility; antiinfertility; contraceptive;  
 KW receptor.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO2004037860-A1.  
 XX  
 PD 06-MAY-2004.  
 XX  
 XX 21-OCT-2003; 2003WO-EF011662.  
 XX  
 XX 22-OCT-2002; 2002US-0419979P.  
 XX  
 XX (SCHD ) SCHERING AG.  
 XX  
 PI Kirchhoff C, Obermann-Pless H, Samalecos A, Osterhoff C;  
 PI Gottwald U, Nubbemeyer R;  
 XX  
 DR WPI; 2004-357427/33.  
 DR N-PSDB; ADN88584.  
 XX  
 XX Novel isolated human, mouse or rat epididymis-specific receptor protein-6  
 PT polypeptide, useful for isolating agents used for treating male  
 PT infertility, or for male contraception.  
 XX  
 PS Claim 58; SEQ ID NO 48; 127pp; English.

CC The invention relates to the human epididymis-specific receptor protein-6  
 CC (HE6) polypeptide, the mouse epididymis-specific receptor protein-6 (ME6)  
 CC polypeptide and the rat epididymis-specific receptor protein-6 (RE6)  
 CC polypeptide. The invention also relates to an antibody or its fragment  
 CC specific for the HE6, ME6 or RE6 polypeptide, a pharmaceutical  
 CC composition comprising an antisense nucleotide which can bind with any of  
 CC the nucleotide sequences encoding an epididymis-specific receptor protein  
 CC -6 of the invention, a pharmaceutical composition for treating a male  
 CC reproductive disorder comprising a polynucleotide of the invention, a  
 CC method of diagnosing infertility in a male mammal and a method of  
 CC treating infertility in a male mammal. The polynucleotides encoding the  
 CC polypeptides are useful for isolating an agent that modulates expression  
 CC or activity of the polypeptides. The sequences are useful for diagnosing  
 CC a male reproductive disorder. This sequence represents an HE6 polypeptide  
 CC of the invention.  
 XX  
 SQ Sequence 1071 AA;  
 Query Match 100.0%; Score 63; DB 8; Length 1071;  
 Best Local Similarity 100.0%; Pred. No. 0.2;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CWINNAVY 10  
 |||||||||  
 Db 832 CWINNAVY 841  
 RESULT 40  
 ADF70415  
 ID ADF70415 standard; protein; 1252 AA.  
 XX  
 AC ADF70415;  
 XX  
 DT 12-FEB-2004 (first entry)  
 XX  
 DE Orphan receptor ligand-related human protein SeqID38.  
 XX  
 KW ligand; orphan receptor protein; fusion protein; fluorescent protein;  
 KW cell expression; green fluorescent protein; GFP; GFP-1; wild-type GFP;  
 KW GFPuv; Enhanced GFP; EGFP; human.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO2003071272-A1.  
 XX  
 PD 28-AUG-2003.  
 XX  
 XX 21-FEB-2003; 2003WO-JP001901.  
 XX  
 XX 22-FEB-2002; 2002JP-00045728.  
 PR 23-JUL-2002; 2002JP-00213949.  
 PR 11-OCT-2002; 2002JP-00298237.  
 XX  
 XX (TAKE ) TAKEDA CHEM IND LTD.  
 XX  
 XX Hinuma S, Fujii R, Ogi K, Komatsu H, Kawamata Y, Hosoya M;  
 PI WPI; 2003-697654/66.  
 DR N-PSDB; ADF70517.  
 XX  
 PT Transformation of cells with a fusion protein of an orphan receptor  
 PT protein with a fluorescent protein useful for identification of ligands  
 PT to the orphan receptor.  
 XX  
 PS Disclosure; SEQ ID NO 38; 594pp; Japanese.  
 XX  
 CC This invention relates to a novel method of identifying ligands to an  
 CC orphan receptor protein which comprises transforming cells with DNA  
 CC encoding a fusion protein of the orphan receptor with a fluorescent  
 CC protein, so that the fusion protein is expressed in the cells (or cell  
 CC membranes isolated from them) and contacting the cells with the potential  
 CC ligand to be tested. A suitable fluorescent protein for incorporation in  
 CC the fusion protein is green fluorescent protein (GFP), for example GFP-1,

CC wild-type GFP, GFPuv or Enhanced GFP (EGFP). The method is useful for the  
 CC identification of ligands binding to an orphan receptor protein.

XX  
 SQ Sequence 1252 AA;

Query Match 100.0%; Score 63; DB 7; Length 1252;  
 Best Local Similarity 100.0%; Pred. NO. 0.23;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNAVFY 10  
 |||||  
 Db 775 CWINNAVFY 784

Search completed: October 20, 2005, 07:41:25  
 Job time : 166 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 20, 2005, 05:49:15 ; Search time 22 Seconds  
(without alignments)  
43.735 Million cell updates/sec

Title: US-10-668-181-6

Perfect score: 63

Sequence: 1 CWINNNAVFY 10

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR\_79:\*

1: pir1:\*

2: pir2:\*

3: pir3:\*

4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	47	74.6	621	2 T22904	hypothetical prote
2	41	65.1	534	2 S44886	ZK112.1 protein -
3	40	63.5	413	2 I50662	lecithin-cholester
4	40	63.5	440	1 XXHUN	phosphatidylcholin
5	40	63.5	440	1 XXRTN	phosphatidylcholin
6	40	63.5	440	2 J1502	phosphatidylcholin
7	39	61.9	204	2 S22616	hypothetical prote
8	39	61.9	438	1 XXMSN	phosphatidylcholin
9	39	61.9	564	2 A96999	pectate lyase rela
10	39	61.9	590	2 I40608	csPA protein - Clo
11	39	61.9	635	2 S57714	csPB protein - Clo
12	38.5	61.1	559	1 JQ2010	transcription fact
13	38	60.3	162	2 G95998	probable acetyltra
14	38	60.3	355	2 T12032	NADH2 dehydrogenas
15	38	60.3	355	2 T12031	NADH2 dehydrogenas
16	38	60.3	355	2 T12033	NADH2 dehydrogenas
17	38	60.3	355	2 T77588	O-antigen polymera
18	38	60.3	438	2 D83251	B-band O-antigen p
19	38	60.3	575	2 S72283	DNA-directed RNA p
20	38	60.3	712	1 ALBSG3	cyclomaltodextrin
21	38	60.3	713	1 ALBSG1	cyclomaltodextrin
22	38	60.3	2817	2 B97033	uncharacterized pr
23	37	58.7	255	2 T50655	expansin EXP5 [imp
24	37	58.7	258	2 T48247	expansin-like prot
25	37	58.7	375	2 AC1350	N-acetylmuramoyl-L
26	37	58.7	395	2 S28606	Stilp protein - fi
27	37	58.7	490	2 D84998	low-affinity inorg
28	37	58.7	677	2 T11231	NADH2 dehydrogenas
29	37	58.7	778	2 T31037	hypothetical prote

#### ALIGNMENTS

##### RESULT 1

T22904

hypothetical protein F58B4.1 - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C>Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 09-Jul-2004

C:Accession: T22904

R:Wilkinson, J.

submitted to the EMBL Data Library, June 1996

A:Reference number: Z19634

A:Accession: T22904

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-621 <WIL>

A:Cross-references: UNIPROT:Q20975; EMBL:Z74038; PIDN:CAA98497.1; GSPDB:GN00023; CESP:F5

A:Experimental source: clone F58B4

C:Genetics:

A:Gene: CESP:F58B4.1

A:Map position: 5

A:Introns: 47/3; 94/3; 135/2; 157/1; 185/1; 218/3; 253/3; 328/1; 366/3; 447/2; 511/2; 58

Query Match 74.6%; Score 47; DB 2; Length 621;

Best Local Similarity 70.0%; Pred. No. 3.2;

Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 CWINNNAVFY 10

Db 612 CWMNNNNFY 621

##### RESULT 2

S44886

ZK112.1 protein - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C>Date: 14-Sep-1994 #sequence\_revision 12-May-1995 #text\_change 09-Jul-2004

C:Accession: S44886

R:Du, Z.

submitted to the EMBL Data Library, May 1993

A:Description: Sequence of the C. elegans cosmid ZK112.

A:Reference number: S44616

A:Accession: S44886

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-534 <DUZ>

A:Cross-references: UNIPROT:P34610; EMBL:L14324; NID:G289740; PID:G289741

C:Genetics:

A:Introns: 25/3; 65/2; 196/2; 249/1; 275/1; 385/2; 415/2

C:Superfamily: Caenorhabditis elegans ZK688.6 protein

Query Match 65.1%; Score 41; DB 2; Length 534;

Best Local Similarity 75.0%; Pred. No. 28;

Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

conserved hypothet  
baseplate protein  
microbial collagen  
hypothetical prote  
hypothetical prote  
hypothetical prote  
hypothetical prote  
hypothetical prote  
expansin EXP1 [imp  
probable expansin  
hypothetical prote  
hypothetical prote  
msAPla - mouse  
amino acid transpo  
probable serine ca  
fusion of Uroporph  
cAMP receptor subt



C:Superfamily: phosphatidylcholine-sterol acyltransferase  
C:Keywords: acyltransferase; glycoprotein; lipid metabolism; lipoprotein  
F:1-24/Domain: signal sequence #status predicted <SIG>  
F:25-438/Product: phosphatidylcholine-sterol acyltransferase #status predicted <MAT>  
F:44,108,296,408/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 63.5%; Score 40; DB 1; Length 440;  
Best Local Similarity 60.0%; Pred. No. 34;  
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 CWINNNAVFY 10  
|||:|:|  
Db 98 CWIDNTRVY 107

RESULT 6  
JC1502  
phosphatidylcholine-sterol O-acyltransferase (EC 2.3.1.43) precursor - baboon  
A:Alternate names: lecithin-cholesterol acyltransferase  
C:Species: Papio sp. (baboon)  
C:Date: 24-Feb-1994 #sequence\_revision 24-Feb-1994 #text\_change 03-Jun-2002  
C:Accession: JC1502  
R:Hixson, J.E.; Driscoll, D.M.; Birnbaum, S.; Britten, M.L.  
Gene 128, 235-299, 1993  
A:Title: Baboon lecithin cholesterol acyltransferase (LCAT): cDNA sequences of two alleles  
A:Reference number: JC1502; MUID:93293002; PMID:8514197  
A:Accession: JC1502  
A:Molecule type: mRNA  
A:Residues: 1-440 <HIX>  
A:Cross-references: GB:L08633; NID:gl76591; PIDN:AAA35388.1; PID:gl76592  
C:Comment: This enzyme is a key enzyme of cholesterol metabolism that catalyzes esterification  
C:Genetics:  
A:Gene: LCAT  
C:Superfamily: phosphatidylcholine-sterol acyltransferase  
C:Keywords: acyltransferase  
F:1-24/Domain: signal sequence #status predicted <SIG>  
F:25-440/Product: phosphatidylcholine-sterol O-acyltransferase #status predicted <PPC>

Query Match 63.5%; Score 40; DB 2; Length 440;  
Best Local Similarity 60.0%; Pred. No. 34;  
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 CWINNNAVFY 10  
|||:|:|  
Db 98 CWIDNTRVY 107

RESULT 7  
S22616  
hypothetical protein 14.9 - Salmonella choleraesuis  
C:Species: Salmonella choleraesuis  
C:Date: 22-Nov-1993 #sequence\_revision 26-May-1995 #text\_change 22-Oct-1999  
C:Accession: S22616  
R:Brown, P.K.; Romana, L.K.; Reeves, P.R.  
Mol. Microbiol. 6, 1385-1394, 1992  
A:Title: Molecular analysis of the rfb gene cluster of Salmonella serovar muenchen (strain 14.9)  
A:Reference number: S22613; MUID:92349566; PMID:1379320  
A:Accession: S22616  
A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
A:Molecule type: DNA  
A:Residues: 1-204 <BRO>  
A:Cross-references: EMBL:X61917; NID:G47004; PIDN:CAA43910.1; PID:G47008  
C:Superfamily: galactoside acetyltransferase

Query Match 61.9%; Score 39; DB 2; Length 204;  
Best Local Similarity 75.0%; Pred. No. 23;  
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CWINNNAV 8  
|||:|:|  
Db 156 CWIGNNAV 163

C:Superfamily: phosphatidylcholine-sterol O-acyltransferase (EC 2.3.1.43) precursor - mouse  
A:Alternate names: lecithin-cholesterol acyltransferase precursor; phospholipid-cholesterol  
C:Species: Mus musculus (house mouse)  
C:Date: 30-Sep-1993 #sequence\_revision 30-Sep-1993 #text\_change 09-Jul-2004  
C:Accession: A34158; S21370  
R:Warden, C.H.; Langner, C.A.; Gordon, J.I.; Taylor, B.A.; McLean, J.W.; Luisis, A.J.  
J. Biol. Chem. 264, 21573-21581, 1989  
A:Title: Tissue-specific expression, developmental regulation, and chromosomal mapping of  
A:Reference number: A34158; MUID:90094326; PMID:2600083  
A:Accession: A34158  
A:Molecule type: mRNA  
A:Residues: 1-438 <WAR>  
A:Cross-references: UNIPROT:P16301; GB:J05154; NID:gl98759; PIDN:AAA39419.1; PID:G293697  
A:Note: the authors translated the codon ATG for residue 411 as Leu  
R:Meroni, G.; Malgarutti, N.; Magnaghi, P.; Taramelli, R.  
submitted to the EMBL Data Library, July 1990  
A:Description: Promoter and 5' flanking sequences of the mouse LCAT gene.  
A:Reference number: S21370  
A:Accession: S21370  
A:Molecule type: DNA  
A:Residues: 1-14 <MER>  
A:Cross-references: EMBL:X54095; NID:G52873; PIDN:CAA38029.1; PID:G52874  
C:Comment: The active enzyme catalyzes the transfer of acyl groups from lecithin to sterol  
including cholesterol, can act as acceptor. Apolipoprotein A-I is a potent activator for the  
C:Superfamily: phosphatidylcholine-sterol acyltransferase  
C:Keywords: acyltransferase; glycoprotein; lipid metabolism; lipoprotein  
F:1-24/Domain: signal sequence #status predicted <SIG>  
F:25-438/Product: phosphatidylcholine-sterol acyltransferase #status predicted <MAT>  
F:44,108,296,408/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 61.9%; Score 39; DB 1; Length 438;  
Best Local Similarity 50.0%; Pred. No. 50;  
Matches 5; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 CWINNNAVFY 10  
|||:|:|  
Db 98 CWIDNTRVY 107

RESULT 9  
A96999  
pectate lyase related protein, secreted [imported] - Clostridium acetobutylicum  
C:Species: Clostridium acetobutylicum  
C:Date: 14-Sep-2001 #sequence\_revision 14-Sep-2001 #text\_change 09-Jul-2004  
C:Accession: A96999  
R:Nolling, J.; Breton, G.; Omelchenko, M.V.; Markarova, K.S.; Zeng, Q.; Gibson, R.; Lee, J.; Daly, M.J.; Bennett, G.N.; Koonin, E.V.; Smith, D.R.  
J. Bacteriol. 183, 4823-4838, 2001  
A:Title: Genome Sequence and Comparative Analysis of the Solvent-Producing Bacterium Clostridium acetobutylicum ATCC824  
A:Reference number: A96900; MUID:21359325; PMID:21359325  
A:Accession: A96999  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-564 <KUR>  
A:Cross-references: UNIPROT:Q97KW2; GB:AE001437; PIDN:AAK78780.1; PID:G15023693; GSPDB:G15023693  
A:Experimental source: Clostridium acetobutylicum ATCC824  
C:Genetics:  
A:Gene: CAC0804

Query Match 61.9%; Score 39; DB 2; Length 564;  
Best Local Similarity 55.6%; Pred. No. 64;  
Matches 5; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2 WINNNNAVY 10  
||:|:|:|  
Db 299 WWHNNDLFY 307

RESULT 10  
140608  
cspA protein - Clostridium acetobutylicum

C;Species: Clostridium acetobutylicum  
C;Date: 12-Aug-1996 #sequence\_revision 12-Aug-1996 #text\_change 09-Jul-2004  
C;Accession: J40608; S49255  
R;Sanchez-Beato, A.R.; Ronda, C.; Garcia, J.L.  
J. Bacteriol. 177, 1098-1103, 1995  
A;Title: Tracking the evolution of the bacterial choline-binding domain: molecular characterization  
A;Reference number: J40607; MUID:95164512; PMID:7860591  
A;Accession: J40608  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-590 <RES>  
A;Cross-references: UNIPROT:Q45819; EMBL:Z37723; NID:G550295; PIDN:CAA85778.1; PID:G550295  
C;Genetics:  
A;Gene: csbA  
F;501-520/Domain: cpl repeat homology <CP1>  
F;521-540/Domain: cpl repeat homology <CP2>  
F;541-560/Domain: cpl repeat homology <CP3>

Query Match 61.9%; Score 39; DB 2; Length 590;  
Best Local Similarity 55.6%; Pred. No. 67;  
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2 WINNNVAFY 10  
|:|:|  
Db 554 WLNDNGTFY 562

RESULT 11  
S57714  
csb protein - Clostridium acetobutylicum  
C;Species: Clostridium acetobutylicum  
C;Date: 19-Oct-1995 #sequence\_revision 03-Nov-1995 #text\_change 09-Jul-2004  
C;Accession: S57714  
R;Sanchez-Beato, A.; Garcia, J.  
submitted to the EMBL Data Library, July 1995  
A;Description: Molecular characterization of a family of choline-binding proteins of Clostridium  
A;Reference number: S57714  
A;Accession: S57714  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-635 <SAN>  
A;Cross-references: UNIPROT:Q45820; EMBL:Z50008; NID:G895756; PIDN:CAA90303.1; PID:G895756  
F;522-541/Domain: cpl repeat homology <CP1>  
F;542-561/Domain: cpl repeat homology <CP2>  
F;602-621/Domain: cpl repeat homology <CP3>

Query Match 61.9%; Score 39; DB 2; Length 635;  
Best Local Similarity 55.6%; Pred. No. 72;  
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2 WINNNVAFY 10  
|:|:|:|  
Db 575 WLNNNGTWY 583

RESULT 12  
JQ2010  
transcription factor POU-1 - planarian (Dugesia japonica)  
C;Species: Dugesia japonica  
C;Date: 03-Feb-1994 #sequence\_revision 03-Feb-1994 #text\_change 09-Jul-2004  
C;Accession: JQ2010  
R;Orli, H.; Agata, K.; Watanabe, K.  
Biochem. Biophys. Res. Commun. 192, 1395-1402, 1993  
A;Title: POU-domain genes in planarian Dugesia japonica: the structure and expression.  
A;Reference number: JQ2010; MUID:93282851; PMID:8099480  
A;Accession: JQ2010  
A;Molecule type: mRNA  
A;Residues: 1-559 <ORI>  
A;Cross-references: UNIPROT:P31370; DBJ:D12924; NID:G217311; PIDN:BAA02308.1; PID:G217311  
A;Experimental source: strain G1  
C;Genetics:  
A;Gene: DjpPOU1  
C;Superfamily: planarian transcription factor POU-1; homeobox homolog; POU domain homolog



Query Match 60.3%; Score 38; DB 2; Length 355;  
Best Local Similarity 55.6%; Pred. No. 59;  
Matches 5; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2 WINNNAVFY 10  
|:|:|  
Db 260 WWSNSLVFY 268

## RESULT 15

TI2031  
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 5 - Carabus cribratus mitochondrion  
C:Species: mitochondrion Carabus cribratus  
C:Date: 05-Nov-1999 #sequence\_revision 05-Nov-1999 #text\_change 09-Jul-2004  
C:Accession: TI2031  
R:Imura, Y.; Su, Z.H.; Kim, C.G.; Osawa, S.  
Elytra 26, 223-248, 1998  
A:Title: Reorganization of the Oreocarabus complex (Coleoptera, Carabidae) based on endo  
A:Reference number: Z17381  
A:Accession: TI2031  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: DNA  
A:Residues: 1-355 <IMU>  
A:Cross-references: UNIPROT:O79579; EMBL:AB017460; PIDN:BAA33176.1  
A:Experimental source: isolate Artvin Turkey; adult; thorax muscle  
C:Genetics:  
A:Genome: mitochondrion  
A:Note: ND5  
C:Superfamily: NADH dehydrogenase (ubiquinone) chain 5  
C:Keywords: membrane-associated complex; mitochondrion; NAD; oxidative phosphorylation;

Query Match 60.3%; Score 38; DB 2; Length 355;  
Best Local Similarity 55.6%; Pred. No. 59;  
Matches 5; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2 WINNNAVFY 10  
|:|:|  
Db 260 WWSNSLVFY 268

Search completed: October 20, 2005, 05:49:54  
Job time : 26 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 20, 2005, 05:49:15 ; Search time 55 Seconds  
(without alignments)  
93.105 Million cell updates/sec

Title: US-10-668-181-6  
Perfect score: 63  
Sequence: 1 CWINNAVY 10

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt\_03.\*

1: uniprot\_sprot.\*

2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	63	100.0	1017	1	GP64 HUMAN
2	54	85.7	1009	1	Q812P9 homo sapien
3	49	77.8	1013	1	Q812P9 mus musculus
4	47	74.6	578	2	Q20975 caenorhabdi
5	44	69.8	566	2	Q6CSG6 kluyveromyc
6	43	68.3	2799	1	G112 HUMAN
7	42	66.7	128	2	Q81FE2
8	42	66.7	168	2	Q9LQW3
9	42	66.7	268	2	Q9EPES
10	42	66.7	779	2	Q7RLD7
11	41	65.1	105	2	Q70UX2
12	41	65.1	125	2	Q70UX6
13	41	65.1	126	2	Q70UX1
14	41	65.1	136	2	Q70UX9
15	41	65.1	136	2	Q70UX0
16	41	65.1	136	2	Q70UX3
17	41	65.1	136	2	Q70UX4
18	41	65.1	136	2	Q70UX7
19	41	65.1	141	2	Q9GLR5
20	41	65.1	191	2	Q64SF1
21	41	65.1	282	2	Q832C2
22	41	65.1	297	2	Q35591
23	41	65.1	299	1	LCAT_ELIQU
24	41	65.1	565	1	PCPI_CAEEL
25	41	65.1	572	2	Q7RF10
26	40	63.5	124	2	Q70UX5
27	40	63.5	134	2	Q08942
28	40	63.5	134	2	Q70UW8
29	40	63.5	135	2	Q9ESE7
30	40	63.5	138	2	Q08935
31	40	63.5	140	2	O08944

32 40 63.5 148 2 Q9GLR6 Q9glr6 didelphis m  
33 40 63.5 201 2 Q811B4 Q811e4 mus musculus  
34 40 63.5 209 2 Q8HZA0 Q8hza0 macaca sp.  
35 40 63.5 209 2 Q8HZA1 Q8hza1 pongo pygma  
36 40 63.5 256 2 Q9EPC9 Q9epc9 sicista kaz  
37 40 63.5 258 2 Q9EPD6 Q9epd6 deomys ferr  
38 40 63.5 264 2 Q9EPD6 Q9epd6 macrotarson  
39 40 63.5 264 2 Q9EPD6 Q9epd6 acromys cahi  
40 40 63.5 265 2 Q91YB3 Q91yb3 snccostomus  
41 40 63.5 265 2 Q9EPD7 Q9epd7 mesocricetu  
42 40 63.5 266 2 Q9EPC8 Q9epc8 steatomys s  
43 40 63.5 267 2 Q9EPC7 Q9epc7 uranomyia ru  
44 40 63.5 267 2 Q9EPE0 Q9epc0 jaculus jac  
45 40 63.5 268 2 Q91YH4 Q91yh4 cricetomys

## ALIGNMENTS

RESULT 1  
GP64\_HUMAN  
ID GP64\_HUMAN STANDARD; PRT: 1017 AA.  
AC Q81ZP9; O00406; Q81WT2; Q81ZE4; Q81ZE5; Q81ZE6; Q81ZE7; Q81ZP3;  
AC Q81ZP4;  
DT 29-MAR-2004 (Rel. 43, Created)  
DT 29-MAR-2004 (Rel. 43, Last sequence update)  
DT 25-OCT-2004 (Rel. 45, Last annotation update)  
DE G protein-coupled receptor 64 precursor (Epididymis-specific protein  
6) (Hsf receptor).  
DE Name=Q81ZP4; Synonyms=HE6, TM7LN2;  
GN Homo sapiens (Human).  
OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A. (ISOFORM 2).  
RC TISSUE=Epididymis;  
RX MEDLINE=97294669; PubMed=9150425;  
RA Osterhoff C., Ivell R., Kirchhoff C.;  
RT "Cloning of a human epididymis-specific mRNA, HE6, encoding a novel  
member of the seven transmembrane-domain receptor superfamily.";  
RL DNA Cell Biol. 16:379-389(1997).  
[2]  
RN SEQUENCE FROM N.A. (ISOFORMS 1; 3; 4; 5; 6; 7; 8 AND 9).  
RP SEQUENCE=Epididymis;  
RX MEDLINE=22307585; PubMed=12420295; DOI=10.1002/mrd.10220;  
RA Obermann H., Samaleos A., Osterhoff C., Schroeder B., Heller R.,  
Kirchhoff C.;  
RT "HE6, a two-subunit heptahelical receptor associated with apical  
membranes of efferent and epididymal duct epithelia.";  
RL Mol. Reprod. Dev. 64:13-26(2003).  
CC -!- FUNCTION: Could be involved in a signal transduction pathway  
controlling epididymal function and male fertility.  
CC -!- SUBUNIT: Forms a heterodimer, consisting of a large extracellular  
region linked to a seven-transmembrane moiety (Probable).  
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
CC -!- ALTERNATIVE PRODUCTS:  
Event=Alternative splicing; Named isoforms=9;  
Name=1; Synonyms=Long splice variant;  
IsoId=Q81ZP9-1; Sequence=Displayed;  
Name=2;  
IsoId=Q81ZP9-2; Sequence=VSP\_009791;  
Name=3; Synonyms=d1;  
IsoId=Q81ZP9-3; Sequence=VSP\_009792;  
Name=4; Synonyms=24;  
IsoId=Q81ZP9-4; Sequence=VSP\_009793;  
Name=5; Synonyms=23;  
IsoId=Q81ZP9-5; Sequence=VSP\_009794;  
Name=6; Synonyms=d3;  
IsoId=Q81ZP9-6; Sequence=VSP\_009795;  
Name=7; Synonyms=d2;  
IsoId=Q81ZP9-7; Sequence=VSP\_009796;  
Name=8; Synonyms=21;



RA Schriml L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,  
RA Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.E., Cousins S.,  
RA Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,  
RA Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,  
RA Grimmer S., Gusninch S., Hirokawa N., Jackson I.J., Jarvis E.D.,  
RA Kanai A., Kawai H., Kawasawa Y., Kedzierski R.M., King B.L.,  
RA Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,  
RA Maglott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,  
RA Nagashima T., Numata K., Okido T., Pavan W.J., Pettea G., Pesole G.,  
RA Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,  
RA Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,  
RA Sandelin A., Schneider C., Sempile C.A., Setou M., Shimada K.,  
RA Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,  
RA Verardo D., Wagner L., Mahlestedt C., Wang Y., Watanabe Y., Wells C.,  
RA Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang I., Yang L.,  
RA Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,  
RA Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,  
RA Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,  
RA Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,  
RA Miyazaki A., Sakai K., Sasaki K., Shibata K., Shinagawa A.,  
RA Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,  
RA Birney E., Havaishizaki Y.,  
RT "Analysis of the mouse transcriptome based on functional annotation of  
RT 60,770 full-length cDNAs";  
RL Nature 420:563-573(2002).  
CC -!- FUNCTION: Could be involved in a signal transduction pathway  
CC controlling epididymal function and male fertility.  
CC -!- SUBUNIT: Forms a heterodimer, consisting of a large extracellular  
CC region linked to a seven-transmembrane moiety (Probable).  
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
CC -!- ALTERNATIVE PRODUCTS:  
CC Event-Alternative splicing; Named isoforms=5;  
CC Name=1; Synonyms=Long;  
CC IsoId=Q8CJ12-1; Sequence=Displayed;  
CC Name=2; Synonyms=d2; Sequence=VSP\_009808;  
CC Name=3; Synonyms=d1;  
CC IsoId=Q8CJ12-2; Sequence=VSP\_009809;  
CC Name=4; Synonyms=d3;  
CC IsoId=Q8CJ12-3; Sequence=VSP\_009807;  
CC Name=5;  
CC IsoId=Q8CJ12-4; Sequence=VSP\_009807;  
CC Name=5;  
CC IsoId=Q8CJ12-5; Sequence=VSP\_009806;  
CC -!- TISSUE SPECIFICITY: Epididymis-specific expression. Both subunits  
CC were associated with apical membranes of efferent ductule and  
CC proximal epididymal duct epithelia.  
CC -!- PTM: Proteolytically cleaved into 2 subunits, an extracellular  
CC subunit and a seven-transmembrane subunit (potential).  
CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.  
CC LN-TM7 subfamily.  
CC -!- SIMILARITY: Contains 1 GPS domain.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; AF538952; AAN33054.1; -;  
DR EMBL; AF538955; AAN33057.1; -;  
DR EMBL; AF538956; AAN33058.1; -;  
DR EMBL; AF538957; AAN33059.1; -;  
DR EMBL; AK046871; BAC32902.1; -;  
DR MGD; MGI:2446854; Gpr64.  
DR InterPro; IPR000832; GPCR\_secretin.  
DR InterPro; IPR002023; PKD\_Cys\_rich.  
DR Pfam; PF00002; 7tm\_2; 1.  
DR Pfam; PF01825; GPS; 1.  
DR PRINTS; PR00249; GPCRSECRETIN.  
DR SMART; SM00303; GPS; 1.  
DR PROSITE; PS00650; G\_PROTEIN\_RECEP\_F2\_2; FALSE\_NEG.  
DR PROSITE; PS0261; G\_PROTEIN\_RECEP\_F2\_4; 1.

DR PROSITE; PS0221; GPS; 1.  
KW Alternative splicing; G-protein coupled receptor; Glycoprotein;  
KW Signal; Transmembrane.  
FT SIGNAL 1 37  
FT CHAIN 38 1009  
FT DOMAIN 38 619  
FT TRANSMEM 620 640  
FT DOMAIN 641 659  
FT TRANSMEM 660 680  
FT DOMAIN 681 683  
FT TRANSMEM 684 704  
FT DOMAIN 705 729  
FT TRANSMEM 730 750  
FT DOMAIN 751 781  
FT TRANSMEM 782 802  
FT DOMAIN 803 826  
FT TRANSMEM 827 847  
FT DOMAIN 848 849  
FT TRANSMEM 850 870  
FT DOMAIN 871 1009  
FT DOMAIN 559 610  
FT DOMAIN 248 251  
FT DOMAIN 664 669  
FT DOMAIN 808 811  
FT DOMAIN 917 922  
FT CARBOHYD 43 43  
FT CARBOHYD 77 77  
FT CARBOHYD 91 91  
FT CARBOHYD 103 103  
FT CARBOHYD 109 109  
FT CARBOHYD 127 127  
FT CARBOHYD 136 136  
FT CARBOHYD 154 154  
FT CARBOHYD 178 178  
FT CARBOHYD 186 186  
FT CARBOHYD 362 362  
FT CARBOHYD 427 427  
FT CARBOHYD 448 448  
FT CARBOHYD 453 453  
FT CARBOHYD 520 520  
FT CARBOHYD 534 534  
FT CARBOHYD 539 539  
FT CARBOHYD 543 543  
FT CARBOHYD 589 589  
FT CARBOHYD 849 849  
FT VARSPLIC 40 66  
FT VARSPLIC 51 66  
FT VARSPLIC 64 66  
FT VARSPLIC 80 93  
FT CONFLICT 781 781  
SQ SEQUENCE 1009 AA; 110199 MW; A53C67C5527A5B6C CRC64;

Query Match 85.7%; Score 54; DB 1; Length 1009;

Best Local Similarity 80.0%; Pred No. 2,1;  
Matches 8; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CWINNAVVFY 10  
Db 770 CWINNAVVFY 779

RESULT 3  
GP64 RAT

ID GP64 RAT STANDARD; PRT; 1013 AA.  
AC Q8CJ11; Q8CJ06; Q8CJ07;  
DT 29-MAR-2004 (Rel. 43, Created)  
DT 29-MAR-2004 (Rel. 43, Last sequence update)  
DT 25-OCT-2004 (Rel. 45, Last annotation update)  
DE G protein-coupled receptor 64 precursor (Epididymis-specific protein

DE 6) (Re6 receptor).  
GN Name=Gpr84; Synonyms=Ref6;  
OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]  
RP SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).  
RC STRAIN=Lewis; TISSUE=Epididymis;  
RX MEDLINE=22307585; PubMed=12420295; DOI=10.1002/mrd.10220;  
RA Obermann H., Samalecos A., Osterhoff C., Schroeder B., Heller R.,  
RA Kirchhoff C.;  
RT membranes of efferent and epididymal duct epithelia.";  
RL Mol. Reprod. Dev. 64:13-26(2003).  
CC -1- FUNCTION: Could be involved in a signal transduction pathway  
CC CONTROLLING epididymal function and male fertility.  
CC -1- SUBUNIT: Forms a heterodimer, consisting of a large extracellular  
CC region linked to a seven-transmembrane moiety (Probable).  
CC -1- SUBCELLULAR LOCATION: Integral membrane protein.  
CC -1- ALTERNATIVE PRODUCTS:  
CC Event=Alternative splicing; Named isoforms=3;  
CC Name=1; Synonyms=long;  
CC IsoId=Q8CJ11-1; Sequence=Displayed;  
CC Name=2; Synonyms=d2;  
CC IsoId=Q8CJ11-2; Sequence=VSP\_009810;  
CC Name=3; Synonyms=dl;  
CC IsoId=Q8CJ11-3; Sequence=VSP\_009811;  
CC -1- TISSUE SPECIFICITY: Epididymys-specific expression. Both subunits  
CC were associated with apical membranes of efferent ductule and  
CC proximal epididymal duct epithelia.  
CC -1- PTM: Proteolytically cleaved into 2 subunits, an extracellular  
CC subunit and a seven-transmembrane subunit (Potential).  
CC -1- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.  
CC LN-TM7 subfamily.  
CC -1- SIMILARITY: Contains 1 GPS domain.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
CC -----  
DR EMBL; AF538953; AAN33055.1; -;  
DR EMBL; AF538958; AAN33060.1; -;  
DR EMBL; AF538959; AAN33061.1; -;  
DR RGD; 628618; Gpr64.  
DR InterPro; IPR000832; GPCR\_secretin.  
DR InterPro; IPR002034; PKD\_Cys\_rich.  
DR Pfam; PF00002; 7tm.2; 1.  
DR Pfam; PF01825; GPS; 1.  
DR PRINTS; PR00249; GPCRSECRETIN.  
DR SMART; SMO0303; GPS; 1.  
DR PROSITE; PS00650; G\_PROTEIN\_RECEP\_F2\_2; FALSE\_NEG.  
DR PROSITE; PS0261; G\_PROTEIN\_RECEP\_F2\_4; 1.  
DR PROSITE; PS0221; GPS; 1.  
DR Alternative splicing; G-protein coupled receptor; Glycoprotein;  
KW Signal; Transmembrane.  
FT SIGNAL 1 37 Potential.  
FT CHAIN 38 1013 G protein-coupled receptor 64.  
FT DOMAIN 38 623 Extracellular (Potential).  
FT TRANSMEM 624 644 1 (Potential).  
FT DOMAIN 645 663 Cytoplasmic (Potential).  
FT TRANSMEM 664 684 2 (Potential).  
FT DOMAIN 685 688 Extracellular (Potential).  
FT TRANSMEM 689 709 3 (Potential).  
FT DOMAIN 710 733 Cytoplasmic (Potential).  
FT TRANSMEM 734 754 4 (Potential).  
FT DOMAIN 755 785 Extracellular (Potential).  
FT TRANSMEM 786 806 5 (Potential).  
FT DOMAIN 807 830 Cytoplasmic (Potential).

FT TRANSMEM 831 851 6 (Potential).  
FT DOMAIN 852 853 Extracellular (Potential).  
FT TRANSMEM 854 874 7 (Potential).  
FT DOMAIN 875 1013 Cytoplasmic (Potential).  
FT DOMAIN 563 614 GPS.  
FT DOMAIN 249 252 Poly-Ser.  
FT DOMAIN 668 673 Poly-Leu.  
FT DOMAIN 812 815 Poly-Lys.  
FT DOMAIN 921 926 Poly-Ser.  
FT CARBOHYD 44 44 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 78 78 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 92 92 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 104 104 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 128 128 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 137 137 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 155 155 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 179 179 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 187 187 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 366 366 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 431 431 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 452 452 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 457 457 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 524 524 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 538 538 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 543 543 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 547 547 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 593 593 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 777 777 N-linked (GLNAC. . .) (Potential).  
FT CARBOHYD 853 853 N-linked (GLNAC. . .) (Potential).  
FT VARSPLIC 40 67 Missing (in isoform 2).  
FT FT Missing (in isoform 3).  
FT VARSPLIC 52 67 Missing (in isoform 3).  
FT FT Missing (in isoform 3).  
FT FT Missing (in isoform 3).  
SQ SEQUENCE 1013 AA; 110700 MW; 03C5467D84527216 CRC64;  
Query Match 77.8%; Score 49; DB 1; Length 1013;  
Best Local Similarity 70.0%; Pred No; 14;  
Matches 7; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
Oy 1 CWINNAVVFY 10  
| | | | | : | | |  
Db 774 CWINSSVVFY 783  
RESULT 4  
Q20975 PRELIMINARY; PRT; 578 AA.  
AC Q20975;  
DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE Hypothetical protein F58B4.1a.  
GN Names=F58B4.1a; ORFNames=F58B4.1;  
OS Caenorhabditis elegans.  
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;  
OC Rhabditidae; Peloderinae; Caenorhabditis.  
OX NCBI\_TaxID=6239;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Bristol N2;  
RX MEDLINE=99069613; PubMed=9851916;  
RA none;  
RT "Genome sequence of the nematode C.elegans: A platform for  
RT investigating biology.";  
RL Science 282:2012-2018(1998).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Bristol N2;  
RA Wilkinson J.;  
RL Submitted (JUN-1996) to the EMBL/GenBank/DBJ databases.  
DR EMBL; Z74038; CAA98497.2; -.  
DR PIR; T22904; T22904.  
DR HSP; P07584; IIAE.

```

DR WormBase; WBGene00003549; F58B4.1.
DR WormPep; F58B4.1a; CE358B1.
DR GO; GO:0008533; F:astacin activity; IEA.
DR GO; GO:0008237; F:metalloproteinase activity; IEA.
DR GO; GO:0006508; P:proteolysis and peptidolysis; IEA.
DR InterPro; IPR000859; CUB.
DR InterPro; IPR006209; EGF-like.
DR InterPro; IPR006026; Peptidase M.
DR InterPro; IPR001506; Peptidase M12A.
DR InterPro; IPR006025; Pept_M_Zn_BS.
DR InterPro; IPR003582; SHKT.
DR Pfam; PF01400; Astacin; 1.
DR Pfam; PF01549; SHKT; 1.
DR PRINTS; PR00480; ASTACIN.
DR SMART; SM00254; SHKT; 1.
DR SMART; SM00235; ZnMC; 1.
DR PROSITE; PS01180; CUB; 1.
DR PROSITE; PS00022; EGF_1; UNKNOWN_1.
DR PROSITE; PS01186; EGF_2; 1.
DR PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 578 AA; 64678 MW; 2975A841FE70E5E2 CRC64;

Query Match 74.6%; Score 47; DB 2; Length 578;
Best Local Similarity 70.0%; Pred. No. 18;
Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 CWINNAVY 10
   |||||
Db 569 CWMNNNNFY 578

RESULT 5
Q6CSG6 PRELIMINARY; PRT; 566 AA.
ID Q6CSG6
AC Q6CSG6;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Similar to sp|Q12001|Saccharomyces cerevisiae YOR002w ALG6
DE glucosyltransferase.
GN ORFNames=KLLA0D0121g;
OS Kluyveromyces lactis NRRL Y-1140.
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Kluyveromyces.
OX NCBI_TaxID=284590;
[1]
RN SEQUENCE FROM N.A.
RP STRAIN=NRRL Y-1140;
RC Genolevures;
RA Dufon B., Sherman D., Fischer G., Durrans P., Casaregola S.,
RA Lafontaine I., de Montigny J., Marck C., Neuvéglise C., Talia E.,
RA Goffard N., Frangeul L., Aigle M., Anthouard V., Babour A., Barbe V.,
RA Barnay S., Blanchin S., Beckerich J.M., Beyne E., Bleykasten C.,
RA Boisrame A., Boyer E., Cattolico L., Confanioli F., de Daruvar A.,
RA Despons L., Fabre E., Fairhead C., Ferry-Dumazet H., Groppi A.,
RA Hantraye F., Hennequin C., Jauniaux N., Joyet P., Kachouri R.,
RA Kerrest A., Koszul R., Lemaire M., Lesur I., Ma L., Muller H.,
RA Nicaud J.M., Nikolski M., Oztas S., Ozier-Kalogeropoulos O.,
RA Pellenz S., Potier S., Richard G.F., Straub M.L., Suleau A.,
RA Swennen D., Tekala F., Wesolowski-Louvel M., Westhof E., Wirth B.,
RA Zeniou-Meyer M., Zivanovic I., Bolotin-Fukuhara M., Thierry A.,
RA Bouchier C., Caudron B., Scarpelli C., Gaillardin C., Weissenbach J.,
RA Wincker P., Souciet J.L.;
RT "Genome evolution in yeasts.";
RL Nature 430:35-44 (2004).
[2]
RN SEQUENCE FROM N.A.
RP STRAIN=NRRL Y-1140;
RC Genoscope;
RA Submitted (JUL-2004) to the EMBL/GenBank/DBSJ databases.
DR EMBL; CR382124; CAH00219.1; -.
DR GO; GO:0016740; F:transferase activity; IEA.

```

---

```

DR InterPro; IPR004856; Alg6_Alg8.
DR Pfam; PF03155; Alg6_Alg8; 1.
DR KW Transferase.
SQ SEQUENCE 566 AA; 65161 MW; BEF7D2A4E2D6C074 CRC64;

Query Match 69.8%; Score 44; DB 2; Length 566;
Best Local Similarity 77.8%; Pred. No. 54;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 CWINNAVF 9
   |||||
Db 427 CWINNALF 435

RESULT 6
G112 HUMAN
ID G112 HUMAN STANDARD; PRT; 2799 AA.
AC Q81ZF6; Q86SM6;
DT 25-OCT-2004 (Rel. 45, Created)
DT 25-OCT-2004 (Rel. 45, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE G-protein coupled receptor GPR112.
GN Name=GPR112;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
[1]
RN SEQUENCE FROM N.A.
RP PubMed=12435584; DOI=10.1016/S0014-5793(02)03574-3;
RX Fredriksson R., Lagerstrom M.C., Hoeglund P.J., Schioeth H.B.;
RA "Novel human G protein-coupled receptors with long N-terminals
RA containing GPS domains and Ser/Thr-rich regions.";
RL FEBS Lett. 531:407-414 (2002).
[2]
RN SEQUENCE OF 279-1549 FROM N.A.
RX MEDLINE=22584407; PubMed=12679517; DOI=10.1073/pnas.0230374100;
RA Vassilatis D.K., Hohmann J.G., Zeng H., Li F., Ranchalis J.E.,
RA Mortrud M.T., Brown A., Rodriguez S.S., Weller J.R., Wright A.C.,
RA Bergmann J.E., Gaitanaris G.A.;
RL "The G protein-coupled receptor repertoire of human and mouse.";
RT Proc. Natl. Acad. Sci. U.S.A. 100:4903-4908 (2003).
CC -!- FUNCTION: Orphan receptor.
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC -!- SIMILARITY: Contains 1 GPS domain.
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (see http://www.isb-sib.ch/announce/
or send an email to license@sib-sib.ch).
-----
EMBL; AY140954; AAM46668.1; -.
DR EMBL; AY255561; AAC85093.1; -.
DR Genew; HGNC:18992; GPR112.
DR InterPro; IPR008985; ConA_like lec gl.
DR InterPro; IPR000832; GPCR_secretin.
DR InterPro; IPR000203; PKD_Cys_rich.
DR Pfam; PF00002; 7tm_2; 1.
DR Pfam; PF01825; GPS; 1.
DR PRINTS; PR00249; GPCRSECRETIN.
DR SMART; SM00303; GPS; 1.
DR PROSITE; PS02021; GPS; 1.
DR PROSITE; PS00649; G_PROTEIN_RECP_F2_1; FALSE_NEG.
DR PROSITE; PS00650; G_PROTEIN_RECP_F2_2; FALSE_NEG.
DR PROSITE; PS00650; G_PROTEIN_RECP_F2_3; FALSE_NEG.
DR PROSITE; PS02027; G_PROTEIN_RECP_F2_4; 1.
DR PROSITE; PS02027; G_PROTEIN_RECP_F2_4; 1.
DR KW G-protein coupled receptor; Glycoprotein; Transmembrane.
DR DOMAIN 1 2491 Extracellular (Potential).

```





RA Nguyen M., Palm C.J., Sakurai T., Satou M., Seki M., Shinn P.,  
 RA Southwick A., Tripp M.G., Wu T., Shinozaki K., Davis R.W., Ecker J.R.,  
 RA Theologis A.;  
 RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.

RN [6]  
 RP SEQUENCE FROM N.A.  
 RA Yamada K., Chan M.M., Chang C.H., Dale J.M., Huan V.W., Lee J.M.,  
 RA Onodera C.S., Quach H.L., Tang C., Toriumi M., Wong C., Wu H.C.,  
 RA Yu G., Yuan S., Carninci P., Chen H., Cheuk R., Hayashizaki Y.,  
 RA Ishida J., Jones T., Kaniya A., Kawai J., Kim C.J., Narusaka M.,  
 RA Nguyen M., Palm C.J., Sakurai T., Satou M., Seki M., Shinn P.,  
 RA Southwick A., Tripp M.G., Wu T., Shinozaki K., Davis R.W., Ecker J.R.,  
 RA Theologis A.;  
 RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.

RL EMBL; AC006917; AAF79220.1; -;  
 DR EMBL; AY086523; AAM63522.1; -;  
 DR EMBL; BT003942; AAO1987.1; -;  
 DR EMBL; BT005027; AAO05060.1; -;  
 DR InterPro; IPR006455; Homeo\_ZF\_HD.  
 DR Pfam; PF04770; ZF-HD dimer; 1.  
 DR TIGRFAMs; TIGR01565; homeo\_ZF\_HD; 1.  
 DR TIGRFAMs; TIGR01566; ZF\_HD\_prot\_N; 1.  
 KW Hypothetical protein.  
 SQ SEQUENCE 168 AA; 19922 MW; BFB68E8E0A32B94 CRC64;

Query Match 66.7%; Score 42; DB 2; Length 168;  
 Best Local Similarity 66.7%; Pred. No. 36;  
 Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2 WINNNAVY 10  
 Db 159 WVNKKKFV 167

RESULT 9

ID Q9EPES PRELIMINARY; PRT; 268 AA.  
 AC Q9EPES;  
 DT 01-MAR-2001 (TREMBLrel. 16, Created)  
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)  
 DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)  
 DE Lecithin cholesterol acyl transferase (Fragment).  
 GN Name=lcac;  
 OS Calomyscus mystax (Afghan mouse-like hamster).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Calomyscinae;  
 OC Calomyscus.  
 OX NCBI\_TaxID=109677;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=20538273; PubMed=11083941; DOI=10.1006/mpev.2000.0849;  
 RA Michaux J.R., Catzeffis F.W.;  
 RT "The bushlike radiation of murid rodents is exemplified by the  
 RL molecular phylogeny of the LCAT nuclear gene."  
 RL Mol. Phylogenet. Evol. 17:280-293 (2000).  
 DR EMBL; AJ275538; CAC18113.1; -;  
 DR EMBL; AJ275539; CAC18113.1; JOINED.  
 DR EMBL; AJ275540; CAC18113.1; JOINED.  
 DR EMBL; AJ275541; CAC18113.1; JOINED.  
 DR EMBL; AJ275542; CAC18113.1; JOINED.  
 DR GO; GO:0004607; F:phosphatidylcholine-sterol O-acyltransferase. . .; IEA.  
 DR GO; GO:0016740; F:transferase activity; IEA.  
 DR GO; GO:0006629; P:lipid metabolism; IEA.  
 DR InterPro; IPR003386; LACT.  
 DR InterPro; IPR008262; Lipase\_AS.  
 DR Pfam; PF02450; LACT; 1.  
 DR PROSITE; PS00120; LIPASE\_SER; UNKNOWN\_1.  
 KW Transferase.  
 FT NON\_TER 1 1  
 FT NON\_TER 268 268  
 SQ SEQUENCE 268 AA; 30975 MW; E733B8D375EA2533 CRC64;

Query Match 66.7%; Score 42; DB 2; Length 268;  
 Best Local Similarity 60.0%; Pred. No. 56;  
 Matches 6; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 CWINNNAVY 10  
 Db 18 CWDINTSVVY 27

RESULT 10

QYRLD7 PRELIMINARY; PRT; 779 AA.  
 ID Q7RLD7;  
 AC Q7RLD7;  
 DT 01-MAR-2004 (TREMBLrel. 26, Created)  
 DT 01-MAR-2004 (TREMBLrel. 26, Last sequence update)  
 DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)  
 DE Hypothetical protein.  
 GN Name=PY02609;  
 OS Plasmodium yoelii yoelii.  
 OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.  
 OX NCBI\_TaxID=73239;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=17XNL;  
 RX PubMed=12368865; DOI=10.1038/nature01099;  
 RA Carlton J.M., Anguoli S.V., Suh B.B., Kooij T.W., Perte M.,  
 RA Silva J.C., Ermolaeva M.D., Allen J.E., Selengut J.D., Koo H.L.,  
 RA Peterson J.D., Pop M., Kosack D.S., Shumway M.F., Bidwell S.L.,  
 RA Shallow S.J., van Aken S.E., Riedmuller S.B., Feldblyum T.V.,  
 RA Cho J.K., Quackenbush J., Sedegah M., Shoaibi A., Cummings L.M.,  
 RA Florens L., Yates F.R. III, Raine J.D., Sinden R.E., Harris M.A.,  
 RA Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B.,  
 RA van Lin L.H., Janse C.J., Waters A.P., Smith H.O., White O.R.,  
 RA Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J.,  
 RA Carucci D.J.;  
 RT "Genome sequence and comparative analysis of the model rodent malaria  
 parasite Plasmodium yoelii yoelii.";  
 RL Nature 419:512-519 (2002).  
 CC -!- CAUTION: The sequence shown here is derived from an  
 CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is  
 CC preliminary data.  
 CC EMBL; AABL01000716; EAA22076.1; -;  
 DR InterPro; IPR001279; Blactmase-like.  
 DR Pfam; PF00753; Lactamase\_B; 1.  
 KW Hypothetical protein.  
 SQ SEQUENCE 779 AA; 92558 MW; BF20EE74D050B462 CRC64;

Query Match 66.7%; Score 42; DB 2; Length 779;  
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CWINNN 6  
 Db 433 CWINNN 438

RESULT 11

QY0UX2 PRELIMINARY; PRT; 105 AA.  
 ID Q70UX2;  
 AC Q70UX2;  
 DT 05-JUL-2004 (TREMBLrel. 27, Created)  
 DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)  
 DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)  
 DE Lecithin cholesterol acyl transferase (Fragment).  
 GN Name=lcac;  
 OS Graphiurus platyops (rock dormouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Myoxidae; Graphiurinae;  
 OC Graphiurus.  
 OX NCBI\_TaxID=221699;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Montgelard C., Matthee C.A., Robinson T.J.;

RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ536378; CAD67534.1; -.  
 DR GO: 0016740; F:transferase activity; IEA.  
 DR InterPro; IPR003386; LACT.  
 DR Pfam; PF02450; LACT; 1.  
 KW Transferase.  
 FT NON\_TER 105 105  
 FT NON\_TER 105 105  
 SQ SEQUENCE 105 AA; 11769 MW; A52FDB70A7B2F5CC CRC64;

Query Match 65.1%; Score 41; DB 2; Length 105;  
 Best Local Similarity 60.0%; Pred. No. 33;  
 Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 CWINNNAVFY 10  
 |||:| |  
 Db 17 CWDNTRVY 26

RESULT 12  
 Q70UX6 PRELIMINARY; PRT; 125 AA.  
 AC Q70UX6;  
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
 DE Lecithin cholesterol acyl transferase (Fragment).  
 GN Name=Icat;  
 OS Dryomys laniger (woolly dormouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Myoxidae; Leithiinae;  
 OC Dryomys.  
 OX NCBI\_TaxID=221696;  
 RN [1]  
 RP SEQUENCE FROM N.A.

RA Montgelaard C., Matthee C.A., Robinson T.J.;  
 RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ536374; CAD67532.1; -.  
 DR GO: 0016740; F:transferase activity; IEA.  
 DR InterPro; IPR003386; LACT.  
 DR Pfam; PF02450; LACT; 1.  
 DR PROSITE; PS00120; LIPASE\_SER; UNKNOWN\_1.  
 KW Transferase.  
 FT NON\_TER 1 125  
 FT NON\_TER 125 125  
 SQ SEQUENCE 125 AA; 14467 MW; 1156855CEAB7B97D CRC64;

Query Match 65.1%; Score 41; DB 2; Length 125;  
 Best Local Similarity 60.0%; Pred. No. 39;  
 Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 CWINNNAVFY 10  
 |||:| |  
 Db 17 CWDNTRVY 26

RESULT 13  
 Q70UX1 PRELIMINARY; PRT; 126 AA.  
 AC Q70UX1;  
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
 DE Lecithin cholesterol acyl transferase (Fragment).  
 GN Name=Icat;  
 OS Graphiurus ocularis (spectacled dormouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Myoxidae; Graphiurinae;  
 OC Graphiurus.  
 OX NCBI\_TaxID=221698;  
 RN [1]  
 RP SEQUENCE FROM N.A.

RA Montgelaard C., Matthee C.A., Robinson T.J.;  
 RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ536379; CAD67539.1; -.  
 DR GO: 0016740; F:transferase activity; IEA.  
 DR InterPro; IPR003386; LACT.  
 DR InterPro; IPR008262; Lipase\_AS.  
 DR InterPro; IPR000379; Ser\_esters.  
 DR Pfam; PF02450; LACT; 1.  
 DR PROSITE; PS00120; LIPASE\_SER; UNKNOWN\_1.  
 KW Transferase.  
 FT NON\_TER 1 126  
 FT NON\_TER 126 126  
 SQ SEQUENCE 126 AA; 14461 MW; DC978F5758D24EEB CRC64;

Query Match 65.1%; Score 41; DB 2; Length 126;  
 Best Local Similarity 60.0%; Pred. No. 39;  
 Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 CWINNNAVFY 10  
 |||:| |  
 Db 10 CWDNTRVY 19

RESULT 14  
 Q70UW9 PRELIMINARY; PRT; 136 AA.  
 AC Q70UW9;  
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
 DE Lecithin cholesterol acyl transferase (Fragment).  
 GN Name=Icat;  
 OS Graphiurus lorraeus (Lorrain dormouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Myoxidae; Graphiurinae;  
 OC Graphiurus.  
 OX NCBI\_TaxID=221682;  
 RN [1]  
 RP SEQUENCE FROM N.A.

RA Montgelaard C., Matthee C.A., Robinson T.J.;  
 RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ536381; CAD67541.1; -.  
 DR GO: 0004607; F:phosphatidylcholine-sterol O-acyltransferase. . .; IEA.  
 DR GO: 0016740; F:transferase activity; IEA.  
 DR GO: 0006629; P:lipid metabolism; IEA.  
 DR InterPro; IPR003386; LACT.  
 DR InterPro; IPR008262; Lipase\_AS.  
 DR PROSITE; PS00120; LIPASE\_SER; UNKNOWN\_1.  
 KW Transferase.  
 FT NON\_TER 1 136  
 FT NON\_TER 136 136  
 SQ SEQUENCE 136 AA; 15779 MW; C4477D97DC9B96B4 CRC64;

Query Match 65.1%; Score 41; DB 2; Length 136;  
 Best Local Similarity 60.0%; Pred. No. 42;  
 Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 CWINNNAVFY 10  
 |||:| |  
 Db 17 CWDNTRVY 26

RESULT 15  
 Q70UX0 PRELIMINARY; PRT; 136 AA.  
 AC Q70UX0;  
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
 DE Lecithin cholesterol acyl transferase (Fragment).  
 GN Name=Icat;  
 OS Graphiurus parvus (savanna dormouse).  
 OS Graphiurus parvus (savanna dormouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Myoxidae; Graphiurinae;  
 OC Graphiurus.  
 OX NCBI\_TaxID=221697;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Montgelard C., Matthee C.A., Robinson T.J.;  
 RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ536380; CAD67540.1;  
 DR GO; GO:0004607; F:phosphatidylcholine-sterol O-acyltransferase. . .; IEA.  
 DR GO; GO:0016740; F:transferase activity; IEA.  
 DR GO; GO:0006629; P:lipid metabolism; IEA.  
 DR InterPro; IPR003386; LACT.  
 DR InterPro; IPR008262; Lipase\_AS.  
 DR Pfam; PF02450; LACT; 1.  
 DR PROSITE; PS00120; LIPASE\_SER; UNKNOWN\_1.  
 KW Transferase.  
 FT NON\_TER 1 .1  
 FT NON\_TER 136 136  
 SQ SEQUENCE 136 AA; 15779 MW; C4477D97DC9B96B4 CRC64;

Query Match 65.1%; Score 41; DB 2; Length 136;  
 Best Local Similarity 60.0%; Pred. No. 42;  
 Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 CWINNNVAVFY 10  
 Db 17 CWIDNTRVIY 26

Search completed: October 20, 2005, 05:54:14  
 Job time : 59 secs

**THIS PAGE BLANK (USPTO)**